1 |BT| (ROOT (S (NP (NP (NP (NN Monitoring) (NNS patients)) (PP (IN for) (NP (JJ adverse) (NNS events)))) (, ,) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NN dose) (NNS adjustments)))) (, ,) (CC or) (NP (NP (DT both)) (PP (IN during) (NP (NP (NN coadministration)) (PP (IN with) (NP (NN posaconazole))))))) (VP (MD may) (VP (VB be) (VP (VBN warranted) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NP (NNS benzodiazepines)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADVP (RB predominantly)) (VP (VBN metabolized) (PP (IN through) (NP (NNP CYP3A4))))))) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN midazolam))) (-RRB- -RRB-))))))))))) (. .))) |ET| |BV| 1:-0.78979158401489258 2:-0.58866101503372192 3:-0.50207614898681641 4:0.22971972823143005 5:1.0234830379486084 6:0.78828704357147217 7:-0.15948094427585602 8:-0.00097798008937388659 9:0.73214215040206909 10:-0.26119983196258545 11:-1.1348884105682373 12:0.008027191273868084 13:0.31622371077537537 14:0.38099229335784912 15:-0.98981839418411255 16:-0.18961744010448456 17:-0.79919236898422241 18:-0.20809629559516907 19:0.2563663125038147 20:-0.37937512993812561 21:-0.33319580554962158 22:-0.99600750207901001 23:-0.36023229360580444 24:-0.92181026935577393 25:0.70081371068954468 26:0.1302991509437561 27:-1.0233551263809204 28:-0.31179019808769226 29:-0.067936509847640991 30:-0.072507545351982117 31:0.083184622228145599 32:-0.4980456531047821 33:-0.090666599571704865 34:-0.080993279814720154 35:-0.4362177848815918 36:0.82062733173370361 37:-0.23244357109069824 38:-0.10020839422941208 39:0.24677145481109619 40:-1.4766076803207397 41:-0.16772039 42:0.27030492 43:0.035899766 44:-0.2042307 45:0.058817174 46:0.32141963 47:0.53227121 48:-0.34179607 49:0.23373675 50:0.39511076 51:0.062264528 52:0.5808931 53:0.009949795 54:0.80117011 55:-0.15728521 56:-0.39057025 57:0.083487339 58:0.54840708 59:0.52147019 60:-0.56140709  |EV|
1 |BT| (ROOT (S (NP (NP (NP (NNS CONCLUSIONS)) (: :) (NP (NP (NP (JJ High) (NN clonidine) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD 75) (NN microg)) (-RRB- -RRB-))) (VP (VBN associated) (PP (TO to) (NP (JJ hyperbaric) (NN bupivacaine))) (PP (IN during) (NP (JJ high-level) (JJ spinal) (NN anesthesia)))))) (PRN (-LRB- -LRB-) (NP (NNP T4)) (-RRB- -RRB-))) (VP (VP (VBZ induces) (NP (NP (DT a) (JJR higher) (NN incidence)) (PP (IN of) (NP (JJ arterial) (NN hypotension))))) (CC but) (VP (VBZ prolongs) (NP (NP (JJ sensory) (NN block) (CC and) (NN postoperative) (NN analgesia)) (ADJP (JJ similar) (PP (TO to) (NP (JJR lower) (NN clonidine) (NN dose)))) (PRN (-LRB- -LRB-) (NP (CD 45) (NN microg)) (-RRB- -RRB-))) (PP (IN during) (NP (JJ upper) (JJ spinal) (NN anesthesia))))) (. .))) |ET| |BV| 1:-0.34696581959724426 2:-0.0097431344911456108 3:-0.23105962574481964 4:-0.50302809476852417 5:-0.020926365628838539 6:0.28707119822502136 7:-0.03687683492898941 8:-0.00093980529345571995 9:0.57171630859375 10:-0.061133615672588348 11:0.55941510200500488 12:-0.38323381543159485 13:0.034318916499614716 14:-0.24120934307575226 15:-0.67039000988006592 16:0.42504683136940002 17:0.50754982233047485 18:0.30065628886222839 19:-0.016009297221899033 20:-0.086647823452949524 21:-0.89050740003585815 22:-0.068780981004238129 23:-0.47116345167160034 24:-0.32579430937767029 25:-0.21974571049213409 26:-0.086479373276233673 27:0.31466415524482727 28:-0.11319269239902496 29:0.079392373561859131 30:0.18790373206138611 31:0.23570172488689423 32:-0.12637585401535034 33:0.10259231925010681 34:-0.49600061774253845 35:-0.25592780113220215 36:0.32329067587852478 37:0.42616134881973267 38:0.28018206357955933 39:-0.76101130247116089 40:0.10418049246072769 41:-0.76491618 42:0.24518801 43:0.17853083 44:-0.23840232 45:0.34070531 46:-0.064233221 47:-0.65283954 48:0.11207738 49:0.090207815 50:-0.27262828 51:-0.45396826 52:-0.46814615 53:-0.5591079 54:0.023902979 55:-0.26819465 56:-0.20253927 57:-0.18586649 58:0.19122948 59:-0.16243209 60:0.14149334  |EV|
1 |BT| (ROOT (S (S (VP (VBG Examining) (NP (NP (DT the) (NNS details)) (PP (IN of) (NP (NP (DT the) (JJ temporal) (NNS features)) (PP (IN of) (NP (DT the) (JJ evoked) (NNS profiles)))))))) (VP (VBZ reveals) (NP (NP (DT no) (JJ clear) (NN evidence)) (PP (IN for) (NP (NP (JJ long-distance) (NN diffusion)) (PP (IN of) (NP (NP (NN dopamine)) (PP (IN between) (NP (ADJP (JJ fast) (CC and) (JJ slow)) (NNS domains)))))))) (, ,) (SBAR (RB even) (IN though) (S (NP (NP (JJ uptake) (NN inhibition)) (PP (IN by) (NP (NN nomifensine)))) (VP (ADVP (RB clearly)) (VBZ prolongs) (NP (DT the) (NN time)) (SBAR (IN that) (S (NP (NN dopamine)) (VP (VBZ resides) (PP (IN in) (NP (DT the) (NN extracellular) (NN space)))))))))) (. .))) |ET| |BV| 1:-1.4352881908416748 2:0.23550102114677429 3:0.28739452362060547 4:-1.6928144693374634 5:-0.10965687781572342 6:-0.60174739360809326 7:0.74265700578689575 8:-0.91238713264465332 9:0.85570979118347168 10:0.39382100105285645 11:0.48118779063224792 12:-0.74184155464172363 13:1.2862356901168823 14:-0.52537065744400024 15:0.68416064977645874 16:0.93611735105514526 17:0.49343380331993103 18:0.52505773305892944 19:-0.21933048963546753 20:1.0926527976989746 21:-0.52288627624511719 22:0.064634568989276886 23:0.43291720747947693 24:-0.59934920072555542 25:0.067319102585315704 26:-0.54065132141113281 27:0.75569421052932739 28:0.22499477863311768 29:0.75093740224838257 30:0.50299102067947388 31:0.66871351003646851 32:-0.46396654844284058 33:0.70376694202423096 34:0.35963043570518494 35:0.027474602684378624 36:0.40848967432975769 37:0.32412928342819214 38:-0.051923949271440506 39:0.47423961758613586 40:0.30214890837669373 41:-0.18680191 42:0.031823594 43:-0.066329129 44:-0.16584101 45:0.43341047 46:-0.64443189 47:0.049082715 48:0.018523032 49:-0.28769046 50:0.57131511 51:-0.10905656 52:0.061138332 53:0.10274614 54:-0.22704844 55:-0.087608151 56:0.10404284 57:0.34588921 58:0.22590666 59:-0.4927125 60:0.060855482  |EV|
1 |BT| (ROOT (S (NP (NNP Chlordiazepoxide)) (VP (VBD produced) (NP (JJ significant) (NNS decreases)) (PP (PP (IN in) (NP (NP (JJ food-maintained) (VBG responding)) (CC and) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NP (NN ethanol)) (VP (VBN presented))))))) (, ,) (CONJP (CC but) (RB only)) (PP (IN at) (NP (NP (DT the) (JJS highest) (NN dose)) (VP (VBN tested)))))) (. .))) |ET| |BV| 1:-0.18262425065040588 2:-0.27455565333366394 3:-0.63187038898468018 4:-0.20303082466125488 5:-0.49805775284767151 6:-0.36358526349067688 7:-0.67585134506225586 8:-0.18507486581802368 9:0.57143604755401611 10:-0.13132448494434357 11:0.033105544745922089 12:0.3947727382183075 13:0.014030230231583118 14:-0.085290499031543732 15:0.069696143269538879 16:0.078646555542945862 17:-0.25420689582824707 18:-0.09992583841085434 19:0.4503624439239502 20:0.5757184624671936 21:-1.1399068832397461 22:-0.051731899380683899 23:-1.3472412824630737 24:-0.11247903108596802 25:0.35895267128944397 26:-0.78500241041183472 27:-1.8944214582443237 28:0.49661213159561157 29:1.838792085647583 30:0.36294636130332947 31:-0.65767848491668701 32:0.029336947947740555 33:0.013183736242353916 34:0.34426984190940857 35:-0.32096600532531738 36:-0.17584007978439331 37:0.018173908814787865 38:0.39964738488197327 39:0.34451034665107727 40:0.53582203388214111 41:-0.22235754 42:-0.35752195 43:0.10931377 44:0.3466202 45:0.19532886 46:-0.18904051 47:0.20533572 48:-0.43493101 49:-0.43030122 50:-0.039110955 51:0.17364885 52:0.36153713 53:0.076109618 54:0.093946531 55:-0.16439913 56:0.091444574 57:0.72916645 58:0.14645554 59:0.23365995 60:0.29246813  |EV|
1 |BT| (ROOT (NP (NP (NNS CONCLUSIONS)) (: :) (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (JJ chronic) (ADJP (JJ amiodarone) (CC and) (JJ acute)) (NN ranolazine)) (SBAR (S (VP (VBZ produces) (NP (NP (DT a) (JJ synergistic) (JJ use-dependent) (NN depression)) (PP (IN of) (NP (NP (PRP I)) (PRN (-LRB- -LRB-) (NP (NNP Na)) (-RRB- -RRB-))))))))))) (: -) (NP (NP (JJ dependent) (NNS parameters)) (PP (IN in) (NP (JJ isolated) (JJ canine) (NN atria)))) (, ,) (VP (VBG leading) (PP (TO to) (NP (NP (DT a) (JJ potent) (NN effect)) (PP (IN of) (NP (DT the) (NN drug) (NN combination))))) (S (VP (TO to) (VP (VB prevent) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (JJ atrial) (NN fibrillation)))))))) (. .))) |ET| |BV| 1:-0.16469965875148773 2:0.022516429424285889 3:-0.73193413019180298 4:0.045193154364824295 5:0.42221939563751221 6:0.036796849220991135 7:0.23524349927902222 8:-0.27031907439231873 9:0.41419598460197449 10:0.20313477516174316 11:-0.29296407103538513 12:-0.33279585838317871 13:0.23716504871845245 14:-0.2083229273557663 15:-0.14375141263008118 16:-0.043305229395627975 17:-0.10976047813892365 18:-0.43185728788375854 19:0.68558299541473389 20:0.1834789514541626 21:-0.50797927379608154 22:0.22242394089698792 23:-0.58503681421279907 24:-1.116124153137207 25:0.29811209440231323 26:-0.20458292961120605 27:0.28309065103530884 28:-0.53003603219985962 29:1.2892283201217651 30:1.1058322191238403 31:-0.64361739158630371 32:-1.1454899311065674 33:-0.13492609560489655 34:0.29871371388435364 35:-0.53236901760101318 36:-0.1592826247215271 37:-0.58320420980453491 38:-0.17344428598880768 39:0.83502084016799927 40:-0.22067239880561829 41:-0.6961236 42:-0.22058751 43:0.068752035 44:-0.25931942 45:0.30157036 46:-0.22566921 47:0.26623222 48:0.11536221 49:0.32593679 50:-0.13486694 51:-0.054787338 52:-0.90097779 53:0.12251316 54:0.44120902 55:0.020446632 56:0.27535501 57:0.22570048 58:0.21483344 59:0.18371722 60:-0.27874658  |EV|
1 |BT| (ROOT (NP (NP (NNP Antagonism)) (PP (IN of) (NP (NP (DT the) (ADJP (JJ antithrombotic) (CC and) (JJ anti-atherosclerotic)) (NNS actions)) (PP (IN of) (NP (NN aspirin))))) (PP (IN by) (NP (NN rofecoxib))) (PP (IN in) (NP (DT the) (JJ cholesterol-fed) (NN rabbit))) (. .))) |ET| |BV| 1:0.18413414061069489 2:-1.2404204607009888 3:-0.24337346851825714 4:0.47839879989624023 5:-0.54357165098190308 6:0.25719764828681946 7:-0.66916507482528687 8:-0.43968144059181213 9:1.0442491769790649 10:-0.45525747537612915 11:-0.078946493566036224 12:1.3175220489501953 13:1.1431878805160522 14:-2.6085827350616455 15:-0.17483136057853699 16:1.2728421688079834 17:-0.59851855039596558 18:-0.7126011848449707 19:-0.057639375329017639 20:-0.84565258026123047 21:-0.45031630992889404 22:0.15654109418392181 23:-0.1405574232339859 24:0.57517284154891968 25:0.19980970025062561 26:-0.0032609140034765005 27:-0.33045914769172668 28:-0.79845482110977173 29:0.21623410284519196 30:-0.19117653369903564 31:-0.26789900660514832 32:0.13184972107410431 33:0.56898230314254761 34:-0.53675496578216553 35:-0.2580471932888031 36:0.65332514047622681 37:-0.48971584439277649 38:-0.86091041564941406 39:0.14939133822917938 40:-0.010001880116760731 41:-0.049917482 42:-0.24687789 43:0.20389214 44:-0.19835202 45:0.1175063 46:-0.043385059 47:-0.20002733 48:-0.35882074 49:-0.019832287 50:0.28691065 51:-0.14373778 52:0.50583249 53:0.036804058 54:-0.29259381 55:-0.34638202 56:0.41542119 57:0.50908768 58:0.084679425 59:-0.11858629 60:-0.27503875  |EV|
1 |BT| (ROOT (S (NP (NP (JJ Several) (NNS drugs)) (, ,) (PP (VBG including) (NP (NP (NN sucralfate)) (, ,) (NP (NN acarbose)) (, ,) (NP (JJ cytotoxic) (NNS agents)) (, ,) (CC and) (NP (JJ enzyme) (NNS inducers)))) (, ,)) (VP (MD can) (VP (VB reduce) (NP (JJ digoxin) (NN plasma) (NNS concentrations)))) (. .))) |ET| |BV| 1:-1.0121845006942749 2:0.14595584571361542 3:0.44600823521614075 4:-0.25769731402397156 5:-0.37429839372634888 6:0.023680463433265686 7:0.67091608047485352 8:0.2029632180929184 9:1.660767674446106 10:0.61272507905960083 11:-0.86790186166763306 12:0.55626851320266724 13:0.33811837434768677 14:-1.0848907232284546 15:-0.81710273027420044 16:0.16831640899181366 17:-0.089263282716274261 18:-0.56630611419677734 19:0.6957777738571167 20:-0.74892586469650269 21:-0.60551023483276367 22:0.79024237394332886 23:-1.4789502620697021 24:-0.06369423121213913 25:0.52428078651428223 26:0.011539914645254612 27:-0.44888067245483398 28:-0.28743380308151245 29:1.0391918420791626 30:0.14282526075839996 31:-0.6410103440284729 32:0.20663228631019592 33:0.57818228006362915 34:-0.28894764184951782 35:-0.11183440685272217 36:0.23218049108982086 37:0.074597075581550598 38:-0.25530752539634705 39:0.1373317539691925 40:-0.53306454420089722 41:-0.31519055 42:-0.1250736 43:0.45796633 44:0.46528739 45:0.23173526 46:0.20864008 47:-0.029604094 48:-0.35758504 49:0.55659491 50:0.073550396 51:0.41324598 52:0.21355695 53:0.028693797 54:-0.14827161 55:0.2351398 56:0.043548752 57:0.13677995 58:0.40026498 59:0.22347628 60:-0.27246344  |EV|
1 |BT| (ROOT (S (NP (NP (NNP CONCLUSIONS) (CC AND) (NNP POTENTIAL) (NNP RELEVANCE)) (: :) (NP (NP (DT A) (JJ dexmedetomidine) (NN CRI)) (PP (IN at) (NP (DT the) (VBN reported) (NN dose))))) (ADVP (RB significantly)) (VP (VBZ reduces) (NP (NP (DT the) (NX (NNP MAC))) (PP (IN of) (NP (NN sevoflurane))))) (. .))) |ET| |BV| 1:-0.77053290605545044 2:-0.48575147986412048 3:-0.84432661533355713 4:-1.0948235988616943 5:0.79077690839767456 6:-0.38421624898910522 7:-0.094402462244033813 8:-0.7633662223815918 9:-0.38017043471336365 10:0.042292214930057526 11:-0.44345054030418396 12:-0.75959682464599609 13:-0.44020324945449829 14:-0.11750142276287079 15:0.36356458067893982 16:1.1747187376022339 17:0.36346834897994995 18:0.23654294013977051 19:-0.10545375198125839 20:-0.92121630907058716 21:-0.51583421230316162 22:-0.15732002258300781 23:-0.6730111837387085 24:-0.94175428152084351 25:0.24679912626743317 26:-0.6743507981300354 27:-0.21775585412979126 28:0.045891992747783661 29:-0.18093675374984741 30:0.41452351212501526 31:-0.35863405466079712 32:0.27835530042648315 33:0.19278877973556519 34:-1.1857702732086182 35:0.0078831156715750694 36:0.32769522070884705 37:0.64750874042510986 38:0.40576273202896118 39:-0.44038063287734985 40:-0.45647451281547546 41:-0.15608221 42:0.31538296 43:-0.065818056 44:-0.029752484 45:0.3562502 46:0.14041375 47:0.089476928 48:-0.20142746 49:-0.34333619 50:0.41449988 51:0.30833274 52:-0.30665585 53:0.11021344 54:0.26009935 55:-0.46767002 56:0.26406145 57:0.70687705 58:-0.24935602 59:0.37277356 60:-0.016976733  |EV|
1 |BT| (ROOT (S (NP (PRP$ Our) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN modafinil)) (VP (MD can) (VP (VP (VB interfere) (PP (IN with) (NP (JJ methamphetamine) (NNS actions)))) (CC and) (VP (VB provide) (NP (NN protection)) (PP (IN against) (NP (NP (JJ dopamine) (NN toxicity)) (, ,) (NP (NN cell) (NN death)) (, ,) (CC and) (NP (NP (NN neuroinflammation)) (PP (IN in) (NP (DT the) (NN mouse) (NN striatum)))))))))))) (. .))) |ET| |BV| 1:0.027203679084777832 2:-0.44145473837852478 3:0.19782429933547974 4:-0.29811137914657593 5:0.22199876606464386 6:-0.42937174439430237 7:-0.12837471067905426 8:-0.4298664927482605 9:0.51660990715026855 10:0.45310685038566589 11:0.3033214807510376 12:0.0084803774952888489 13:-0.29091501235961914 14:0.30512857437133789 15:0.11571419984102249 16:0.49818620085716248 17:-0.052969720214605331 18:0.16757877171039581 19:0.68114298582077026 20:0.48334053158760071 21:-0.11594255268573761 22:-0.51243990659713745 23:-0.22024177014827728 24:-0.41140586137771606 25:-0.064051806926727295 26:-0.74794524908065796 27:-1.6191600561141968 28:-1.0811833143234253 29:0.50388538837432861 30:0.16303075850009918 31:-0.042243145406246185 32:0.11824001371860504 33:-0.59603452682495117 34:0.60282111167907715 35:-1.1580085754394531 36:1.3130836486816406 37:-0.59139764308929443 38:1.0908020734786987 39:-0.36715441942214966 40:0.88050574064254761 41:0.0011498228 42:-0.33488002 43:0.025831804 44:-0.20449509 45:0.3785471 46:-0.32272053 47:-0.15697743 48:0.11565983 49:0.12671818 50:0.38314155 51:0.14023679 52:0.79046482 53:0.37624115 54:-0.11012566 55:0.10984369 56:0.19161691 57:0.057213083 58:-0.082648337 59:-0.04898759 60:0.051528007  |EV|
1 |BT| (ROOT (FRAG (NP (NNS METHODS) (CC AND) (NNS RESULTS)) (: :) (S (NP (NP (JJ Pravastatin) (PRN (-LRB- -LRB-) (NP (CD 112) (NN nmol/L)) (-RRB- -RRB-)) (NN pretreatment)) (PP (IN for) (NP (CD 60) (NN min)))) (VP (VBD reduced) (NP (PDT both) (DT the) (NN potency) (CC and) (JJ maximal) (NN constrictor) (NNS responses)) (PP (TO to) (NP (NN phenylephrine))) (, ,) (NP (NP (NN thromboxane)) (PRN (-LRB- -LRB-) (NP (NNP U46619)) (-RRB- -RRB-)) (CC and) (NP (NP (NN serotonin)) (PP (IN in) (NP (JJ small) (NNS vessels))))))) (. .))) |ET| |BV| 1:-0.29991701245307922 2:-0.32896068692207336 3:-0.69324624538421631 4:-1.0911616086959839 5:0.3539905846118927 6:-0.10250002145767212 7:0.39163857698440552 8:-0.35641288757324219 9:0.19815751910209656 10:0.13153271377086639 11:0.58596199750900269 12:-0.79918879270553589 13:-0.10417470335960388 14:-0.49502533674240112 15:0.4668823778629303 16:0.28145709633827209 17:-0.51942658424377441 18:-0.21242213249206543 19:-0.45488372445106506 20:-0.3516385555267334 21:-0.085458740592002869 22:-0.26855319738388062 23:-0.95891404151916504 24:0.34266898036003113 25:-0.14177185297012329 26:-1.6798561811447144 27:-0.37157264351844788 28:0.36406892538070679 29:-0.41499808430671692 30:-0.049521941691637039 31:-0.14231882989406586 32:0.5092577338218689 33:0.38048642873764038 34:-0.19903287291526794 35:-0.67934930324554443 36:1.0915193557739258 37:0.41261297464370728 38:-0.87610542774200439 39:1.9340692758560181 40:-1.4697438478469849 41:-0.78685957 42:-0.025923936 43:0.040827677 44:-0.12168234 45:-0.38836396 46:-0.0030694625 47:0.22624081 48:0.15349112 49:-0.20691702 50:0.23347811 51:-0.0098274536 52:0.020269917 53:-0.0079178419 54:0.24336936 55:-0.468692 56:0.43465945 57:0.2024505 58:0.019488683 59:-0.64056653 60:-0.12111836  |EV|
1 |BT| (ROOT (FRAG (NP (NNP CONCLUSION)) (: :) (S (NP (NNP Ketamine)) (VP (MD can) (ADVP (RB remarkably)) (VP (VB inhibit) (NP (NN calcium) (NNS currents)) (PP (IN in) (NP (NP (DT the) (JJ central) (NNS neurons)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB explain) (PP (ADVP (IN at) (JJS least)) (RB partly) (NP (DT the) (NN action))) (PP (IN of) (NP (NP (NN ketamine)) (PP (IN on) (NP (JJ central) (JJ nervous) (NN system)))))))))))))) (. .))) |ET| |BV| 1:-0.11668428778648376 2:-0.74165034294128418 3:-1.0241296291351318 4:-0.74730932712554932 5:0.10768051445484161 6:-0.027183696627616882 7:-0.37243309617042542 8:0.063145764172077179 9:0.61295735836029053 10:0.35496282577514648 11:0.77447646856307983 12:-0.233793705701828 13:0.25274378061294556 14:-0.15525589883327484 15:-0.4126114547252655 16:0.58029055595397949 17:0.033387862145900726 18:0.43734666705131531 19:-0.18863105773925781 20:-0.29837921261787415 21:-0.76733154058456421 22:0.24607940018177032 23:-0.3637290894985199 24:-0.26238524913787842 25:-0.33067521452903748 26:-0.33500140905380249 27:-0.08953440934419632 28:0.13414254784584045 29:0.37700408697128296 30:0.26008978486061096 31:-0.075949981808662415 32:-0.24670501053333282 33:0.17961160838603973 34:-0.15187470614910126 35:-1.0580264329910278 36:-0.25400683283805847 37:-0.31937047839164734 38:0.033552780747413635 39:0.48308485746383667 40:-0.69982004165649414 41:-0.11363626 42:0.022131165 43:0.12533018 44:0.0041282559 45:0.37490556 46:-0.57854283 47:-0.050534822 48:-0.18694185 49:-0.033041459 50:0.2962434 51:-0.2781719 52:-0.0035328257 53:-0.079793364 54:-0.16357665 55:-0.18437088 56:0.096353397 57:0.050870422 58:-0.34409943 59:-0.23008823 60:0.43239722  |EV|
1 |BT| (ROOT (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (ADJP (JJ vasodilative) (, ,) (JJ antianginal) (CC and) (JJ antiarrhythmic)) (NNS actions)) (PP (IN of) (NP (NN amiodarone)))) (VP (MD may) (VP (VB be) (VP (RBR further) (VBN enhanced) (PP (IN by) (NP (NP (DT the) (JJ simultaneous) (NN supplementation)) (PP (IN of) (NP (NP (NN calcium) (NN channel) (NNS blockers)) (PP (IN via) (NP (JJ synergistic) (NNS mechanisms))))) (, ,) (VP (VBG supporting) (NP (NP (DT the) (JJ clinical) (NN use)) (PP (IN of) (NP (JJ such) (NN drug) (NNS combinations)))))))))) (. .))) |ET| |BV| 1:-0.4020153135061264 2:0.26041409869988758 3:-0.33256416395306587 4:-0.4774930477142334 5:-0.57279710968335473 6:0.030752117435137432 7:-0.033705521374940872 8:0.35309721032778424 9:0.86477917432785034 10:0.27282262345155078 11:-0.11382813006639481 12:-0.568149134516716 13:0.24151221414407095 14:-0.036625973569850125 15:-1.466590404510498 16:-0.45977588494618732 17:-0.25449221829573315 18:-0.13983984788258871 19:0.50851893424987793 20:-0.67701019843419397 21:-0.16469965875148773 22:0.022516429424285889 23:-0.73193413019180298 24:0.045193154364824295 25:0.42221939563751221 26:0.036796849220991135 27:0.23524349927902222 28:-0.27031907439231873 29:0.41419598460197449 30:0.20313477516174316 31:-0.29296407103538513 32:-0.33279585838317871 33:0.23716504871845245 34:-0.2083229273557663 35:-0.14375141263008118 36:-0.043305229395627975 37:-0.10976047813892365 38:-0.43185728788375854 39:0.68558299541473389 40:0.1834789514541626 41:-0.60841829 42:-0.20048393 43:0.62815654 44:0.092391551 45:0.36841097 46:-0.00071928446 47:-0.32054833 48:-0.1099953 49:0.19344208 50:0.56079072 51:0.19191693 52:0.2797282 53:0.15170592 54:-0.10124607 55:0.054922797 56:0.086886637 57:0.49230745 58:0.078592889 59:-0.2667661 60:-0.56223077  |EV|
1 |BT| (ROOT (S (NP (PRP We)) (VP (VBP propose) (SBAR (IN that) (S (NP (NP (JJR earlier) (NN introduction)) (PP (IN of) (NP (NN rituximab)))) (VP (MD may) (VP (VB reduce) (S (NP (DT the) (NN side) (NNS effects)) (ADJP (VBN related) (PP (TO to) (NP (NP (JJ other) (JJ cytotoxic) (NN therapy)) (ADJP (RB mainly) (JJ steroids) (CC and) (JJ cyclophosphamide))))))))))) (. .))) |ET| |BV| 1:-0.8092041015625 2:-0.19329148530960083 3:-0.70447874069213867 4:0.16662487387657166 5:0.29772061109542847 6:-0.64029854536056519 7:-0.70728737115859985 8:-0.16949117183685303 9:-0.54650425910949707 10:1.4144823551177979 11:-0.060322113335132599 12:0.17590384185314178 13:-0.13637727499008179 14:0.23657388985157013 15:-0.5770295262336731 16:1.4925574064254761 17:0.57485455274581909 18:-0.11306485533714294 19:0.70975369215011597 20:-1.2286081314086914 21:-0.25624138116836548 22:-0.26062014698982239 23:0.16864459216594696 24:0.1016928032040596 25:0.094414539635181427 26:0.40387216210365295 27:0.81406813859939575 28:-0.69259363412857056 29:-0.25558885931968689 30:0.54672831296920776 31:-0.46322447061538696 32:-0.02742513082921505 33:-0.035071287304162979 34:0.21702952682971954 35:0.44882351160049438 36:0.7733343243598938 37:-0.46913328766822815 38:-0.64461928606033325 39:0.30856242775917053 40:0.097931087017059326 41:0.16633591 42:0.065021738 43:0.17110889 44:0.17646554 45:-0.091481015 46:-0.10278995 47:0.024598153 48:-0.5407055 49:-0.05047391 50:0.57116812 51:0.21961136 52:0.1560477 53:0.032716319 54:0.37944219 55:0.020566043 56:0.0012731787 57:0.014923286 58:0.22276877 59:0.27619025 60:-0.11370695  |EV|
1 |BT| (ROOT (S (NP (NNP Addition)) (VP (ADVP (IN of)) (VBZ L-NAME) (-LRB- -LRB-) (NP (CD 10))) (. ?))) |ET| |BV| 1:-0.29991701245307922 2:-0.32896068692207336 3:-0.69324624538421631 4:-1.0911616086959839 5:0.3539905846118927 6:-0.10250002145767212 7:0.39163857698440552 8:-0.35641288757324219 9:0.19815751910209656 10:0.13153271377086639 11:0.58596199750900269 12:-0.79918879270553589 13:-0.10417470335960388 14:-0.49502533674240112 15:0.4668823778629303 16:0.28145709633827209 17:-0.51942658424377441 18:-0.21242213249206543 19:-0.45488372445106506 20:-0.3516385555267334 21:-0.74559247493743896 22:-0.92662256956100464 23:-0.0948047935962677 24:-1.0139914751052856 25:-0.31690508127212524 26:-0.2176826149225235 27:0.49653452634811401 28:0.90447181463241577 29:0.071511663496494293 30:-0.20202994346618652 31:0.063019894063472748 32:-0.83182251453399658 33:-0.51941019296646118 34:0.37375232577323914 35:-0.064919739961624146 36:-0.22771221399307251 37:-0.74174892902374268 38:-0.23774406313896179 39:-0.24274754524230957 40:-0.076648838818073273 41:-0.5185281 42:-0.7219348 43:-0.26535568 44:-0.33659416 45:0.35703728 46:-0.56103665 47:-0.096939683 48:-0.013583369 49:-0.63936836 50:0.16969082 51:0.32175457 52:0.13346069 53:0.072000608 54:-0.037328582 55:0.0084037492 56:0.050877023 57:0.81833345 58:0.40231639 59:-0.10890339 60:0.091367833  |EV|
1 |BT| (ROOT (S (NP (NNP Cyproheptadine)) (VP (VBZ blocks) (NP (NP (DT all) (NNS transformations)) (PP (IN with) (NP (NN progesterone) (CC or) (NN HO-progesterone)))) (PP (IN as) (S (VP (VBG starting) (NP (NN point)))))) (. .))) |ET| |BV| 1:-0.27791854739189148 2:-1.9419111013412476 3:0.49334105849266052 4:0.30221548676490784 5:0.77765125036239624 6:-0.11540044844150543 7:0.92698359489440918 8:1.2718743085861206 9:-0.46127715706825256 10:1.259757399559021 11:-0.26252549886703491 12:0.0078048286959528923 13:1.4247032403945923 14:-0.20076532661914825 15:-1.2998760938644409 16:-0.067311681807041168 17:1.4078093767166138 18:0.29920348525047302 19:1.2955601215362549 20:-0.031746264547109604 21:-0.70291984081268311 22:0.10596521198749542 23:0.40353924036026001 24:-0.0082024643197655678 25:0.51516556739807129 26:-0.42482960224151611 27:0.15003122389316559 28:0.12399149686098099 29:0.20275136828422546 30:0.48732560873031616 31:0.47781708836555481 32:-0.14894188940525055 33:0.51152008771896362 34:0.33163288235664368 35:-0.59081339836120605 36:0.57499492168426514 37:0.029747411608695984 38:0.1139160692691803 39:0.40241897106170654 40:0.63742589950561523 41:-0.35305032 42:-0.4524101 43:-0.08457648 44:-0.22547582 45:0.48539174 46:-0.23283583 47:-0.029635534 48:0.19868575 49:0.18919443 50:-0.020114535 51:0.44707873 52:-0.20469512 53:-0.19786438 54:0.026881995 55:0.13744402 56:-0.18406853 57:0.49954224 58:0.080206595 59:-0.5275498 60:-0.05908864  |EV|
1 |BT| (ROOT (S (NP (NP (NNP Cinacalcet)) (, ,) (PP (IN for) (NP (NN example))) (, ,)) (VP (VBZ is) (NP (NP (DT a) (NN drug)) (SBAR (SBAR (WHNP (WDT that)) (S (ADVP (RB allosterically)) (VP (VBZ modifies) (NP (DT the) (NN receptor)) (ADVP (RB so) (RB as)) (S (VP (TO to) (VP (VB increase) (NP (PRP$ its) (NN sensitivity)) (PP (TO to) (S (VP (VBG circulating) (NP (NN calcium))))) (PRN (-LRB- -LRB-) (ADVP (RB thus) (NP (DT the) (NN name))) (ADJP (`` ``) (JJ calcimimetic) ('' '')) (-RRB- -RRB-)))))))) (CC and) (SBAR (IN in) (S (NP (DT this) (NN way)) (VP (VBZ decreases) (NP (JJ parathyroid) (NN hormone) (NN secretion)))))))) (. .))) |ET| |BV| 1:-0.7300487756729126 2:-1.0319269895553589 3:-0.19360065460205078 4:-0.0095260581001639366 5:-0.15709367394447327 6:-0.15227627754211426 7:-0.79149168729782104 8:0.42398419976234436 9:-0.079996921122074127 10:1.0777498483657837 11:0.058074116706848145 12:-0.14017753303050995 13:0.09984191507101059 14:0.22981210052967072 15:-0.89009690284729004 16:0.85412561893463135 17:-0.43766206502914429 18:0.19068843126296997 19:0.22167737782001495 20:-0.43719613552093506 21:-0.76733154058456421 22:0.24607940018177032 23:-0.3637290894985199 24:-0.26238524913787842 25:-0.33067521452903748 26:-0.33500140905380249 27:-0.08953440934419632 28:0.13414254784584045 29:0.37700408697128296 30:0.26008978486061096 31:-0.075949981808662415 32:-0.24670501053333282 33:0.17961160838603973 34:-0.15187470614910126 35:-1.0580264329910278 36:-0.25400683283805847 37:-0.31937047839164734 38:0.033552780747413635 39:0.48308485746383667 40:-0.69982004165649414 41:-0.095457762 42:-0.119698 43:0.13229862 44:-0.070296139 45:0.1005244 46:0.30357286 47:-0.14314541 48:-0.14556548 49:-0.08461044 50:0.31633195 51:-0.17051397 52:0.11074489 53:0.048266828 54:-0.3887338 55:-0.071701817 56:0.2325535 57:0.14667387 58:0.08313635 59:-0.036476303 60:0.17199352  |EV|
1 |BT| (ROOT (FRAG (NP (NNP Conclusion)) (: :) (S (S (NP (NNP Etanercept) (CC and) (NN anakinra) (NNS efficiently) (CC and) (NN dose-dependently)) (VP (VBP prevent) (NP (JJ cytokine-induced) (NN bone) (NN growth) (NN impairment)))) (, ,) (CC and) (S (NP (NP (NN combination)) (PP (IN with) (NP (NNP IGF-I)))) (VP (ADVP (RBR further)) (VBZ improves) (NP (NN bone) (NN growth))))) (. .))) |ET| |BV| 1:-0.94483369588851929 2:-1.1720799207687378 3:-0.21976928412914276 4:0.053598131984472275 5:-1.6204743385314941 6:-1.8191205263137817 7:-0.4556976854801178 8:-0.55438995361328125 9:-0.76254987716674805 10:-0.4777996838092804 11:0.2022436112165451 12:-0.88376659154891968 13:0.32213646173477173 14:1.1307764053344727 15:-0.023874465376138687 16:0.92231470346450806 17:-0.80786710977554321 18:-0.86718744039535522 19:0.15088288486003876 20:-0.253091961145401 21:-1.5968940258026123 22:-0.78697842359542847 23:-1.5109490156173706 24:0.51721739768981934 25:-1.4647456407546997 26:-0.55207967758178711 27:-0.41307622194290161 28:-1.0079505443572998 29:0.016854064539074898 30:-0.058697953820228577 31:-0.034399349242448807 32:-1.0416425466537476 33:0.41075316071510315 34:0.81969016790390015 35:0.35323616862297058 36:1.1244910955429077 37:-0.28098848462104797 38:-0.24923591315746307 39:0.20871326327323914 40:0.19867250323295593 41:-0.3441565 42:-0.2785342 43:0.10139197 44:0.11196058 45:0.27015987 46:-0.24094439 47:-0.078733921 48:-0.32805887 49:0.025581963 50:-0.0038116053 51:0.29081509 52:0.068547443 53:0.64466673 54:0.50583422 55:0.35711536 56:0.030563382 57:0.50197816 58:0.52946103 59:-0.18454069 60:-0.63856828  |EV|
1 |BT| (ROOT (S (NP (NP (NNP Pretreatment)) (PP (IN with) (NP (DT the) (ADJP (ADJP (JJ poly)) (PRN (-LRB- -LRB-) (NP (NNP ADP-ribose)) (-RRB- -RRB-))) (NN polymerase) (PRN (-LRB- -LRB-) (NP (NNP PARP)) (-RRB- -RRB-)) (JJ inhibitor) (NN nicotinamide)))) (VP (VBD was) (ADJP (JJ able) (S (VP (TO to) (VP (VB prevent) (NP (CD HCN2) (NN cell) (NN death))))))) (. .))) |ET| |BV| 1:-1.1993156671524048 2:0.053196605294942856 3:0.12248830497264862 4:-1.9055473804473877 5:-0.9290921688079834 6:-0.64883863925933838 7:0.30231109261512756 8:1.3207569122314453 9:-0.42110952734947205 10:-0.78424996137619019 11:-0.56691229343414307 12:-0.42819502949714661 13:0.48882344365119934 14:0.77929699420928955 15:-0.079202443361282349 16:0.58030307292938232 17:-1.0447641611099243 18:0.72934699058532715 19:0.48482397198677063 20:-1.1021203994750977 21:-0.16018864015738168 22:-0.20164066304763159 23:0.48393661777178448 24:-0.35485359529654187 25:-0.2958649794260661 26:-0.69610826174418128 27:0.59243098894755042 28:0.71105279525121057 29:-0.21807660659154257 30:-0.076776210218667984 31:0.18077846368153891 32:0.11973685522874196 33:-0.23570933192968369 34:1.1153556108474731 35:-0.10737976680199306 36:0.15242310985922813 37:-0.40505867203076679 38:0.15672458211580911 39:-0.11915536721547444 40:-0.34048091371854144 41:-0.18662667 42:-0.46376848 43:0.062977754 44:-0.4639048 45:0.15059537 46:-0.092401959 47:0.25971705 48:0.0075230338 49:0.0033323055 50:-0.32721618 51:0.19921748 52:0.028093984 53:0.11199475 54:0.16654766 55:-0.083239749 56:0.34423569 57:0.61986649 58:0.013610451 59:-0.0072255651 60:-0.14489049  |EV|
1 |BT| (ROOT (S (NP (PRP We)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (ADJP (JJ low) (, ,) (JJ ineffective)) (NNS doses)) (PP (IN of) (NP (NP (NP (NNP NMDA) (NNP antagonists)) (-LRB- -LRB-) (NP (NP (NP (DT the) (JJ competitive) (NNP NMDA) (NN antagonist)) (ADJP (NP (NNP CGP) (CD 37849) (, ,) (CD 0.3)) (JJ mg/kg))) (: ;) (NP (NP (DT an) (NN antagonist)) (PP (IN of) (NP (DT the) (ADJP (JJ glycineB) (NP-TMP (NP (NNS sites)) (, ,) (NP (NNP L-701) (CD ,324) (, ,) (CD 1)))) (NN mg/kg)))) (: ;) (NP (NP (DT a) (JJ partial) (NN agonist)) (PP (IN of) (NP (NP (NP (DT the) (JJ glycineB) (NNS sites)) (, ,) (NP (NNP D-cycloserine)) (, ,)) (ADJP (CD 2.5) (JJ mg/kg))))) (: ;) (CC and) (NP (NP (DT the) (JJ non-competitive) (NNP NMDA) (NN antagonist) (NN MK-801)) (, ,) (NP (CD 0.05) (NN mg/kg)))) (-RRB- -RRB-)) (VP (VBN administered) (ADVP (RB together)) (PP (IN with) (NP (NP (DT an) (JJ ineffective) (NN dose)) (PP (IN of) (NP (NP (NN magnesium)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-)))))))))) (VP (VBD evoked) (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN percentage)) (PP (IN of) (NP (NP (NN time)) (VP (VBN spent) (PP (IN in) (NP (NP (DT the) (JJ open) (NN arm)) (PP (IN of) (NP (NP (DT the) (NN maze)) (PRN (-LRB- -LRB-) (NP (NP (DT an) (NN index)) (PP (IN of) (NP (NN anxiety)))) (-RRB- -RRB-))))))))))))))) (. .))) |ET| |BV| 21:-0.69870471954345703 22:-0.24796676635742188 23:-0.81360667943954468 24:-0.01056311558932066 25:0.23021408915519714 26:-0.49103528261184692 27:-0.12774047255516052 28:0.32772007584571838 29:-0.10109277069568634 30:0.37758281826972961 31:-0.10246789455413818 32:-0.1783854216337204 33:-0.4138738214969635 34:-0.30004423856735229 35:-0.1044161394238472 36:0.11705338954925537 37:-0.51407170295715332 38:0.68735867738723755 39:0.66774976253509521 40:-0.36981764435768127 41:-0.17929016 42:-0.48915225 43:0.40144381 44:-0.21350884 45:0.66443074 46:-0.099982217 47:-0.44317305 48:-0.63355392 49:0.049792826 50:-0.24860612 51:0.4650588 52:0.26322609 53:0.21710432 54:-0.35157239 55:0.045225006 56:-0.2926738 57:-0.097702369 58:-0.15896466 59:-0.24270134 60:0.22951385  |EV|
1 |BT| (ROOT (S (NP (NP (JJ Many) (ADJP (RB commonly) (JJ used)) (NNS drugs)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN bile) (NN acid) (NNS sequestrants)) (, ,) (NP (JJ ferrous) (NN sulphate)) (, ,) (NP (NN sucralfate)) (, ,) (NP (NN calcium) (NN carbonate)) (, ,) (NP (JJ aluminium-containing) (NNS antacids)) (, ,) (NP (JJ phosphate) (NNS binders)) (, ,) (NP (NN raloxifene)) (CC and) (NP (JJ proton-pump) (NNS inhibitors)))) (, ,)) (VP (VBP have) (ADVP (RB also)) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN levothyroxine))))))))))) (. .))) |ET| |BV| 1:-0.29329422116279602 2:-0.00032358587486669421 3:-0.52397876977920532 4:-0.1497969776391983 5:0.18156200647354126 6:-0.15531416237354279 7:-0.94168329238891602 8:-1.0400300025939941 9:-0.020318012684583664 10:-0.00048563216114416718 11:-0.29679405689239502 12:0.17399097979068756 13:-0.26366597414016724 14:-0.16816861927509308 15:-1.0546118021011353 16:0.86308473348617554 17:-0.27049592137336731 18:-0.4229009747505188 19:0.27473413944244385 20:-0.4172770082950592 21:-0.4291355311870575 22:-1.4204275608062744 23:-0.18450769782066345 24:-0.17486822605133057 25:-0.23320828378200531 26:-0.70937651395797729 27:0.44843989610671997 28:0.076854005455970764 29:-0.28111052513122559 30:0.35369068384170532 31:-0.21005453169345856 32:0.49035081267356873 33:0.23017047345638275 34:-0.28456178307533264 35:-1.3246332406997681 36:0.68069863319396973 37:-0.10216844081878662 38:0.6025090217590332 39:0.58728557825088501 40:0.31180346012115479 41:-0.22720583 42:-0.24226001 43:0.36310989 44:0.66716933 45:0.346138 46:-0.18039674 47:-0.31450996 48:0.1037826 49:0.18795817 50:0.089048557 51:0.70327199 52:0.1130985 53:-0.043622714 54:-0.44350961 55:0.30346686 56:0.45103353 57:-0.10387065 58:0.44122136 59:-0.51673943 60:0.16441642  |EV|
1 |BT| (ROOT (S (NP (PRP It)) (VP (VBD was) (ADVP (RB recently)) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (DT the) (JJ benzoxaborole) (JJ antifungal) (NN compound) (NN AN2690)) (PRN (-LRB- -LRB-) (NP (NN 5-fluoro-1) (CD ,3)) (: -) (NP (NP (JJ dihydro-1-hydroxy-1) (CD ,2)) (: -) (NP (NN benzoxaborole))) (-RRB- -RRB-))) (VP (VBZ inhibits) (NP (NNS LeuRS)) (PP (IN by) (S (VP (VBG forming) (NP (NP (DT a) (JJ covalent) (NN adduct)) (PP (IN with) (NP (DT the) (CD 3) ('' ') (NN adenosine))) (PP (IN of) (NP (NP (NN tRNA)) (PRN (-LRB- -LRB-) (NP (NN leu)) (-RRB- -RRB-))))) (PP (IN at) (NP (DT the) (NN editing) (NN site))) (, ,) (S (ADVP (RB thus)) (VP (VBG locking) (NP (DT the) (NN enzyme)) (PP (IN in) (NP (DT an) (JJ inactive) (NN conformation))))))))))))) (. .))) |ET| |BV| 1:-1.4009562730789185 2:-1.5814769268035889 3:0.49416431784629822 4:0.52210378646850586 5:-0.019844569265842438 6:-1.0101516246795654 7:0.88953322172164917 8:0.38296341896057129 9:0.64190757274627686 10:-0.87704145908355713 11:0.28260985016822815 12:0.91117328405380249 13:0.12393590062856674 14:-0.088209144771099091 15:0.32299581170082092 16:-0.10356184840202332 17:-0.22162216901779175 18:-0.51198089122772217 19:0.65916210412979126 20:-1.2448484897613525 21:-1.4069480895996094 22:-1.0754959583282471 23:0.73630088567733765 24:0.14236891269683838 25:-0.059509687125682831 26:-0.69115632772445679 27:0.2442021369934082 28:0.14046579599380493 29:-0.34585404396057129 30:-0.90413206815719604 31:-0.30341196060180664 32:0.60986959934234619 33:1.0032714605331421 34:0.10490896552801132 35:0.6082313060760498 36:-0.85505229234695435 37:-0.50288063287734985 38:-0.46083354949951172 39:2.1474571228027344 40:-1.322556734085083 41:-0.35740626 42:-0.64486313 43:-0.24115458 44:-0.18268776 45:0.12594779 46:-0.30661178 47:-0.2484213 48:0.033529665 49:0.16844782 50:0.41002226 51:0.19995184 52:-0.034642503 53:-0.11106802 54:-0.16693349 55:0.19326207 56:0.031277787 57:0.059685953 58:0.31206495 59:-0.020300008 60:-0.073638663  |EV|
1 |BT| (ROOT (S (NP (PRP We)) (VP (VBD co-administered) (NP (NN carbidopa)) (PP (IN with) (NP (NN levodopa))) (S (VP (TO to) (VP (VP (VB prevent) (NP (NP (JJ peripheral) (NN synthesis)) (PP (IN of) (NP (ADJP (ADJP (JJ dopamine) (PP (IN from) (NP (NN levodopa)))) (, ,) (CC and) (ADJP (JJ observed) (JJ tactile)) (, ,)) (NN cold))))) (, ,) (CC and) (VP (VB heat) (NP (NP (NN allodynia) (NN pre-administration)) (, ,) (CC and) (ADVP (IN at) (NP (CD 15))) (, ,) (NP (CD 30)) (, ,) (NP (CD 60)) (, ,) (NP (CD 90)) (, ,) (NP (CD 120)) (, ,) (NP (CD 150)) (, ,) (NP (CD 180)) (, ,) (CC and) (NP (CD 240) (NN min))) (PP (IN after) (NP (NN drug) (NN administration)))))))) (. .))) |ET| |BV| 1:0.28785473108291626 2:0.33784043788909912 3:-0.077978126704692841 4:-0.70704013109207153 5:0.86684584617614746 6:-0.37076586484909058 7:-0.067946955561637878 8:-0.2022843062877655 9:0.32697808742523193 10:0.71971499919891357 11:0.19001258909702301 12:-0.033035218715667725 13:-0.073462016880512238 14:-0.11689435690641403 15:-0.00086127908434718847 16:0.72606879472732544 17:-0.16583561897277832 18:0.075561679899692535 19:0.12820369005203247 20:0.77919751405715942 21:-0.64544391632080078 22:-0.4498380720615387 23:-0.34344029426574707 24:-1.209587574005127 25:0.45658329129219055 26:-0.69317513704299927 27:-0.016772545874118805 28:0.045951526612043381 29:0.75048917531967163 30:0.34895226359367371 31:0.028257850557565689 32:-0.40035602450370789 33:0.83469516038894653 34:-0.095092199742794037 35:0.34242990612983704 36:1.5515862703323364 37:-0.044769357889890671 38:0.76400512456893921 39:0.17933918535709381 40:0.63299578428268433 41:0.091936685 42:-0.20212761 43:0.61215627 44:-0.57111537 45:0.53473794 46:-0.52292252 47:0.51268625 48:-0.21048023 49:-0.52308983 50:-0.10698354 51:0.22619526 52:0.80689484 53:-0.63964802 54:-0.4812541 55:0.12798703 56:0.15573078 57:-0.2056195 58:0.20286341 59:-0.11386026 60:0.37224671  |EV|
1 |BT| (ROOT (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NNP Topiramate)) (VP (MD could) (VP (VB prevent) (NP (JJ olanzapine) (JJ induced) (NN weight) (NN gain) (CC and) (JJ adverse) (NN metabolic) (NNS effects))))) (. .))) |ET| |BV| 1:0.13194823265075684 2:0.34916895627975464 3:-0.75300949811935425 4:-0.43338528275489807 5:0.26798152923583984 6:1.1201753616333008 7:0.01382522564381361 8:-0.61208021640777588 9:0.21881662309169769 10:0.52568149566650391 11:0.83086210489273071 12:1.0212095975875854 13:0.50689417123794556 14:0.01392732560634613 15:-0.75837433338165283 16:-0.098990470170974731 17:0.5405307412147522 18:-0.7868351936340332 19:0.38124319911003113 20:0.087259933352470398 21:-0.60522341728210449 22:0.27817165851593018 23:-0.90040552616119385 24:-0.31354764103889465 25:0.31086519360542297 26:-0.032624341547489166 27:-0.59054386615753174 28:-0.83233338594436646 29:1.3101377487182617 30:0.53893619775772095 31:0.28208523988723755 32:0.10082464665174484 33:1.5436033010482788 34:0.41065362095832825 35:0.59445726871490479 36:0.13318267464637756 37:0.30581635236740112 38:-1.0496582984924316 39:0.30787700414657593 40:0.6356998085975647 41:-0.022051398 42:-0.19173475 43:0.27052844 44:0.18240513 45:0.61012048 46:-0.16928996 47:0.067366391 48:-0.25596905 49:-0.0062662228 50:0.030988824 51:-0.11297582 52:0.12557976 53:0.11082303 54:0.45737624 55:-0.093955308 56:0.21011567 57:0.49456543 58:0.046179846 59:-0.18107736 60:0.49071524  |EV|
1 |BT| (ROOT (S (SBAR (IN As) (RB even) (S (NP (NP (DT the) (JJR lower) (NNP OTC) (NN dose)) (PP (IN of) (NP (NP (NN ibuprofen)) (PRN (-LRB- -LRB-) (NP (QP (CD 150) (CD mg))) (-RRB- -RRB-))))) (VP (VBD was) (ADJP (JJ enough) (S (VP (TO to) (VP (VB affect) (NP (NP (DT the) (JJ antiplatelet) (NN effect)) (PP (IN of) (NP (NN aspirin))))))))))) (, ,) (NP (NN health) (NNS professionals)) (VP (MD should) (VP (VB take) (PP (IN into) (NP (NN account) (NNS patients))))))) |ET| |BV| 1:-0.45031630992889404 2:0.15654109418392181 3:-0.1405574232339859 4:0.57517284154891968 5:0.19980970025062561 6:-0.0032609140034765005 7:-0.33045914769172668 8:-0.79845482110977173 9:0.21623410284519196 10:-0.19117653369903564 11:-0.26789900660514832 12:0.13184972107410431 13:0.56898230314254761 14:-0.53675496578216553 15:-0.2580471932888031 16:0.65332514047622681 17:-0.48971584439277649 18:-0.86091041564941406 19:0.14939133822917938 20:-0.010001880116760731 21:0.2490612119436264 22:-0.99049872159957886 23:-0.41239464282989502 24:-0.044612977653741837 25:0.39299872517585754 26:0.28446468710899353 27:0.3846886157989502 28:-0.28248655796051025 29:0.67045301198959351 30:0.5261768102645874 31:-0.22174780070781708 32:0.23442170023918152 33:-0.71098858118057251 34:-0.73123657703399658 35:-0.32787027955055237 36:0.053887158632278442 37:0.38661277294158936 38:0.071346871554851532 39:0.66734158992767334 40:0.3804037868976593 41:-0.0093137976 42:0.018462202 43:0.015216661 44:-0.024045145 45:0.0070015639 46:0.010395795 47:0.019300697 48:-0.017343938 49:-0.010206613 50:0.012936257 51:-0.02208625 52:-0.0040375357 53:-0.01831731 54:-0.016737947 55:0.016575975 56:0.016731003 57:0.0043863808 58:-0.010104505 59:0.0094967494 60:-0.0042639249  |EV|
1 |BT| (ROOT (S (PP (IN In) (NP (NN conclusion))) (NP (PRP$ our) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (NP (NN morphine)) (PP (IN with) (NP (NN buspirone)))))) (VP (MD may) (VP (VB produce) (NP (NP (JJ good) (NN cancer) (NN pain) (NN control) (CC and) (NN attenuate) (NN development)) (PP (IN of) (NP (NN tolerance))))))))) (. .))) |ET| |BV| 1:-0.49507847428321838 2:-0.71530449390411377 3:-0.77657246589660645 4:-0.1343672126531601 5:1.016160249710083 6:-1.4441125392913818 7:-0.52347862720489502 8:-1.493584156036377 9:0.88833487033843994 10:0.65763008594512939 11:0.19560350477695465 12:0.40116825699806213 13:0.060763649642467499 14:-0.23411643505096436 15:0.47297179698944092 16:0.41687619686126709 17:0.52853536605834961 18:-0.12988424301147461 19:0.21823957562446594 20:-0.31002545356750488 21:-0.45263946056365967 22:-0.44811126589775085 23:-0.40243950486183167 24:-0.3595319390296936 25:0.29140186309814453 26:-0.3102668821811676 27:-0.16002285480499268 28:0.027013452723622322 29:0.46951276063919067 30:0.70688903331756592 31:0.51139503717422485 32:-0.31645745038986206 33:0.28384193778038025 34:-0.14880067110061646 35:-0.087615728378295898 36:-0.37213057279586792 37:0.33573028445243835 38:0.14914470911026001 39:-0.28276950120925903 40:0.36941593885421753 41:0.091693901 42:0.32548028 43:0.43764916 44:0.51747513 45:0.19535899 46:0.027892163 47:-0.19995555 48:-0.36302069 49:-0.068299182 50:0.0079165641 51:-0.018338172 52:0.47815737 53:0.38058698 54:0.35721511 55:0.019564636 56:0.14336304 57:-0.13666575 58:-0.10139389 59:-0.71600759 60:0.21857794  |EV|
1 |BT| (ROOT (S (ADVP (RB Therefore)) (, ,) (NP (NNS clinicians)) (VP (MD should) (VP (VB be) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT the) (ADJP (RB potentially) (JJ severe)) (JJ adverse) (NNS reactions)) (SBAR (WHNP (WDT that)) (S (VP (MD might) (VP (VB occur) (PP (IN during) (NP (JJ concomitant) (NN treatment))) (PP (IN with) (NP (NN fluvoxamine) (CC and) (NN topiramate)))))))))))) (. .))) |ET| |BV| 1:-0.40733423829078674 2:0.088755883276462555 3:0.10718788206577301 4:0.013866343535482883 5:1.355576753616333 6:0.27399253845214844 7:0.034641779959201813 8:-0.61042720079421997 9:0.84492230415344238 10:1.2903488874435425 11:-0.54146254062652588 12:0.10418819636106491 13:0.42105644941329956 14:-0.4151419997215271 15:0.24828852713108063 16:0.62464570999145508 17:0.32119452953338623 18:-0.51380950212478638 19:0.29288890957832336 20:0.75004053115844727 21:-0.60522341728210449 22:0.27817165851593018 23:-0.90040552616119385 24:-0.31354764103889465 25:0.31086519360542297 26:-0.032624341547489166 27:-0.59054386615753174 28:-0.83233338594436646 29:1.3101377487182617 30:0.53893619775772095 31:0.28208523988723755 32:0.10082464665174484 33:1.5436033010482788 34:0.41065362095832825 35:0.59445726871490479 36:0.13318267464637756 37:0.30581635236740112 38:-1.0496582984924316 39:0.30787700414657593 40:0.6356998085975647 41:0.033959888 42:0.027510187 43:0.32678607 44:0.22634886 45:0.2587229 46:-0.077155985 47:0.068695538 48:-0.2624152 49:0.17027704 50:0.05064458 51:0.1582194 52:-0.51965088 53:-0.40854359 54:0.26124856 55:0.27135313 56:0.064434551 57:0.5344246 58:0.24181905 59:0.085832022 60:0.21217079  |EV|
1 |BT| (ROOT (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (NN memantine)) (VP (VBZ blocks) (NP (NP (JJ extrasynaptic) (JJ NMDAR-mediated) (NNS currents)) (VP (VBN induced) (PP (IN by) (NP (NP (NN bath) (NN application)) (PP (IN of) (NP (CD 100) (JJ microM) (NNP NMDA/10) (NN microM) (NN glycine))))) (PP (IN with) (NP (NP (DT a) (ADJP (RB twofold) (JJR higher)) (NN potency)) (PP (IN than) (NP (NP (PRP$ its) (NN blockade)) (PP (IN of) (NP (NP (DT the) (JJ NMDAR) (NN component)) (PP (IN of) (NP (NP (NP (JJ evoked) (NNS EPSCs)) (-LRB- -LRB-) (NP (NNP EPSCs)) (PRN (-LRB- -LRB-) (NP (NNP NMDAR)) (-RRB- -RRB-)) (-RRB- -RRB-)) (: ;) (S (NP (DT this) (NN effect)) (VP (VBZ persists) (PP (IN under) (NP (NP (NNS conditions)) (PP (IN of) (NP (JJ pathological) (NN depolarization))))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (CD 1) (NN mm) (NN extracellular) (NNS Mg))))))))))))) (PRN (-LRB- -LRB-) (NP (QP (CD 2) (CD +))) (-RRB- -RRB-)))))))))) (. .))) |ET| |BV| 1:0.037619635462760925 2:-1.3707722425460815 3:-0.78813481330871582 4:0.11216473579406738 5:-0.087420791387557983 6:0.39344969391822815 7:0.66902333498001099 8:-0.39446058869361877 9:0.60788220167160034 10:1.2609564065933228 11:0.59104782342910767 12:0.54957419633865356 13:-0.17848747968673706 14:-0.89857041835784912 15:-0.0059450156986713409 16:0.21829332411289215 17:-0.33531233668327332 18:-0.43005263805389404 19:0.40840953588485718 20:-0.71890801191329956 21:-1.2198920249938965 22:0.22954350709915161 23:0.34183743596076965 24:-0.32787293195724487 25:-0.34051555395126343 26:-0.81820976734161377 27:1.095084547996521 28:0.30548694729804993 29:0.53864842653274536 30:-0.17523771524429321 31:0.33607840538024902 32:0.44189682602882385 33:0.075850948691368103 34:0.20910802483558655 35:-1.0593968629837036 36:0.53212761878967285 37:-0.25781393051147461 38:-0.43844366073608398 39:1.0987780094146729 40:-0.21287421882152557 41:-0.24275327 42:0.23940989 43:0.16326427 44:-0.68348515 45:-0.45819315 46:-0.7039308 47:0.064832881 48:-0.44956934 49:-0.080455489 50:-0.076916426 51:0.58827525 52:-0.026850931 53:0.30010059 54:-0.070069924 55:-0.47175941 56:0.3185094 57:-0.036001243 58:0.034302302 59:0.0715013 60:0.070368357  |EV|
1 |BT| (ROOT (FRAG (NP (NNP CONCLUSION)) (: :) (S (NP (NNP Caudal)) (VP (VBP clonidine) (PP (IN at) (NP (NP (DT a) (JJR lower) (NN dose)) (-LRB- -LRB-) (NP (CD 1) (NN µg)) (ADVP (RB kg)))))) (. ?))) |ET| |BV| 1:-0.34696581959724426 2:-0.0097431344911456108 3:-0.23105962574481964 4:-0.50302809476852417 5:-0.020926365628838539 6:0.28707119822502136 7:-0.03687683492898941 8:-0.00093980529345571995 9:0.57171630859375 10:-0.061133615672588348 11:0.55941510200500488 12:-0.38323381543159485 13:0.034318916499614716 14:-0.24120934307575226 15:-0.67039000988006592 16:0.42504683136940002 17:0.50754982233047485 18:0.30065628886222839 19:-0.016009297221899033 20:-0.086647823452949524 21:-0.51583421230316162 22:-0.15732002258300781 23:-0.6730111837387085 24:-0.94175428152084351 25:0.24679912626743317 26:-0.6743507981300354 27:-0.21775585412979126 28:0.045891992747783661 29:-0.18093675374984741 30:0.41452351212501526 31:-0.35863405466079712 32:0.27835530042648315 33:0.19278877973556519 34:-1.1857702732086182 35:0.0078831156715750694 36:0.32769522070884705 37:0.64750874042510986 38:0.40576273202896118 39:-0.44038063287734985 40:-0.45647451281547546 41:-0.10761163 42:-0.054392014 43:-0.15049385 44:0.070999056 45:0.14322309 46:-0.05423969 47:-0.65809071 48:-0.40447691 49:0.058322854 50:0.066104859 51:-0.31503156 52:0.095424451 53:-0.13669065 54:0.41309538 55:-0.45929831 56:0.10554063 57:0.60425711 58:0.19599248 59:0.054755546 60:-0.069189131  |EV|
1 |BT| (ROOT (FRAG (NP (NNP CONCLUSION)) (: :) (S (NP (NP (JJ Intraoperative) (NN reversal)) (PP (IN of) (NP (NP (JJ shallow) (JJ rocuronium-induced) (NN block)) (PP (IN with) (NP (DT either) (NN sugammadex) (CC or) (NN neostigmine)))))) (VP (VBZ is) (NP (DT an) (JJ efficient) (NN method)))) (. .))) |ET| |BV| 1:-0.73282301425933838 2:-0.62496715784072876 3:-0.55196630954742432 4:-0.59960639476776123 5:0.041034616529941559 6:-0.34943714737892151 7:0.12115459144115448 8:0.74872982501983643 9:0.71173536777496338 10:-0.54305732250213623 11:0.92430597543716431 12:-0.20378845930099487 13:0.71527504920959473 14:-0.89005416631698608 15:-1.0758097171783447 16:1.0591765642166138 17:-0.083953075110912323 18:0.84651631116867065 19:-0.49481835961341858 20:-0.20741775631904602 21:-0.28035849332809448 22:-0.66492360830307007 23:-1.4868038892745972 24:-1.2775158882141113 25:-0.98333829641342163 26:-0.078630149364471436 27:-0.38102743029594421 28:0.35317224264144897 29:0.38730725646018982 30:1.2455751895904541 31:-1.1416823863983154 32:1.3641848564147949 33:-0.38747262954711914 34:-0.81455057859420776 35:1.2371265888214111 36:0.3230431079864502 37:-0.1005539745092392 38:0.5543944239616394 39:-0.33715426921844482 40:0.62531954050064087 41:-0.1911501 42:-0.064142168 43:0.080318287 44:0.12172906 45:-0.0679444 46:-0.38642785 47:-0.075485706 48:-0.39173815 49:0.082309857 50:0.20881766 51:-0.16660972 52:0.054589316 53:-0.11797197 54:-0.20701867 55:-0.43976885 56:-0.010314 57:0.05650153 58:-0.13493067 59:-0.6235109 60:0.018977882  |EV|
1 |BT| (ROOT (NP (NP (NNP CONCLUSIONS) (CC AND) (NNP CLINICAL) (NNP RELEVANCE)) (: :) (S (NP (NNS Results)) (VP (VBD indicated) (SBAR (S (NP (NNP GFR)) (VP (VBD decreased) (PP (IN after) (NP (NP (CD 8) (NNS days)) (PP (IN of) (NP (NP (NP (JJ concurrent) (NN administration)) (PP (IN of) (NP (NN furosemide) (CC and) (NN carprofen)))) (CC or) (ADJP (JJ furosemide) (CC and) (JJ etodolac)))))) (PP (TO to) (NP (NNS dogs)))))))) (. .))) |ET| |BV| 1:-0.35126665234565735 2:-0.35966041684150696 3:-1.299602746963501 4:0.33869659900665283 5:0.57237958908081055 6:-0.45514419674873352 7:0.61909174919128418 8:-0.39228793978691101 9:-0.39884531497955322 10:0.13205176591873169 11:0.36984586715698242 12:-0.12144777923822403 13:0.32529017329216003 14:-1.1934534311294556 15:-0.072098195552825928 16:-0.35082137584686279 17:-0.55683654546737671 18:-0.31578785181045532 19:0.44719502329826355 20:-0.57014626264572144 21:-0.4842107892036438 22:-1.1287499666213989 23:-2.0836501121520996 24:0.35519877076148987 25:0.39339938759803772 26:0.15301744639873505 27:0.23268714547157288 28:-1.1000103950500488 29:0.2058558464050293 30:-0.054519765079021454 31:0.70638853311538696 32:-0.60043603181838989 33:-0.18472500145435333 34:-1.0133271217346191 35:-0.40158906579017639 36:-0.65332186222076416 37:0.25478646159172058 38:-0.44143196940422058 39:-0.0095129134133458138 40:-0.5165097713470459 41:-0.13787584 42:0.22905584 43:0.11288229 44:0.26910439 45:-0.012605 46:-0.13184425 47:-0.19608331 48:-0.19864675 49:-0.34608155 50:0.47461173 51:0.15770796 52:-0.27253968 53:0.18563646 54:0.085415475 55:0.048456632 56:-0.093080647 57:-0.24917749 58:0.16052054 59:-0.79285282 60:-0.082639083  |EV|
1 |BT| (ROOT (S (NP (PRP We)) (VP (VBP find) (SBAR (IN that) (S (NP (NP (JJ microtubule) (NN depolymerization)) (PP (IN in) (NP (NP (DT the) (NNP SCN)) (VP (VBG using) (ADJP (DT either) (JJ Colcemid) (CC or) (JJ nocodazole)))))) (VP (VBZ enhances) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (CD 10) (JJ pm) (NN melatonin) (S (VP (TO to) (VP (VB phase-shift) (NP (NP (DT the) (NN activity) (NNS rhythms)) (PP (IN of) (NP (DT the) (NNP Long) (NNP Evans) (NN rat)))))))))))))) (. .))) |ET| |BV| 1:-0.41765859723091125 2:-0.68634277582168579 3:-0.59409254789352417 4:0.4222644567489624 5:0.10007560253143311 6:-0.37648990750312805 7:-0.22770603001117706 8:0.20558573305606842 9:0.65462660789489746 10:0.6435583233833313 11:0.83729344606399536 12:-0.063424356281757355 13:0.33500063419342041 14:0.31329020857810974 15:0.52702087163925171 16:-0.65230077505111694 17:-0.26013901829719543 18:0.57008057832717896 19:-0.13120672106742859 20:0.10561328381299973 21:0.14181807637214661 22:-2.4269382953643799 23:-0.84405088424682617 24:-0.53943479061126709 25:-0.42466804385185242 26:-0.82872939109802246 27:-0.44055548310279846 28:0.02221028134226799 29:1.0151965618133545 30:0.39334690570831299 31:0.96631979942321777 32:-0.2554493248462677 33:0.15719510614871979 34:0.36114248633384705 35:-0.482736736536026 36:0.19398429989814758 37:-1.0067675113677979 38:0.58725923299789429 39:-1.1392194032669067 40:-0.81571042537689209 41:-0.49851003 42:0.017982302 43:0.20432484 44:0.37905493 45:-0.06482134 46:-0.14704335 47:0.41416767 48:-0.079732224 49:-0.077219173 50:0.23643932 51:0.76747173 52:0.017314436 53:0.38471863 54:-0.11618458 55:-0.11766621 56:0.22682501 57:-0.2027905 58:0.0084129274 59:-0.34750932 60:-0.25483564  |EV|
1 |BT| (ROOT (S (S (NP (DT This) (NN study)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (DT the) (JJ haloperidol-induced) (JJ interoceptive) (NN drug) (NN state)) (VP (VBZ is) (ADJP (RB directly) (VBN involved) (PP (IN in) (NP (PRP$ its) (JJ antiavoidance) (NN action))))))))) (, ,) (CC and) (S (NP (NN chlordiazepoxide)) (VP (MD may) (VP (VB attenuate) (NP (NP (DT the) (JJ antiavoidance) (NN efficacy)) (PP (IN of) (NP (NP (NNS antipsychotics)) (PRN (-LRB- -LRB-) (ADJP (RB especially) (JJ olanzapine)) (-RRB- -RRB-)))))))) (. .))) |ET| |BV| 1:0.13194823265075684 2:0.34916895627975464 3:-0.75300949811935425 4:-0.43338528275489807 5:0.26798152923583984 6:1.1201753616333008 7:0.01382522564381361 8:-0.61208021640777588 9:0.21881662309169769 10:0.52568149566650391 11:0.83086210489273071 12:1.0212095975875854 13:0.50689417123794556 14:0.01392732560634613 15:-0.75837433338165283 16:-0.098990470170974731 17:0.5405307412147522 18:-0.7868351936340332 19:0.38124319911003113 20:0.087259933352470398 21:-1.1399068832397461 22:-0.051731899380683899 23:-1.3472412824630737 24:-0.11247903108596802 25:0.35895267128944397 26:-0.78500241041183472 27:-1.8944214582443237 28:0.49661213159561157 29:1.838792085647583 30:0.36294636130332947 31:-0.65767848491668701 32:0.029336947947740555 33:0.013183736242353916 34:0.34426984190940857 35:-0.32096600532531738 36:-0.17584007978439331 37:0.018173908814787865 38:0.39964738488197327 39:0.34451034665107727 40:0.53582203388214111 41:0.3678374 42:-0.13182457 43:-0.058484748 44:-0.61339414 45:0.31494701 46:0.1335351 47:-0.081001848 48:0.12900026 49:0.11893929 50:0.61827773 51:-0.32562399 52:-0.058520108 53:-0.0079880757 54:0.026817579 55:0.30697981 56:0.39717978 57:-0.047811665 58:-0.16747265 59:0.13505782 60:0.18526416  |EV|
1 |BT| (ROOT (S (NP (DT These) (NNS results)) (VP (VBP are) (PP (IN in) (NP (NN contrast))) (PP (TO to) (NP (JJ previous) (NNS reports))) (SBAR (IN that) (S (NP (DT the) (JJ sulfonamide-based) (NNP ERA) (NN bosentan)) (VP (MD can) (VP (VB cause) (NP (JJ marked) (NNS decreases)) (PP (IN in) (NP (NP (DT the) (NN exposure)) (PP (IN of) (NP (NN tadalafil)))))))))) (. .))) |ET| |BV| 1:-0.9487273097038269 2:0.92150312662124634 3:-1.3880236148834229 4:0.062727883458137512 5:-0.43740385770797729 6:-0.72818338871002197 7:-0.27547451853752136 8:0.23511835932731628 9:0.80953073501586914 10:0.5146602988243103 11:-0.50171864032745361 12:0.33801734447479248 13:1.3743784427642822 14:0.23980531096458435 15:0.0043691010214388371 16:0.088416725397109985 17:1.211998462677002 18:0.71767830848693848 19:0.20200036466121674 20:0.080322585999965668 21:-0.66392791271209717 22:0.17296601831912994 23:-1.9547040462493896 24:0.12645058333873749 25:0.51305586099624634 26:-0.52545052766799927 27:-0.43873226642608643 28:0.12440299987792969 29:0.66505593061447144 30:0.60883855819702148 31:-0.21927803754806519 32:1.009028434753418 33:1.8023819923400879 34:1.2283170223236084 35:0.47323548793792725 36:0.86399060487747192 37:-0.54214644432067871 38:0.044938117265701294 39:-0.063308112323284149 40:0.55163604021072388 41:-0.059625588 42:0.13267758 43:-0.28590429 44:0.36782923 45:0.4363713 46:0.051295076 47:0.28762883 48:0.45142454 49:-0.72979832 50:0.60670763 51:-0.11368788 52:0.11871683 53:0.49273792 54:-0.026877282 55:0.22425406 56:0.24237001 57:0.30429631 58:0.22445272 59:-0.20453891 60:-0.15003856  |EV|
1 |BT| (ROOT (S (PP (IN In) (NP (NN rat) (NNS synaptosomes))) (, ,) (NP (NN nomifensine)) (VP (VBD reduced) (NP (NP (DT the) (NN potency)) (PP (IN of) (NP (NN amphetamine)))) (S (VP (TO to) (VP (VB induce) (S (NP (NNP DA)) (VP (VB release) (ADJP (RB approximately) (JJ 270-fold))))))) (, ,) (S (ADVP (RB potentially)) (VP (VBG explaining) (NP (PRP$ its) (NN action)) (PP (IN in) (S (VP (VBG ameliorating) (NP (JJ amphetamine-induced) (NN RHS)))))))) (. .))) |ET| |BV| 1:-1.4352881908416748 2:0.23550102114677429 3:0.28739452362060547 4:-1.6928144693374634 5:-0.10965687781572342 6:-0.60174739360809326 7:0.74265700578689575 8:-0.91238713264465332 9:0.85570979118347168 10:0.39382100105285645 11:0.48118779063224792 12:-0.74184155464172363 13:1.2862356901168823 14:-0.52537065744400024 15:0.68416064977645874 16:0.93611735105514526 17:0.49343380331993103 18:0.52505773305892944 19:-0.21933048963546753 20:1.0926527976989746 21:-0.51009583473205566 22:-0.56838345527648926 23:0.018959643319249153 24:-0.8073391318321228 25:-0.028113126754760742 26:-0.51623201370239258 27:0.14834246039390564 28:-0.50347131490707397 29:0.91042083501815796 30:0.16682194173336029 31:0.37457370758056641 32:-0.095307551324367523 33:0.23110786080360413 34:-0.50809144973754883 35:-0.55485570430755615 36:-0.40123346447944641 37:0.6509438157081604 38:-0.029162149876356125 39:0.42906674742698669 40:1.1775617599487305 41:-0.21981847 42:0.34176943 43:0.55518115 44:-0.068571247 45:-0.021594889 46:-0.54393959 47:0.28206936 48:-0.19955233 49:-0.44449496 50:0.40461808 51:0.42225054 52:-0.26546428 53:0.12369771 54:-0.34355894 55:-0.34539044 56:-0.1203175 57:0.19918683 58:0.15975019 59:-0.31186643 60:0.10940905  |EV|
1 |BT| (ROOT (S (NP (NNP Naltrexone)) (VP (VBD was) (VP (VBN given) (S (VP (TO to) (VP (VB block) (NP (NP (DT the) (JJ opioid) (NNS effects)) (PP (IN of) (NP (NN fentanyl))))))))) (. .))) |ET| |BV| 1:-0.27463066577911377 2:-0.91500186920166016 3:-0.21062798798084259 4:-0.80729401111602783 5:0.75264245271682739 6:-0.25265708565711975 7:0.50812238454818726 8:0.2077176421880722 9:0.7118074893951416 10:0.9222419261932373 11:0.66304022073745728 12:0.29768577218055725 13:0.93442696332931519 14:-0.63969117403030396 15:-0.16151165962219238 16:0.83217006921768188 17:-0.069254249334335327 18:-0.27093815803527832 19:0.50270307064056396 20:-0.3701116144657135 21:-0.59656029939651489 22:-0.6017303466796875 23:-0.56371450424194336 24:-0.7424049973487854 25:0.11047245562076569 26:-0.63334363698959351 27:-0.39095228910446167 28:-0.11231482774019241 29:0.080785229802131653 30:0.339478999376297 31:0.24232865869998932 32:-0.48895210027694702 33:0.044322166591882706 34:-0.77776569128036499 35:-0.32153224945068359 36:0.49588650465011597 37:0.62831389904022217 38:-0.01203435193747282 39:-0.66721820831298828 40:-1.0869570970535278 41:0.042391594 42:-0.087760322 43:0.21589287 44:-0.41139197 45:0.39889482 46:-0.0051261294 47:0.20188522 48:-0.16193476 49:-0.25689802 50:0.11044021 51:-0.16737477 52:0.14578173 53:0.034244936 54:0.060563523 55:-0.15279594 56:-0.013212064 57:-0.074377649 58:-0.049110953 59:-0.17898455 60:0.091567568  |EV|
1 |BT| (ROOT (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN nalbuphine)) (VP (VBZ attenuates) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN sensitization)))) (PP (TO to) (NP (NP (DT the) (JJ behavioral) (NNS effects)) (PP (IN of) (NP (NN cocaine))))))))) (. .))) |ET| |BV| 1:0.04645971953868866 2:-0.24341200292110443 3:-0.12847506999969482 4:-0.020735494792461395 5:0.046708986163139343 6:-0.63118833303451538 7:-0.37865597009658813 8:-0.7709348201751709 9:0.74587637186050415 10:-0.46059706807136536 11:0.0066282842308282852 12:-0.22267381846904755 13:-0.17692463099956512 14:-0.36518228054046631 15:-0.20190101861953735 16:0.29322820901870728 17:-0.080923497676849365 18:-0.1887049674987793 19:0.15922586619853973 20:0.54918378591537476 21:0.63292616605758667 22:-0.50982552766799927 23:-0.2564292848110199 24:-0.45443999767303467 25:-0.97684413194656372 26:0.11316805332899094 27:-0.59628713130950928 28:-0.051975127309560776 29:1.1963232755661011 30:0.4543575644493103 31:-0.31040188670158386 32:-0.37512558698654175 33:0.60222887992858887 34:0.99032032489776611 35:1.4206415414810181 36:0.12770959734916687 37:1.2034941911697388 38:0.71748310327529907 39:0.3982965350151062 40:0.54056239128112793 41:-0.18912211 42:-0.29835558 43:0.10612609 44:-0.1124513 45:0.25890234 46:-0.18938741 47:0.07281708 48:-0.19818535 49:-0.021192284 50:0.075320274 51:0.091683634 52:0.037943937 53:0.23385087 54:0.01202534 55:0.037880037 56:0.15107051 57:0.33303729 58:-0.057089638 59:0.077604711 60:0.035212219  |EV|
1 |BT| (ROOT (S (NP (NP (DT The) (NNP MT-Mla)) (CC and) (NP (DT the) (NNP M) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (NN antagonist) (NN pirenzepine))) (VP (VBD caused) (NP (NP (DT a) (JJ dose-dependent) (NN block)) (PP (IN on) (NP (JJ total) (NNS -LSB-))) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (NP (NP (NNP H) (NNP -RSB-) (JJ inositol) (NN phosphate) (NN accumulation)) (VP (VBN induced) (PP (IN by) (NP (NN carbachol))))))) (. .))) |ET| |BV| 1:-0.26564446091651917 2:0.68711233139038086 3:0.55531096458435059 4:-0.70251047611236572 5:0.95914065837860107 6:0.12103314697742462 7:1.191569447517395 8:0.85151487588882446 9:0.68055474758148193 10:-1.1901578903198242 11:1.6873424053192139 12:0.45639500021934509 13:1.5573532581329346 14:-0.83339327573776245 15:-0.90944850444793701 16:-0.22246953845024109 17:0.07259533554315567 18:0.24501639604568481 19:0.58629965782165527 20:-0.17568555474281311 21:-0.65054059028625488 22:-0.21124956011772156 23:0.1713319718837738 24:-0.061776194721460342 25:-0.37753146886825562 26:-0.68113249540328979 27:0.42972558736801147 28:-0.13692034780979156 29:0.10174468904733658 30:-0.5491376519203186 31:0.49487802386283875 32:-0.13535900413990021 33:-0.27002528309822083 34:-0.52904796600341797 35:-0.31652325391769409 36:0.14843516051769257 37:0.20821590721607208 38:0.50349724292755127 39:0.40614330768585205 40:0.028209950774908066 41:-0.058400705 42:-0.71117145 43:-0.032866087 44:-0.25871566 45:0.47847918 46:-0.43941694 47:0.23059464 48:-0.15433836 49:-0.49508977 50:-0.19659707 51:0.14736114 52:-0.24759406 53:-0.17827643 54:-0.38701552 55:-0.35679951 56:0.39569595 57:0.56317908 58:0.19726054 59:0.22538692 60:0.33765104  |EV|
1 |BT| (ROOT (S (SBAR (IN Because) (S (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN gliclazide)) (PP (IN with) (NP (NP (NN provastatin) (CC and) (NN gemfibrozil)) (PP (IN in) (NP (NN diabetes)))))))) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NNS atherosclerosis))))))) (, ,) (NP (PRP it)) (VP (MD should) (VP (VB be) (VP (VBN contraindicated) (CC or) (VBN used) (PP (IN with) (NP (NN caution)))))) (. .))) |ET| |BV| 1:-0.64380204677581787 2:-0.0097835715860128403 3:-0.56415754556655884 4:0.66292428970336914 5:0.92432618141174316 6:1.6463505029678345 7:-1.1863611936569214 8:-1.2141163349151611 9:-0.026554083451628685 10:0.15865059196949005 11:0.42958202958106995 12:0.72791224718093872 13:0.71058088541030884 14:-0.80931681394577026 15:-0.10776295512914658 16:0.25698867440223694 17:-1.2558001279830933 18:-0.19377107918262482 19:1.4803428649902344 20:0.24702319502830505 21:-0.56941640377044678 22:-0.5343976616859436 23:-0.26903682947158813 24:1.1534308195114136 25:1.0153744220733643 26:0.27208283543586731 27:-0.18659815192222595 28:-0.41079744696617126 29:-0.03707050159573555 30:0.2595733106136322 31:-0.37007790803909302 32:0.035759489983320236 33:0.28977155685424805 34:-0.53668117523193359 35:-1.1458126306533813 36:0.43316948413848877 37:-0.36870491504669189 38:-0.41678375005722046 39:0.63722699880599976 40:-0.06421913206577301 41:-0.31541291 42:-0.11154027 43:0.082977079 44:0.088117301 45:-0.21187115 46:-0.33728549 47:-0.16462645 48:-0.65265858 49:-0.14764537 50:0.031930529 51:0.29476666 52:0.45563793 53:-0.092066631 54:-0.047118578 55:0.14745778 56:0.20787767 57:0.66203606 58:-0.142664 59:0.048430484 60:-0.65778691  |EV|
1 |BT| (ROOT (S (NP (NP (NNS Suggestions)) (PP (IN for) (NP (JJ clinical) (NNS trials)))) (VP (VBP are) (VP (VBN provided) (PP (IN for) (NP (NP (NP (JJ oral) (JJ high-dose) (NN dextromethorphan)) (CC and) (NP (NNP Nuedexta))) (PRN (-LRB- -LRB-) (NP (NP (NN dextromethorphan)) (VP (VBN combined) (PP (IN with) (NP (NN quinidine))) (S (VP (TO to) (VP (VB block) (NP (NN metabolism)) (PP (TO to) (NP (NN dextrorphan)))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG increasing) (NP (JJ dextromethorphan) (NN plasma) (NNS concentrations)))))) (-RRB- -RRB-)))))) (. .))) |ET| |BV| 1:-1.170772910118103 2:0.012263765558600426 3:-0.84103411436080933 4:-0.76736891269683838 5:0.44781982898712158 6:-0.33082962036132812 7:1.1540477275848389 8:0.75352329015731812 9:0.52853262424468994 10:-0.61968284845352173 11:-0.39778149127960205 12:0.53033822774887085 13:1.3973336219787598 14:-1.0261740684509277 15:0.025873467326164246 16:0.64448970556259155 17:0.70441997051239014 18:-0.43234246969223022 19:1.775422215461731 20:-0.80212050676345825 21:-1.0970408916473389 22:0.24929289519786835 23:-0.47835975885391235 24:-0.75830763578414917 25:0.21095426380634308 26:-0.51516789197921753 27:0.80864804983139038 28:-0.71112650632858276 29:0.2655874490737915 30:0.61124283075332642 31:0.57490146160125732 32:-0.90374875068664551 33:0.90670895576477051 34:-0.12755760550498962 35:-0.79162865877151489 36:-0.1532624214887619 37:0.75029796361923218 38:-0.83412212133407593 39:0.74893879890441895 40:-0.039337046444416046 41:0.25539193 42:-0.26039508 43:0.009961904 44:-0.085021324 45:0.019663984 46:0.077245846 47:-0.38111502 48:-0.58264321 49:0.089632101 50:-0.21255884 51:-0.070178941 52:-0.11987563 53:-0.0622679 54:-0.16256726 55:0.39346334 56:0.42196533 57:-0.33701015 58:0.02348353 59:0.031497933 60:0.00622425  |EV|
1 |BT| (ROOT (FRAG (NP (NNP CONCLUSION)) (: :) (S (S (NP (NNP Nicotine)) (VP (VBZ enhances) (NP (NP (DT the) (NN migration) (CC and) (NN invasion)) (PP (IN of) (NP (DT the) (JJ esophageal) (NNS squamous) (NN carcinoma) (NN cell) (NN line)))))) (, ,) (CC and) (S (NP (NN nimesulide)) (ADVP (RB partly)) (VP (VBZ blocks) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ nicotine-enhanced) (ADJP (JJ esophageal) (JJ squamous)) (NN carcinoma) (NN cell) (NN migration)) (CC and) (NP (NN invasion)))))))) (. .))) |ET| |BV| 1:-0.31161078810691833 2:-0.36281344294548035 3:0.18907669186592102 4:0.0857047438621521 5:-0.025418208912014961 6:-0.14755964279174805 7:0.024619143456220627 8:-0.21351070702075958 9:1.1228067874908447 10:0.19449490308761597 11:0.71831655502319336 12:-0.6476479172706604 13:-0.32324349880218506 14:-0.11913424730300903 15:-0.39324352145195007 16:1.1804386377334595 17:0.10067534446716309 18:0.44076952338218689 19:-0.16835710406303406 20:0.32567781209945679 21:-0.60680347681045532 22:-0.42775237560272217 23:0.61553919315338135 24:-0.26859995722770691 25:1.1707162857055664 26:1.5227533578872681 27:0.65517157316207886 28:0.3797890841960907 29:1.1509615182876587 30:-0.42484179139137268 31:-1.1956305503845215 32:0.59127140045166016 33:0.23279979825019836 34:0.30807802081108093 35:-0.51293838024139404 36:0.95876044034957886 37:-0.11718957871198654 38:-0.72043502330780029 39:0.26086607575416565 40:0.47095519304275513 41:-0.091401286 42:-0.20811839 43:-0.23443471 44:-0.11267611 45:0.064704627 46:0.10087411 47:0.0054497705 48:-0.32332611 49:-0.13627668 50:0.78882611 51:0.446859 52:0.35039237 53:-0.16746172 54:-0.1468253 55:-0.084831379 56:0.073958255 57:-0.25757048 58:-0.23169948 59:0.27435941 60:0.025395276  |EV|
1 |BT| (ROOT (S (ADVP (RB Also)) (, ,) (S (NP (NN starch)) (ADVP (RB unexpectedly)) (VP (VBN conditioned) (NP (DT the) (JJR stronger) (NN flavor) (NN preference)) (, ,) (SBAR (IN although) (S (NP (DT this)) (VP (MD can) (VP (VB be) (VP (VBN explained) (PP (IN by) (NP (NP (DT the) (NN differential) (NN post-oral)) (VP (VBG reinforcing) (NP (NP (NNS actions)) (PP (IN of) (NP (NN starch) (CC and) (NN sucrose)))))))))))))) (, ,) (CC and) (S (NP (NN naltrexone)) (VP (VBD blocked) (NP (NP (NP (DT the) (NN expression)) (, ,) (CONJP (CC but) (RB not)) (NP (DT the) (NN acquisition)) (, ,)) (PP (IN of) (NP (DT this) (NN preference)))))) (. .))) |ET| |BV| 1:-0.27463066577911377 2:-0.91500186920166016 3:-0.21062798798084259 4:-0.80729401111602783 5:0.75264245271682739 6:-0.25265708565711975 7:0.50812238454818726 8:0.2077176421880722 9:0.7118074893951416 10:0.9222419261932373 11:0.66304022073745728 12:0.29768577218055725 13:0.93442696332931519 14:-0.63969117403030396 15:-0.16151165962219238 16:0.83217006921768188 17:-0.069254249334335327 18:-0.27093815803527832 19:0.50270307064056396 20:-0.3701116144657135 21:-0.9349932074546814 22:-0.84000343084335327 23:-0.41635552048683167 24:-0.3888784646987915 25:-0.25315806269645691 26:-0.15392397344112396 27:0.025107415392994881 28:0.56973457336425781 29:0.38532906770706177 30:0.37857183814048767 31:0.66472488641738892 32:0.96014046669006348 33:0.74786615371704102 34:-0.18957825005054474 35:-0.72223562002182007 36:-0.079844474792480469 37:-0.32539805769920349 38:0.89657247066497803 39:0.50971692800521851 40:0.36139878630638123 41:-0.51399136 42:-0.17479488 43:0.0458887 44:-0.04103617 45:0.30380768 46:0.36483827 47:-0.33177465 48:0.13461648 49:0.2719641 50:0.43453917 51:0.57531822 52:0.20079257 53:-0.14913259 54:-0.42960742 55:0.21288674 56:0.44449803 57:0.19205268 58:-0.0029294007 59:-0.46648878 60:0.070295535  |EV|
1 |BT| (ROOT (NP (NP (NNP CONCLUSION)) (: :) (NP (NP (JJ RSVL) (NN treatment)) (VP (VBN increased) (NP (NP (DT the) (JJ cytotoxic) (NN activity)) (PP (IN of) (NP (NNP DOX)))) (PP (IN against) (NP (NP (DT the) (NN growth)) (PP (IN of) (NP (JJ human) (NN breast) (NN cancer) (NNS cells))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (S (UCP (DT either) (ADVP (RB simultaneously)) (CC or) (NP (CD 24) (NN h)))) (PP (IN before) (NP (NNP DOX)))))))) (. .))) |ET| |BV| 1:-0.43929073214530945 2:-0.67373716831207275 3:-0.5386122465133667 4:-0.046874858438968658 5:-0.53273952007293701 6:-0.30216258764266968 7:-0.14578676223754883 8:-0.73413217067718506 9:0.44355380535125732 10:-0.04365694522857666 11:-0.57645648717880249 12:0.35209974646568298 13:-0.044508263468742371 14:0.41163665056228638 15:-0.45349112153053284 16:-1.020601749420166 17:-0.23767274618148804 18:-0.83993500471115112 19:-0.47550418972969055 20:0.92739778757095337 21:-1.2889895439147949 22:-0.063427232205867767 23:-0.84276574850082397 24:1.3173348903656006 25:-0.72840911149978638 26:0.017096534371376038 27:-0.20289576053619385 28:-1.1163548231124878 29:-0.27790626883506775 30:1.1979541778564453 31:0.22071042656898499 32:-0.31944265961647034 33:0.37083739042282104 34:0.46889552474021912 35:0.14528438448905945 36:0.93364542722702026 37:-0.12006246298551559 38:-1.0134156942367554 39:0.03673325851559639 40:0.4048667848110199 41:-0.14015959 42:-0.25202194 43:-0.25003257 44:0.47291315 45:-0.23475029 46:-0.41609609 47:0.0520331 48:0.30007082 49:-0.13595416 50:0.21810681 51:0.18289909 52:0.28365561 53:0.54377806 54:0.11507036 55:0.23024531 56:0.038623646 57:0.17944461 58:-0.091930874 59:-0.29189217 60:0.20200916  |EV|
1 |BT| (ROOT (S (S (NP (NP (DT These) (NNS effects)) (PP (IN of) (NP (NN guanfacine)))) (VP (VBD were) (VP (VBN blocked) (PP (IN by) (NP (NP (JJ co-administered) (NN yohimbine)) (, ,) (NP (NP (DT a) (JJ non-selective) (DT a)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)))))))) (: -) (S (NP (NNP AR)) (VP (VBP antagonist))) (. .))) |ET| |BV| 1:-0.8242526650428772 2:-0.88872849941253662 3:0.32665568590164185 4:-1.1507613658905029 5:0.63887143135070801 6:0.21949335932731628 7:-0.11004896461963654 8:0.40453189611434937 9:1.5391494035720825 10:-0.078226938843727112 11:0.3409532904624939 12:0.16447393596172333 13:0.6226661205291748 14:-0.10437248647212982 15:-0.50367969274520874 16:0.76363891363143921 17:0.55498886108398438 18:0.86595380306243896 19:0.86516797542572021 20:-0.053705126047134399 21:-0.89714491367340088 22:-1.1104369163513184 23:0.80272060632705688 24:-1.9180505275726318 25:0.92880183458328247 26:0.17917650938034058 27:-0.23519697785377502 28:0.66925978660583496 29:0.97777557373046875 30:-0.61555343866348267 31:0.64202237129211426 32:-0.15306134521961212 33:0.47153609991073608 34:0.43802297115325928 35:-1.9512648582458496 36:0.25710698962211609 37:0.77113324403762817 38:-0.60681843757629395 39:1.1966632604598999 40:-0.12156482040882111 41:-0.18629229 42:-0.12930734 43:0.1015211 44:-0.46571738 45:0.33528453 46:-0.12253592 47:0.12576793 48:0.51849157 49:-0.28153476 50:0.5437296 51:0.57153225 52:-0.12852766 53:-0.19165665 54:-0.25152349 55:-0.007489006 56:0.14497557 57:-0.18790273 58:-0.48442668 59:0.27011037 60:-0.095364563  |EV|
1 |BT| (ROOT (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NNP Diosmin)) (VP (VP (VBZ inhibits) (NP (JJ platelet) (NN aggregation))) (CC and) (VP (VBZ prolongs) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN norepinephrine)))) (PP (IN on) (NP (JJ venous) (NN tone)))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (VBN increased) (NN venoconstriction))))))) (. .))) |ET| |BV| 1:-1.0374453067779541 2:0.85880064964294434 3:-0.24367348849773407 4:-1.0123558044433594 5:0.1485302597284317 6:0.064390242099761963 7:0.82503896951675415 8:0.057420235127210617 9:0.23259422183036804 10:0.22073723375797272 11:0.85523819923400879 12:-0.6310189962387085 13:0.38975125551223755 14:-0.61011910438537598 15:0.14520935714244843 16:0.3941006064414978 17:-0.23449532687664032 18:0.1393260657787323 19:0.37582126259803772 20:-0.082628250122070312 21:-0.8490561842918396 22:-0.38242501020431519 23:-1.3305420875549316 24:0.063795417547225952 25:-0.48764705657958984 26:-1.2378487586975098 27:-0.37567493319511414 28:0.32431533932685852 29:-0.47060957551002502 30:-0.091480948030948639 31:-0.42965942621231079 32:0.20810635387897491 33:0.77424395084381104 34:0.49745878577232361 35:0.91372197866439819 36:1.916669487953186 37:0.79609304666519165 38:1.2478442192077637 39:0.84441906213760376 40:0.12838126718997955 41:-0.1270657 42:0.19763693 43:0.054239631 44:-0.054814838 45:-0.1175506 46:-0.25290683 47:-0.26520777 48:-0.073643744 49:-0.03985028 50:0.2937369 51:0.34242412 52:-0.2447518 53:-0.12332889 54:-0.29979074 55:-0.047245692 56:0.25683197 57:0.55559826 58:-0.037195664 59:0.36413044 60:0.10089979  |EV|
1 |BT| (ROOT (S (NP (NNP Adenosine) (NNP A2A) (NN receptor) (NNS activation)) (VP (VBZ reduces) (NP (NN recurrence) (CC and) (NN mortality)) (PP (IN from) (NP (NP (NNP Clostridium) (NN difficile) (NN infection)) (PP (IN in) (NP (NP (NNS mice)) (PP (VBG following) (NP (NN vancomycin) (NN treatment)))))))) (. .))) |ET| |BV| 1:-0.2997586727142334 2:-0.90835148096084595 3:-0.35928812623023987 4:-0.40498751401901245 5:-0.070239365100860596 6:-0.54183667898178101 7:-0.41281372308731079 8:0.56097722053527832 9:-0.59817785024642944 10:0.68011802434921265 11:-1.066428542137146 12:-0.33847963809967041 13:-0.050172816962003708 14:1.0202810764312744 15:-0.51219433546066284 16:0.73061972856521606 17:-0.31654056906700134 18:-0.64519917964935303 19:-0.52202326059341431 20:0.206183061003685 21:-0.65978451569875085 22:-0.31617565266788006 23:0.61215858161449432 24:-0.20507357517878214 25:-0.38477788368860882 26:0.017386393000682194 27:1.012074093023936 28:0.55528862277666724 29:0.72523844242095947 30:0.13058755298455557 31:0.55353307723999023 32:-0.43569505028426647 33:1.5484650135040283 34:0.40420932074387866 35:-0.14122427666249374 36:0.40701238811016083 37:0.36283800502618152 38:-0.28290966649850208 39:0.32303816452622414 40:-0.16674691438674927 41:0.060000814 42:-0.26570427 43:0.29985878 44:0.32654765 45:0.082037985 46:-0.042080514 47:-0.31069604 48:-0.058550201 49:-0.54371661 50:0.34423864 51:-0.19239713 52:0.069108181 53:0.18452632 54:0.065499023 55:0.12032666 56:0.072963931 57:0.38348359 58:0.28043589 59:-0.10032836 60:-0.055832706  |EV|
1 |BT| (ROOT (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (JJ Chronic) (JJ low-dose) (JJ oral) (NN amiodarone)) (VP (VBZ attenuates) (NP (NP (DT the) (JJ proarrhythmic) (NNS effects)) (PP (IN of) (NP (NN dobutamine)))) (, ,) (S (VP (VBG increasing) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (JJ ambulatory) (NNP IDI)))))))) (. .))) |ET| |BV| 1:0.60882604122161865 2:-0.23329782485961914 3:-1.6974742412567139 4:-0.35691171884536743 5:-0.29879364371299744 6:-0.13806401193141937 7:0.25545862317085266 8:-0.36142683029174805 9:0.17044505476951599 10:-0.59444350004196167 11:0.24077467620372772 12:-0.20301823318004608 13:0.18098999559879303 14:-0.18655179440975189 15:0.019401097670197487 16:0.23374529182910919 17:-0.54920375347137451 18:-0.50025564432144165 19:-1.1375815868377686 20:0.18487530946731567 21:-0.16469965875148773 22:0.022516429424285889 23:-0.73193413019180298 24:0.045193154364824295 25:0.42221939563751221 26:0.036796849220991135 27:0.23524349927902222 28:-0.27031907439231873 29:0.41419598460197449 30:0.20313477516174316 31:-0.29296407103538513 32:-0.33279585838317871 33:0.23716504871845245 34:-0.2083229273557663 35:-0.14375141263008118 36:-0.043305229395627975 37:-0.10976047813892365 38:-0.43185728788375854 39:0.68558299541473389 40:0.1834789514541626 41:-0.36709806 42:0.08908315 43:0.1374606 44:0.21745056 45:-0.037434354 46:0.24936189 47:0.43517515 48:-0.45619708 49:-0.12915017 50:-0.17014076 51:0.11554941 52:-0.18325271 53:-0.090026043 54:0.06297379 55:0.010368944 56:0.07810808 57:0.39527619 58:0.00020494645 59:0.27816376 60:-0.25906739  |EV|
1 |BT| (ROOT (S (NP (NP (NNP Quercetin)) (VP (VBN administered) (PP (TO to) (NP (JJ pregnant) (JJ diabetic) (NNS rats))))) (VP (VP (VBD controlled) (NP (NN dyslipidemia) (CC and) (JJ improved) (NN lipid) (NNS profiles)) (PP (IN in) (NP (NP (NN diabetes) (NNS mellitus)) (, ,) (VP (VBN regulated) (NP (JJ oxidative) (NN stress)) (PP (IN by) (S (VP (VBG reducing) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (NN lipid) (NNS hydroperoxides)))))))) (, ,)))) (CC and) (VP (VBD increased) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT the) (JJ antioxidant) (JJ enzyme) (NN glutathione) (NN peroxidase)))))) (. .))) |ET| |BV| 1:-1.0285524129867554 2:-2.3016483783721924 3:0.73092299699783325 4:0.65657192468643188 5:0.51125544309616089 6:-0.16373804211616516 7:-0.64307582378387451 8:0.82430934906005859 9:0.15170849859714508 10:0.2230609655380249 11:0.020307015627622604 12:-1.1585944890975952 13:1.1519955396652222 14:0.041456572711467743 15:-1.2895824909210205 16:0.20305891335010529 17:0.47542363405227661 18:0.41058680415153503 19:0.043337997049093246 20:-0.73385173082351685 21:-2.131966233253479 22:1.0506795942783356 23:0.86121746897697449 24:-0.52978295087814331 25:-0.8402726948261261 26:-0.48896053433418274 27:-0.34385865926742554 28:0.59534968435764313 29:-0.29902796074748039 30:0.96731510758399963 31:0.075172229669988155 32:0.12474464997649193 33:1.6130535006523132 34:0.37658464908599854 35:-0.24996968731284142 36:-1.5141645669937134 37:-1.6431140899658203 38:-0.34250835329294205 39:0.28368517756462097 40:-1.1796204149723053 41:-0.45986328 42:-0.074190155 43:0.052184958 44:0.48105171 45:-0.096510798 46:0.22683632 47:-0.13920078 48:0.044212051 49:-0.21483889 50:0.30211842 51:0.56919539 52:-0.23745051 53:0.2306751 54:-0.17022194 55:-0.053008053 56:0.098537087 57:0.41827282 58:0.022013312 59:-0.19443515 60:-0.075295225  |EV|
1 |BT| (ROOT (S (S (VP (VBG Using) (NP (JJ zebrafish) (NNS embryos)) (PP (IN as) (NP (DT the) (NN model))))) (, ,) (NP (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NN morphine)) (VP (VBZ decreases) (NP (JJ miR-133b) (NN expression))))) (, ,) (S (ADVP (RB hence)) (VP (VBG increasing) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (PRP$ its) (NN target)) (, ,) (NP (NNS Pitx3)) (, ,)))) (NP (NP (DT a) (NN transcription) (NN factor)) (SBAR (WHNP (WDT that)) (S (VP (VBZ activates) (NP (JJ tyrosine) (ADJP (JJ hydroxylase) (CC and) (JJ dopamine)) (NN transporter))))))))) (. .))) |ET| |BV| 1:-0.45263946056365967 2:-0.44811126589775085 3:-0.40243950486183167 4:-0.3595319390296936 5:0.29140186309814453 6:-0.3102668821811676 7:-0.16002285480499268 8:0.027013452723622322 9:0.46951276063919067 10:0.70688903331756592 11:0.51139503717422485 12:-0.31645745038986206 13:0.28384193778038025 14:-0.14880067110061646 15:-0.087615728378295898 16:-0.37213057279586792 17:0.33573028445243835 18:0.14914470911026001 19:-0.28276950120925903 20:0.36941593885421753 21:-0.52288627624511719 22:0.064634568989276886 23:0.43291720747947693 24:-0.59934920072555542 25:0.067319102585315704 26:-0.54065132141113281 27:0.75569421052932739 28:0.22499477863311768 29:0.75093740224838257 30:0.50299102067947388 31:0.66871351003646851 32:-0.46396654844284058 33:0.70376694202423096 34:0.35963043570518494 35:0.027474602684378624 36:0.40848967432975769 37:0.32412928342819214 38:-0.051923949271440506 39:0.47423961758613586 40:0.30214890837669373 41:-0.22579339 42:-0.30025807 43:0.11974526 44:-0.12639363 45:0.49724901 46:0.10903224 47:0.39655098 48:-0.30314425 49:-0.09243574 50:0.25542712 51:0.6907146 52:-0.038867123 53:0.21896365 54:-0.53824127 55:-0.26528144 56:0.077603109 57:0.20276619 58:-0.087801449 59:0.062777109 60:-0.10763332  |EV|
1 |BT| (ROOT (S (NP (NP (NP (JJ 20-O-ß-d-glucopyranosyl-20)) (PRN (-LRB- -LRB-) (NP (NNP S)) (-RRB- -RRB-))) (: -) (NP (NP (NN protopanaxadiol)) (, ,) (NP (NP (DT a) (NN metabolite)) (PP (IN of) (NP (NN ginseng))))) (, ,)) (VP (VBZ inhibits) (NP (NN colon) (NN cancer) (NN growth)) (PP (IN by) (S (VP (VBG targeting) (NP (CD TRPC) (JJ channel-mediated) (NN calcium) (NN influx)))))) (. .))) |ET| |BV| 1:-0.76733154058456421 2:0.24607940018177032 3:-0.3637290894985199 4:-0.26238524913787842 5:-0.33067521452903748 6:-0.33500140905380249 7:-0.08953440934419632 8:0.13414254784584045 9:0.37700408697128296 10:0.26008978486061096 11:-0.075949981808662415 12:-0.24670501053333282 13:0.17961160838603973 14:-0.15187470614910126 15:-1.0580264329910278 16:-0.25400683283805847 17:-0.31937047839164734 18:0.033552780747413635 19:0.48308485746383667 20:-0.69982004165649414 21:-0.60878670215606689 22:-0.011024806609687706 23:0.14656920731067657 24:0.36022163679202396 25:0.2953164130449295 26:-0.57830232381820679 27:0.28156733016173047 28:0.47401624172925949 29:0.86442808310190833 30:0.083395811418692276 31:0.12959621846675873 32:0.41102698445320129 33:0.25162068506081897 34:0.064660047491391495 35:-0.10712873935699463 36:-0.28840004776914913 37:-0.44536809126536053 38:-0.029718379179636639 39:0.6224408745765686 40:-0.046636596322059631 41:-0.021951012 42:-0.086069316 43:0.30741966 44:-0.1036191 45:0.0033883832 46:0.071943223 47:-0.38905534 48:0.22787996 49:0.25433129 50:0.32759985 51:0.30417359 52:-0.085765317 53:0.22378229 54:-0.10968653 55:-0.060962465 56:0.31327388 57:-0.21888827 58:0.31850329 59:0.024710931 60:0.033135325  |EV|
1 |BT| (ROOT (S (NP (NP (DT This) (NN phase) (NN I) (NN trial)) (PP (IN in) (NP (JJ healthy) (NNS subjects)))) (VP (VBD investigated) (NP (NP (NP (DT the) (NN bronchodilator) (NN activity)) (PP (IN of) (NP (NN aclidinium)))) (CC and) (NP (PRP$ its) (NN ability) (S (VP (TO to) (VP (VB reduce) (NP (JJ methacholine-induced) (NN bronchoconstriction)))))))) (. .))) |ET| |BV| 1:-0.56929779052734375 2:0.11275182664394379 3:-0.12096316367387772 4:-0.33661121129989624 5:0.015454963780939579 6:-0.54766327142715454 7:-0.41220659017562866 8:-0.22145909070968628 9:0.88924896717071533 10:0.47987499833106995 11:-0.46322622895240784 12:0.27683350443840027 13:1.4367380142211914 14:-0.36349216103553772 15:0.020116759464144707 16:-0.098351910710334778 17:-0.18360976874828339 18:0.025702953338623047 19:-0.42553788423538208 20:-0.72200238704681396 41:-0.158465 42:0.034803238 43:0.16103907 44:-0.31827056 45:0.20409922 46:0.11032236 47:-0.0079452591 48:-0.42260876 49:0.13054189 50:0.071465231 51:0.4752413 52:0.17953965 53:0.11966962 54:0.045247983 55:0.11527257 56:0.0070465468 57:0.19392149 58:-0.47613615 59:0.13856952 60:0.2462654  |EV|
1 |BT| (ROOT (S (S (NP (NP (CD One) (NN interpretation)) (PP (IN of) (NP (DT the) (NNS findings)))) (VP (VBZ is) (SBAR (IN that) (S (NP (NN caffeine)) (VP (VBZ reduces) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (NN calcium)))) (PP (DT both) (PP (IN in) (NP (DT the) (NN membrane))) (CC and) (PP (IN in) (NP (DT the) (NN myoplasm))))))))) (: ;) (S (NP (DT this)) (VP (VBZ increases) (NP (NP (NP (DT the) (`` ``) (NN permeability) ('' '')) (PP (TO to) (NP (NN calcium)))) (CC and) (NP (NP (DT the) (JJ ionic) (NN activity)) (PP (IN of) (NP (NP (NN calcium)) (PP (IN in) (NP (NN muscle))))))))) (. .))) |ET| |BV| 1:-0.76733154058456421 2:0.24607940018177032 3:-0.3637290894985199 4:-0.26238524913787842 5:-0.33067521452903748 6:-0.33500140905380249 7:-0.08953440934419632 8:0.13414254784584045 9:0.37700408697128296 10:0.26008978486061096 11:-0.075949981808662415 12:-0.24670501053333282 13:0.17961160838603973 14:-0.15187470614910126 15:-1.0580264329910278 16:-0.25400683283805847 17:-0.31937047839164734 18:0.033552780747413635 19:0.48308485746383667 20:-0.69982004165649414 21:-0.22717079520225525 22:-0.49435621500015259 23:-0.40642982721328735 24:-0.10535500943660736 25:-0.2724127471446991 26:0.05155457928776741 27:-0.072615057229995728 28:-0.48675423860549927 29:0.82784843444824219 30:0.19380833208560944 31:0.63382118940353394 32:0.076453894376754761 33:-0.12286575883626938 34:-0.33363118767738342 35:-0.37121942639350891 36:-0.018839748576283455 37:0.16713631153106689 38:0.24557870626449585 39:0.42151379585266113 40:0.49096837639808655 41:-0.11066132 42:0.0085656494 43:0.36054519 44:0.40146816 45:-0.28329161 46:-0.017671164 47:-0.31622526 48:0.061480086 49:0.048572283 50:0.37426037 51:-0.18462184 52:0.25033173 53:-0.040978748 54:-0.098860085 55:-0.082847297 56:0.17607558 57:-0.36613628 58:0.16977058 59:-0.75163603 60:-0.013338619  |EV|
1 |BT| (ROOT (NP (NP (NNS CONCLUSIONS)) (: :) (S (S (PP (IN In) (NP (NP (DT an) (NN animal) (NN model)) (PP (IN of) (NP (JJ PCP-induced) (NN cognitive) (NN impairment))))) (, ,) (NP (JJ cariprazine) (NN pretreatment)) (ADVP (RB significantly)) (VP (VBD diminished) (NP (JJ PCP-triggered) (NN cognitive) (NNS deficits)))) (, ,) (CC and) (S (NP (NP (NNS studies)) (PP (IN on) (NP (NN knockout) (NNS mice)))) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NNP dopamine) (NNP D)) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (NNS receptors)) (VP (VBP contribute) (PP (TO to) (NP (DT this) (NN effect))))))))) (. .))) |ET| |BV| 1:0.15640556812286377 2:-0.0074302139692008495 3:0.025819381698966026 4:-0.96807760000228882 5:1.9010213613510132 6:-1.0429587364196777 7:-1.9685529470443726 8:0.591461181640625 9:0.8967900276184082 10:0.12853971123695374 11:0.54297715425491333 12:-0.28713500499725342 13:0.56475460529327393 14:0.053115762770175934 15:-0.52928173542022705 16:-0.37519955635070801 17:-1.3576101064682007 18:-0.51835185289382935 19:-0.04749567061662674 20:0.73703640699386597 21:0.018219152465462685 22:-0.016104124486446381 23:-0.2884095311164856 24:-0.86151820421218872 25:1.1512751579284668 26:0.63539975881576538 27:-0.721260666847229 28:0.20782727003097534 29:0.2683451771736145 30:-0.37172693014144897 31:0.32159009575843811 32:-0.33738383650779724 33:-0.062608078122138977 34:1.4100220203399658 35:-0.93931728601455688 36:-0.16542066633701324 37:-0.7741512656211853 38:-0.41038000583648682 39:1.2455095052719116 40:0.70139086246490479 41:-0.33804488 42:-0.22307211 43:0.021574209 44:-0.39377779 45:0.37182522 46:0.39008608 47:0.29001707 48:-0.52709275 49:-0.17008969 50:0.30041569 51:0.13174185 52:0.22390319 53:0.45256802 54:-0.42137158 55:-0.2676135 56:0.11981118 57:0.0096147945 58:-0.29205677 59:0.11501373 60:-0.33139178  |EV|
1 |BT| (ROOT (S (NP (NNP Clomipramine)) (VP (VBZ is) (NP (NP (DT a) (JJ tricyclic) (NN antidepressant)) (SBAR (WHNP (WDT that)) (S (VP (VBZ inhibits) (NP (NP (DT the) (NN reuptake)) (PP (IN of) (NP (NN serotonin) (CC and) (NN norepinephrine)))) (PP (IN by) (NP (NP (JJ indirect) (NNS actions)) (PP (IN on) (NP (NP (DT the) (JJ dopaminergic) (NN system)) (CC and) (NP (NNP LHPA) (NNS axis))))))))))) (. .))) |ET| |BV| 1:-0.38979417085647583 2:-0.50012701749801636 3:-0.30157360434532166 4:0.064433954656124115 5:0.049931284040212631 6:-1.1039974689483643 7:-0.64272397756576538 8:-0.016858406364917755 9:-0.19306574761867523 10:0.84069532155990601 11:-0.14306119084358215 12:-0.3653310239315033 13:-0.17613606154918671 14:-0.32045415043830872 15:0.047505978494882584 16:0.092567920684814453 17:-0.67962086200714111 18:-0.086598910391330719 19:0.51271539926528931 20:0.77329772710800171 21:-1.0374453067779541 22:0.85880064964294434 23:-0.24367348849773407 24:-1.0123558044433594 25:0.1485302597284317 26:0.064390242099761963 27:0.82503896951675415 28:0.057420235127210617 29:0.23259422183036804 30:0.22073723375797272 31:0.85523819923400879 32:-0.6310189962387085 33:0.38975125551223755 34:-0.61011910438537598 35:0.14520935714244843 36:0.3941006064414978 37:-0.23449532687664032 38:0.1393260657787323 39:0.37582126259803772 40:-0.082628250122070312 41:-0.077239081 42:-0.19914758 43:0.020278506 44:-0.12281031 45:0.43579081 46:-0.42261043 47:-0.0685606 48:-0.18911836 49:0.047354031 50:0.16439024 51:-0.1859255 52:0.10577066 53:-0.21476671 54:-0.29499033 55:-0.16324435 56:0.30024967 57:0.28345016 58:0.33873776 59:0.10391232 60:-0.20117396  |EV|
1 |BT| (ROOT (S (S (S (VP (VBN Considered) (ADVP (RB together)))) (, ,) (NP (NP (DT this) (NN pattern)) (PP (IN of) (NP (NNS findings)))) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (NN bupropion)) (VP (VBZ decreases) (S (VP (VBG responding) (PP (IN for) (NP (NN methamphetamine)))))))))) (, ,) (CC but) (S (NP (DT the) (NNS effects)) (VP (VBP are) (ADVP (RB only)) (ADJP (RB somewhat) (JJ specific)))) (. .))) |ET| |BV| 1:0.027203679084777832 2:-0.44145473837852478 3:0.19782429933547974 4:-0.29811137914657593 5:0.22199876606464386 6:-0.42937174439430237 7:-0.12837471067905426 8:-0.4298664927482605 9:0.51660990715026855 10:0.45310685038566589 11:0.3033214807510376 12:0.0084803774952888489 13:-0.29091501235961914 14:0.30512857437133789 15:0.11571419984102249 16:0.49818620085716248 17:-0.052969720214605331 18:0.16757877171039581 19:0.68114298582077026 20:0.48334053158760071 21:0.43385875225067139 22:-0.70879608392715454 23:-0.15121306478977203 24:-0.49849820137023926 25:0.25945013761520386 26:-0.21913771331310272 27:-0.7705080509185791 28:-0.65597772598266602 29:0.77728211879730225 30:0.75117897987365723 31:0.26791933178901672 32:0.098864078521728516 33:0.040396872907876968 34:0.34282582998275757 35:-0.63833892345428467 36:0.37242758274078369 37:-0.52486193180084229 38:-0.3926006555557251 39:0.14577914774417877 40:0.077141791582107544 41:-0.42586252 42:0.097476102 43:0.068828948 44:0.10124437 45:0.68796414 46:-0.27438805 47:0.11153818 48:0.078145474 49:0.046368867 50:0.14983895 51:0.29451695 52:0.024287337 53:-0.11595449 54:-0.39118788 55:0.083115488 56:0.60174638 57:0.03368073 58:-0.29728624 59:-0.072219074 60:-0.25036153  |EV|
1 |BT| (ROOT (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN sertraline)) (VP (MD may) (VP (VB reduce) (NP (DT the) (JJ membrane) (NN conduction)) (PP (IN through) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ ionic) (NNS channels))) (SBAR (WHNP (WDT which)) (S (VP (VB decrease) (NP (JJ ouabain-induced) (NN arrhythmia)))))))))))) (. .))) |ET| |BV| 1:0.075778111815452576 2:0.33668920397758484 3:-1.1316298246383667 4:-0.38793954253196716 5:1.1202346086502075 6:0.089918151497840881 7:-0.58620196580886841 8:0.83895719051361084 9:0.38686206936836243 10:0.49496409296989441 11:0.45256185531616211 12:0.37516337633132935 13:1.4813621044158936 14:0.1288347989320755 15:-0.43844366073608398 16:0.67904537916183472 17:0.031936708837747574 18:-0.041735757142305374 19:0.98866665363311768 20:-0.61810493469238281 21:0.062594734132289886 22:-0.75768083333969116 23:-1.4813034534454346 24:-0.89769107103347778 25:-0.58773481845855713 26:0.55305027961730957 27:-0.47477197647094727 28:-0.38279101252555847 29:0.86100965738296509 30:-0.23867407441139221 31:0.83104825019836426 32:-0.81104350090026855 33:-0.065309874713420868 34:0.060984265059232712 35:0.051138829439878464 36:-0.71780908107757568 37:0.19032372534275055 38:-0.2665942907333374 39:0.0085575059056282043 40:0.75624537467956543 41:-0.12971602 42:0.17198081 43:0.26141033 44:-0.068379015 45:-0.2540879 46:-0.29883716 47:0.090436451 48:0.16198991 49:-0.17000487 50:0.42197618 51:-0.19756621 52:-0.069918364 53:0.21237314 54:0.0031382905 55:0.0093994159 56:0.11187522 57:0.37786776 58:0.57812023 59:-0.21400197 60:0.10244197  |EV|
1 |BT| (ROOT (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NP (CD 1) (NN microM) (NN cimetidine)) (PP (IN at) (NP (DT the) (JJ basolateral) (NN side)))) (VP (VP (ADVP (RB moderately)) (VBD decreased) (S (NP (NP (DT the) (JJ basolateral-to-apical) (NN transport)) (PP (IN of) (NP (NNP -LSB-) (PRN (-LRB- -LRB-) (NP (CD 14)) (-RRB- -RRB-)) (NNP C)))) (ADJP (RB -RSB-) (JJ metformin)))) (CC and) (VP (ADVP (RB significantly)) (VBD increased) (NP (NP (DT the) (NN intracellular) (NN accumulation)) (PP (IN of) (NP (NNP -LSB-))) (PRN (-LRB- -LRB-) (NP (CD 14)) (-RRB- -RRB-)) (NP (NP (NNP C) (NNP -RSB-)) (VP (VBN metformin) (PP (IN from) (NP (DT the) (JJ basolateral) (NN side)))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (NN cimetidine)) (PP (IN at) (NP (DT a) (JJ low) (NN concentration)))) (VP (VBZ inhibits) (NP (NP (JJ apical) (NNS hMATE1)) (, ,) (CONJP (RB rather) (IN than)) (NP (JJ basolateral) (NNS hOCT2)))))))))) (. .))) |ET| |BV| 1:-0.72917187213897705 2:-0.43784007430076599 3:0.11291414499282837 4:-0.16863709688186646 5:-0.028862541541457176 6:-0.74388736486434937 7:-0.6363111138343811 8:-0.14964120090007782 9:0.082612067461013794 10:0.62254178524017334 11:0.084620065987110138 12:-0.22390963137149811 13:0.23155888915061951 14:0.69729363918304443 15:-0.023859221488237381 16:-0.039339173585176468 17:-0.18612585961818695 18:-0.67083597183227539 19:0.021638147532939911 20:-0.060303330421447754 21:-0.68697547912597656 22:0.096703499555587769 23:-0.11480934172868729 24:-0.28948941826820374 25:-0.42214116454124451 26:-0.34074500203132629 27:-0.0361003577709198 28:-0.3383694589138031 29:-0.29554960131645203 30:0.42614302039146423 31:-0.42998114228248596 32:-0.20018318295478821 33:0.0093365954235196114 34:-0.58310562372207642 35:0.081080563366413116 36:-0.29948404431343079 37:0.23485571146011353 38:0.23559245467185974 39:0.52771729230880737 40:-0.37726154923439026 41:-0.0075099412 42:-0.20610012 43:0.90185982 44:-0.5861463 45:0.01409817 46:-0.26846722 47:-0.126803 48:-0.39803523 49:-0.15482537 50:-0.037867222 51:0.35997832 52:-0.089244798 53:-0.16821414 54:-0.62669241 55:-0.044446278 56:-0.31414622 57:-0.26391244 58:0.3666639 59:0.30231008 60:0.15227282  |EV|
1 |BT| (ROOT (S (NP (NP (NN Darifenacin) (, ,) (NN oxybutynin) (, ,) (NN tolterodine) (, ,) (CC and) (NN solifenacin)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CD µM))) (-RRB- -RRB-))) (ADVP (RB all) (RB significantly)) (VP (VBD depressed) (NP (DT the) (NN frequency) (NNS responses)) (PP (TO to) (NP (NP (NN carbachol)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CD µM))) (-RRB- -RRB-))))) (. .))) |ET| |BV| 1:-0.96398121118545532 2:-0.72986817359924316 3:0.78382325172424316 4:-0.23221229016780853 5:-0.74379467964172363 6:0.24420520663261414 7:0.19699881970882416 8:0.5108187198638916 9:0.50388842821121216 10:-0.36476039886474609 11:0.34553965926170349 12:-0.44905149936676025 13:0.22615537047386169 14:0.035029515624046326 15:-0.70427250862121582 16:0.34291398525238037 17:-0.75787490606307983 18:-0.6668129563331604 19:0.059181526303291321 20:-1.1488304138183594 21:-0.65054059028625488 22:-0.21124956011772156 23:0.1713319718837738 24:-0.061776194721460342 25:-0.37753146886825562 26:-0.68113249540328979 27:0.42972558736801147 28:-0.13692034780979156 29:0.10174468904733658 30:-0.5491376519203186 31:0.49487802386283875 32:-0.13535900413990021 33:-0.27002528309822083 34:-0.52904796600341797 35:-0.31652325391769409 36:0.14843516051769257 37:0.20821590721607208 38:0.50349724292755127 39:0.40614330768585205 40:0.028209950774908066 41:-0.46176362 42:0.22227135 43:-0.26102078 44:-0.22920193 45:0.33080167 46:-0.10427046 47:-0.11518118 48:-0.062471207 49:-0.30371645 50:0.15643853 51:0.74717689 52:0.003257195 53:0.11749375 54:-0.23312649 55:-0.39839873 56:0.11162661 57:0.53589153 58:0.10688544 59:0.21737665 60:-0.38508812  |EV|
1 |BT| (ROOT (S (NP (NP (DT The) (JJ morphine-induced) (NN increase)) (PP (IN in) (NP (NNP OA-sensitive) (NNP PP) (NN activity)))) (VP (VP (VBD was) (ADJP (JJ dependent)) (PP (IN on) (NP (DT the) (NN dose)))) (CC and) (VP (VBD attenuated) (PP (IN by) (NP (NP (DT the) (JJ concurrent) (NN administration)) (PP (IN of) (NP (NP (NN naloxone)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg/kg)) (-RRB- -RRB-)))))))) (. .))) |ET| |BV| 1:-0.057872340083122253 2:-0.78405076265335083 3:-0.23945185542106628 4:-0.92862200736999512 5:0.12370280176401138 6:-1.4632296562194824 7:-0.18947482109069824 8:0.65782111883163452 9:0.86293900012969971 10:0.2909596860408783 11:0.67317628860473633 12:-0.56309270858764648 13:0.58486264944076538 14:-0.58568966388702393 15:-0.41367727518081665 16:-0.58864402770996094 17:0.2738032341003418 18:-0.69504910707473755 19:0.24867840111255646 20:0.60118752717971802 21:-0.45263946056365967 22:-0.44811126589775085 23:-0.40243950486183167 24:-0.3595319390296936 25:0.29140186309814453 26:-0.3102668821811676 27:-0.16002285480499268 28:0.027013452723622322 29:0.46951276063919067 30:0.70688903331756592 31:0.51139503717422485 32:-0.31645745038986206 33:0.28384193778038025 34:-0.14880067110061646 35:-0.087615728378295898 36:-0.37213057279586792 37:0.33573028445243835 38:0.14914470911026001 39:-0.28276950120925903 40:0.36941593885421753 41:-0.61205178 42:0.12588213 43:0.30840448 44:0.1228061 45:0.22554168 46:-0.089570388 47:0.22344178 48:-0.12184786 49:-0.48486999 50:0.15206377 51:0.29158658 52:-0.010471693 53:0.258416 54:-0.089078896 55:-0.35090202 56:0.10321154 57:-0.068160035 58:-0.12700447 59:-0.13700327 60:0.52315933  |EV|
1 |BT| (ROOT (FRAG (NP (NNP CONCLUSIONS)) (: :) (S (NP (PRP$ Our) (NNS findings)) (ADVP (RB further)) (VP (VP (VBP support) (NP (DT the) (NNS hypothesis)) (SBAR (IN that) (S (NP (NP (DT the) (JJ synergistic) (NN effect)) (PP (IN of) (NP (NP (NN olanzapine) (CC and) (NN fluoxetine)) (PP (IN on) (NP (NP (JJ prefrontal) (JJ cortical) (NNS levels)) (PP (IN of) (NP (NN norepinephrine) (CC and) (NN dopamine)))))))) (VP (MD might) (VP (VB be) (NP (NP (DT an) (VBG underlying) (NN mechanism)) (PP (IN for) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NP (JJ olanzapine-fluoxetine) (NN combination)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ treatment-resistant) (NN depression))))))))))))))) (CC and) (VP (PRN (, ,) (SBAR (IN if) (FRAG (ADJP (JJ replicated)))) (, ,)) (MD may) (VP (VB form) (NP (NP (DT a) (NN basis)) (SBAR (WHPP (IN on) (WHNP (WDT which))) (S (NP (NP (NN response)) (PP (TO to) (NP (NP (JJ olanzapine-fluoxetine) (NN combination)) (PP (IN versus) (NP (JJ continued) (NN fluoxetine)))))) (VP (MD can) (VP (VB be) (VP (VBN predicted) (PP (VBN based) (PP (IN on) (NP (NP (NNS variants)) (PP (IN in) (NP (NNP SLC6A2)))))))))))))))) (. .))) |ET| |BV| 1:0.13194823265075684 2:0.34916895627975464 3:-0.75300949811935425 4:-0.43338528275489807 5:0.26798152923583984 6:1.1201753616333008 7:0.01382522564381361 8:-0.61208021640777588 9:0.21881662309169769 10:0.52568149566650391 11:0.83086210489273071 12:1.0212095975875854 13:0.50689417123794556 14:0.01392732560634613 15:-0.75837433338165283 16:-0.098990470170974731 17:0.5405307412147522 18:-0.7868351936340332 19:0.38124319911003113 20:0.087259933352470398 21:-0.18715254962444305 22:0.066955015063285828 23:-0.46771183609962463 24:-0.072080209851264954 25:1.0176843404769897 26:-0.45238834619522095 27:-0.38410946726799011 28:-0.28686091303825378 29:0.14154396951198578 30:0.53410458564758301 31:0.60740607976913452 32:-0.097546875476837158 33:0.4110349714756012 34:0.25003382563591003 35:0.22044035792350769 36:0.19254863262176514 37:-0.37296125292778015 38:-0.78279614448547363 39:0.89931923151016235 40:-0.091693177819252014 41:-0.18657164 42:0.18919772 43:-0.018889196 44:-0.015345511 45:0.45200348 46:-0.095505856 47:-0.35578388 48:0.32600135 49:-0.11797196 50:0.57004982 51:0.093005627 52:-0.31196856 53:-0.039651092 54:0.38389194 55:-0.14716217 56:0.20236784 57:-0.18913902 58:0.084636077 59:-0.10934187 60:-0.023350189  |EV|
1 |BT| (ROOT (S (NP (DT The) (NNS results)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (JJ bilateral)) (CONJP (CC but) (RB not)) (NP (NP (JJ unilateral) (JJ intra-VTA) (NN administration)) (PP (IN of) (NP (NN lidocaine))))) (VP (ADVP (RB significantly)) (VBZ decreases) (NP (NP (DT the) (NN acquisition)) (PRN (-LRB- -LRB-) (NP (NNP P) (NNP <) (NNP 0.01)) (-RRB- -RRB-)) (CC and) (NP (NP (NP (NN expression)) (PRN (-LRB- -LRB-) (NP (NNP P) (NNP <) (NNP 0.05)) (-RRB- -RRB-))) (PP (IN of) (NP (JJ morphine-induced) (NNP CPP))))) (PP (VBN compared) (PP (TO to) (NP (PRP$ their) (JJ respective) (JJ saline-microinjected) (NNS groups)))))))) (. .))) |ET| |BV| 1:-0.45263946056365967 2:-0.44811126589775085 3:-0.40243950486183167 4:-0.3595319390296936 5:0.29140186309814453 6:-0.3102668821811676 7:-0.16002285480499268 8:0.027013452723622322 9:0.46951276063919067 10:0.70688903331756592 11:0.51139503717422485 12:-0.31645745038986206 13:0.28384193778038025 14:-0.14880067110061646 15:-0.087615728378295898 16:-0.37213057279586792 17:0.33573028445243835 18:0.14914470911026001 19:-0.28276950120925903 20:0.36941593885421753 21:-0.18326178193092346 22:-0.63327020406723022 23:-1.2221074104309082 24:-0.77608859539031982 25:0.18754744529724121 26:-0.082618378102779388 27:-0.14242550730705261 28:0.073615573346614838 29:-0.11079295724630356 30:-0.012629220262169838 31:0.16777820885181427 32:0.12226185202598572 33:-0.07135232537984848 34:-0.55858153104782104 35:-0.28625985980033875 36:0.31376615166664124 37:0.34146344661712646 38:0.47314885258674622 39:-0.37956538796424866 40:-0.51146042346954346 41:-0.42424983 42:0.10557403 43:-0.054078311 44:0.34094205 45:0.10015013 46:-0.010194913 47:0.23688002 48:0.086190775 49:-0.29944128 50:0.060071792 51:-0.13022438 52:0.3423616 53:0.15164569 54:-0.3305952 55:-0.49831271 56:0.19626048 57:0.31068483 58:0.100687 59:-0.44201908 60:0.010440249  |EV|
1 |BT| (ROOT (S (PP (IN In) (NP (NN aggregate))) (, ,) (NP (DT these) (NNS data)) (VP (VBP show) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NN crizotinib)))) (S (VP (TO to) (VP (VP (ADVP (RB specifically)) (VB target) (NP (NNP CSC-like-subpopulations))) (, ,) (VP (VB interfere) (PP (IN with) (NP (NN cell-proliferation)))) (, ,) (VP (VB induce) (NP (NNS apoptosis))) (, ,) (VP (VB reduce) (NP (NN migration))) (CC and) (ADVP (RB synergistically)) (VP (VB interact) (PP (IN with) (NP (NN gemcitabine))))))) (, ,) (S (VP (VBG supporting) (NP (JJ further) (NNS studies)) (PP (IN on) (NP (NP (DT this) (JJ novel) (JJ therapeutic) (NN approach)) (PP (IN for) (NP (NNP PDAC)))))))) (. .))) |ET| |BV| 1:-0.32645553350448608 2:-0.51431542634963989 3:-0.22203549742698669 4:0.05484791100025177 5:-0.52514684200286865 6:0.39572903513908386 7:0.60794675350189209 8:0.013867656700313091 9:1.4301471710205078 10:0.94179540872573853 11:-0.6731255054473877 12:-0.0018658601911738515 13:1.2140834331512451 14:0.70735597610473633 15:0.39855563640594482 16:-0.33303973078727722 17:-0.86975240707397461 18:-0.089634500443935394 19:-0.86895334720611572 20:-0.76535707712173462 21:-1.0761337280273438 22:-0.72653055191040039 23:-0.047030564397573471 24:-0.095044218003749847 25:0.87921142578125 26:0.14182645082473755 27:0.56299537420272827 28:0.3043750524520874 29:0.050402730703353882 30:0.2984650731086731 31:-0.08135475218296051 32:0.20232106745243073 33:0.73375540971755981 34:-0.26733201742172241 35:-0.2360379695892334 36:0.81133437156677246 37:-0.324349045753479 38:-1.4542429447174072 39:-0.42247280478477478 40:-0.82956928014755249 41:-0.02221271 42:-0.33393845 43:-0.080343783 44:-0.41405708 45:0.089188173 46:0.16960371 47:-0.12338004 48:-0.52255028 49:0.71358865 50:0.40976417 51:0.37765881 52:0.094765574 53:0.26585048 54:-0.12116871 55:0.067760147 56:0.17826179 57:0.24473719 58:0.00073120458 59:0.44768232 60:-0.028090073  |EV|
1 |BT| (ROOT (S (NP (NNP Dexrazoxane)) (VP (VBZ is) (NP (NP (DT a) (NN cardioprotectant)) (SBAR (WHNP (WDT that)) (S (ADVP (RB significantly)) (VP (VBZ reduces) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (JJ adverse) (JJ cardiac) (NNS events)) (PP (IN in) (NP (NP (NNS women)) (PP (IN with) (NP (NP (JJ advanced) (NN breast) (NN cancer)) (VP (VBN treated) (PP (IN with) (NP (JJ doxorubicin-containing) (NNS regimens)))))))))))))))) (. .))) |ET| |BV| 1:-0.17890270054340363 2:-0.41120195388793945 3:-0.25580734014511108 4:-0.22398032248020172 5:-0.27193513512611389 6:-0.18103229999542236 7:0.51285189390182495 8:-0.62322860956192017 9:0.047982849180698395 10:0.37694168090820312 11:-0.20004165172576904 12:-0.14829115569591522 13:0.25701633095741272 14:0.23248773813247681 15:0.10704895853996277 16:-0.29212647676467896 17:-0.10906627029180527 18:-1.2593998908996582 19:-0.37454131245613098 20:0.28424814343452454 21:-1.4529216289520264 22:0.6165737509727478 23:-0.59227073192596436 24:-0.75131005048751831 25:0.73869931697845459 26:0.0021804128773510456 27:-0.47875696420669556 28:-0.68373328447341919 29:-0.2420169860124588 30:-0.20682798326015472 31:-0.013879194855690002 32:0.44672983884811401 33:0.59701430797576904 34:-0.16675035655498505 35:-0.66908794641494751 36:1.0024240016937256 37:-0.17960155010223389 38:0.22257280349731445 39:-0.67672401666641235 40:-0.38899296522140503 41:-0.27464476 42:0.21355717 43:0.068614274 44:0.40517893 45:-0.067771442 46:0.0458951 47:-0.24671526 48:-0.44378817 49:0.21875574 50:-0.095017873 51:0.24357021 52:0.35755214 53:-0.053961013 54:0.16573529 55:-0.1684579 56:-0.20387162 57:0.77704012 58:-0.16534935 59:0.28079897 60:-0.25592068  |EV|
1 |BT| (ROOT (NP (NP (NNS CONCLUSIONS)) (: :) (NP (NP (PRP$ Our) (NN study)) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (DT the) (NN combination) (NN treatment)) (PP (IN of) (NP (CD two) (JJ different) (JJ analgesic) (NNS modalities))) (, ,) (ADJP (JJ alfentanil) (CC and) (JJ lidocaine)) (, ,)) (VP (MD could) (VP (VP (VB prevent) (NP (NP (DT the) (ADJP (JJ moderate) (CC and) (JJ severe)) (NN pain)) (PP (IN on) (NP (JJ propofol) (NN injection))))) (, ,) (CC and) (VP (VB reduce) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ mild) (NN pain)))) (PP (VBN compared) (PP (IN with) (NP (DT each) (NN drug)) (ADVP (RB alone))))))))))) (. .))) |ET| |BV| 1:-0.18326178193092346 2:-0.63327020406723022 3:-1.2221074104309082 4:-0.77608859539031982 5:0.18754744529724121 6:-0.082618378102779388 7:-0.14242550730705261 8:0.073615573346614838 9:-0.11079295724630356 10:-0.012629220262169838 11:0.16777820885181427 12:0.12226185202598572 13:-0.07135232537984848 14:-0.55858153104782104 15:-0.28625985980033875 16:0.31376615166664124 17:0.34146344661712646 18:0.47314885258674622 19:-0.37956538796424866 20:-0.51146042346954346 21:-1.0112694501876831 22:-0.89826661348342896 23:-0.63906997442245483 24:-1.1833961009979248 25:0.12017841637134552 26:0.39283651113510132 27:-0.20540407299995422 28:-0.22584573924541473 29:0.14834107458591461 30:0.48220682144165039 31:0.42650765180587769 32:-0.26843318343162537 33:-0.06143004447221756 34:-0.5064244270324707 35:-0.23243723809719086 36:0.058564819395542145 37:-0.37802314758300781 38:0.82528674602508545 39:-0.25258520245552063 40:-0.25763019919395447 41:-0.12717439 42:0.2864024 43:0.14180583 44:0.53970879 45:0.78179747 46:-0.18100482 47:-0.0058811735 48:-0.73840731 49:0.036690596 50:-0.62719065 51:-0.19391184 52:-0.13698447 53:-0.13529468 54:0.70689881 55:0.14281528 56:0.16665013 57:0.52882397 58:0.13799286 59:0.27933419 60:0.60259551  |EV|
1 |BT| (ROOT (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NNP Data)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (NN hyperprolactinemia)) (VP (VBN induced) (PP (IN by) (NP (NN metoclopramide))))) (VP (VP (VBZ determines) (NP (JJ endometrial) (NN proliferation))) (CC and) (VP (VBZ interferes) (PP (IN with) (NP (NP (DT the) (NN ovarian) (NN function)) (, ,) (ADVP (RB mainly)))) (PP (IN in) (NP (DT the) (JJ progesterone) (NN production)))))))))) (. .))) |ET| |BV| 1:-0.70291984081268311 2:0.10596521198749542 3:0.40353924036026001 4:-0.0082024643197655678 5:0.51516556739807129 6:-0.42482960224151611 7:0.15003122389316559 8:0.12399149686098099 9:0.20275136828422546 10:0.48732560873031616 11:0.47781708836555481 12:-0.14894188940525055 13:0.51152008771896362 14:0.33163288235664368 15:-0.59081339836120605 16:0.57499492168426514 17:0.029747411608695984 18:0.1139160692691803 19:0.40241897106170654 20:0.63742589950561523 21:-0.18249137699604034 22:-0.10426323115825653 23:-0.17040956020355225 24:-0.23240828514099121 25:1.2175657749176025 26:0.12161293625831604 27:-0.024821899831295013 28:-0.48099514842033386 29:0.19091956317424774 30:-0.18165458738803864 31:0.62016201019287109 32:-0.12164175510406494 33:0.44775670766830444 34:0.3097003698348999 35:-0.55052608251571655 36:0.18322083353996277 37:-0.037191644310951233 38:0.1758992075920105 39:0.136609748005867 40:-0.067096911370754242 41:-0.1174462 42:-0.21725926 43:-0.35735837 44:-0.11957736 45:0.36556014 46:-0.19346571 47:-0.35283735 48:0.042394653 49:0.095075138 50:0.77397537 51:0.18151984 52:-0.26641375 53:-0.0087483572 54:-0.19381598 55:0.20818299 56:0.22266564 57:0.47187969 58:-0.36918333 59:0.04851548 60:0.464174  |EV|
1 |BT| (ROOT (FRAG (NP (NNP RESULTS)) (: :) (S (NP (NP (DT The) (JJS highest) (NN dose)) (PP (IN of) (NP (NP (NN estradiol)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN progesterone)))))))) (VP (VBD was) (VP (VBN associated) (PP (PP (IN with) (NP (DT the) (ADJP (RBS most) (JJ pronounced)) (NN symptom) (NN recurrence))) (, ,) (CC both) (PP (IN in) (NP (NP (NN comparison)) (PP (IN with) (NP (NP (DT a) (JJR lower) (NN dose)) (PP (IN of) (NP (NN estradiol))))))) (ADVP (RB together))) (PP (IN with) (NP (JJ progesterone) (CC and) (JJ estradiol-only) (NN treatment)))))) (. .))) |ET| |BV| 1:-0.85465067625045776 2:-0.12238670140504837 3:0.039865396916866302 4:-0.019043626263737679 5:0.4582093358039856 6:-0.2334979772567749 7:-0.05501941591501236 8:-0.62751144170761108 9:0.28472161293029785 10:0.22962188720703125 11:0.65343540906906128 12:0.033011775463819504 13:0.56688863039016724 14:0.29359838366508484 15:0.41499623656272888 16:0.37236988544464111 17:-0.36746573448181152 18:0.17696653306484222 19:0.45934385061264038 20:0.7460099458694458 21:-0.70291984081268311 22:0.10596521198749542 23:0.40353924036026001 24:-0.0082024643197655678 25:0.51516556739807129 26:-0.42482960224151611 27:0.15003122389316559 28:0.12399149686098099 29:0.20275136828422546 30:0.48732560873031616 31:0.47781708836555481 32:-0.14894188940525055 33:0.51152008771896362 34:0.33163288235664368 35:-0.59081339836120605 36:0.57499492168426514 37:0.029747411608695984 38:0.1139160692691803 39:0.40241897106170654 40:0.63742589950561523 41:-0.054782338 42:0.008420324 43:-0.086031243 44:0.35578576 45:0.33762404 46:-0.059868045 47:-0.62654752 48:-0.12100456 49:-0.034663845 50:0.26551086 51:0.038700636 52:-0.22988118 53:0.26230201 54:0.20914651 55:-0.28321511 56:0.20418559 57:0.98321259 58:0.61721301 59:0.22644742 60:-0.17938238  |EV|
1 |BT| (ROOT (S (NP (PRP$ Our) (NN analysis)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (NNS prophylaxis)) (PP (IN with) (NP (NN peg-filgrastim)))) (VP (MD may) (ADVP (RB considerably)) (VP (VB reduce) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NN grade)))) (NP (NP (QP (CD 3) (CC or) (JJR more)) (NN neutropenia)) (CC and) (, ,) (ADVP (RB possibly)) (, ,) (PP (IN of) (NP (JJ febrile) (NN neutropenia)))) (PP (IN in) (NP (NP (JJ mCRPC) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN cabazitaxel))))))))))) (. .))) |ET| |BV| 1:-0.17127512395381927 2:-0.081878498196601868 3:0.39199337363243103 4:0.72913873195648193 5:1.4089455604553223 6:0.4702630341053009 7:0.54464995861053467 8:-0.87871235609054565 9:-0.73467504978179932 10:-0.12670056521892548 11:-0.79316812753677368 12:-0.47285756468772888 13:-0.36182430386543274 14:0.87553316354751587 15:-1.0385197401046753 16:-0.12822555005550385 17:-0.088221564888954163 18:-0.61373364925384521 19:-0.30714663863182068 20:-0.77258038520812988 21:-0.66210603713989258 22:0.38383519649505615 23:-0.49435830116271973 24:-0.036724291741847992 25:0.72278141975402832 26:-0.081386148929595947 27:-0.38601914048194885 28:-0.47692117094993591 29:0.2572765052318573 30:1.044156551361084 31:-1.3555667400360107 32:1.0722914934158325 33:0.25008437037467957 34:0.20421920716762543 35:0.88996851444244385 36:0.92478823661804199 37:0.56790214776992798 38:0.95575648546218872 39:-0.65361970663070679 40:-0.48245412111282349 41:0.13127542 42:0.10783552 43:-0.29009476 44:0.31877181 45:0.23046258 46:0.24212383 47:-0.25039005 48:0.31367588 49:-0.026833531 50:0.38692692 51:0.37597352 52:0.19827481 53:0.10000693 54:-0.026924517 55:0.65761656 56:-0.19525468 57:0.36977288 58:-0.1233435 59:0.32315329 60:0.21149889  |EV|
1 |BT| (ROOT (S (NP (NNS Results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NN metformin)) (ADVP (RB significantly)) (VP (VBZ decreases) (NP (NP (DT the) (JJ forskolin/phorbol) (NN ester)) (PRN (-LRB- -LRB-) (NP (NNP FSK/PMA)) (-RRB- -RRB-)) (: -) (NP (NP (JJ induced) (NN expression)) (PP (IN of) (NP (ADJP (JJ aromatase) (PP (IN at) (NP (NP (NNS concentrations)) (PP (IN of) (NP (CD 10) (CC and) (CD 50)))))) (NN muM))))))))) (. .))) |ET| |BV| 1:-0.98817074298858643 2:-0.16603375971317291 3:0.78174632787704468 4:-0.90220063924789429 5:0.49547943472862244 6:-1.1498690843582153 7:-0.40438485145568848 8:1.2268531322479248 9:0.10629954189062119 10:0.69180792570114136 11:0.10759706050157547 12:0.38594195246696472 13:0.46916869282722473 14:-1.2533671855926514 15:-0.59006315469741821 16:-0.47759020328521729 17:0.43856263160705566 18:1.3870284557342529 19:0.22676971554756165 20:-0.95803040266036987 21:-0.72917187213897705 22:-0.43784007430076599 23:0.11291414499282837 24:-0.16863709688186646 25:-0.028862541541457176 26:-0.74388736486434937 27:-0.6363111138343811 28:-0.14964120090007782 29:0.082612067461013794 30:0.62254178524017334 31:0.084620065987110138 32:-0.22390963137149811 33:0.23155888915061951 34:0.69729363918304443 35:-0.023859221488237381 36:-0.039339173585176468 37:-0.18612585961818695 38:-0.67083597183227539 39:0.021638147532939911 40:-0.060303330421447754 41:-0.62895966 42:-0.14026448 43:-0.11344119 44:-0.30993387 45:-0.13912851 46:0.26133624 47:0.15538946 48:-0.28124264 49:-0.93133098 50:0.41370296 51:0.44320068 52:0.11055624 53:0.25334534 54:-0.048394196 55:-0.017813999 56:0.17697428 57:0.0018483046 58:0.19902913 59:0.19674 60:0.32524005  |EV|
1 |BT| (ROOT (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (JJR higher) (JJ systemic) (NN progestin) (NNS levels)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN depot))))))) (VP (VBP medroxyprogesterone) (S (NP (NN acetate) (CC and) (NN combination) (JJ oral) (NNS contraceptives)) (VP (VP (VB suppress) (NP (JJ ovarian) (JJ estradiol) (NN production))) (CC and) (VP (VB reduce) (NP (NP (NN acquisition)) (PP (IN of) (NP (NNP BMD)))) (PP (IN in) (NP (NP (NNS teenagers)) (CC and) (NP (NP (JJ young) (NN adult) (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBP use) (NP (JJ injectable) (CC and) (JJ oral) (NNS contraceptives)))))))))))) (. .))) |ET| |BV| 1:0.0075069614722451661 2:-0.76159483194351196 3:0.0072029829025268555 4:0.21510204672813416 5:1.5778798460960388 6:0.032157119363546371 7:-0.081219445914030075 8:-0.9997527003288269 9:-0.40311038494110107 10:0.012075304985046387 11:0.51479554176330566 12:0.48672075010836124 13:-0.51028436422348022 14:-0.29528298228979111 15:0.15372056514024734 16:1.0255860090255737 17:-0.77464368939399719 18:-0.38708534836769104 19:1.0757442712783813 20:0.63239012658596039 21:-0.85465067625045776 22:-0.12238670140504837 23:0.039865396916866302 24:-0.019043626263737679 25:0.4582093358039856 26:-0.2334979772567749 27:-0.05501941591501236 28:-0.62751144170761108 29:0.28472161293029785 30:0.22962188720703125 31:0.65343540906906128 32:0.033011775463819504 33:0.56688863039016724 34:0.29359838366508484 35:0.41499623656272888 36:0.37236988544464111 37:-0.36746573448181152 38:0.17696653306484222 39:0.45934385061264038 40:0.7460099458694458 41:-0.26126534 42:-0.16405618 43:-0.31750327 44:0.041268915 45:0.25356588 46:0.11393085 47:-0.43540379 48:-0.15843214 49:-0.095958613 50:0.12409505 51:-0.24023718 52:0.19074287 53:-0.2754091 54:-0.45372441 55:0.24797782 56:0.4879556 57:0.66895187 58:-0.083837099 59:0.076331407 60:-0.60232747  |EV|
1 |BT| (ROOT (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NP (JJ Routine) (JJ early) (NN eptifibatide) (NN use)) (, ,) (PP (VBN compared) (PP (IN with) (NP (JJ delayed) (JJ provisional) (NN use)))) (, ,)) (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (JJR lower) (JJ 30-day) (NN ischemic) (NN risk)) (PP (IN in) (NP (NP (JJ non-ST-elevation) (JJ acute) (JJ coronary) (NN syndrome) (NNS patients)) (VP (ADVP (RB also)) (VBN treated) (PP (IN with) (NP (NN clopidogrel))) (PP (IN before) (NP (NN angiography)))))))))))) (. .))) |ET| |BV| 1:0.71652036905288696 2:-0.40332907438278198 3:-0.59834402799606323 4:-0.0015883763553574681 5:0.33634546399116516 6:-0.38538181781768799 7:-0.84922444820404053 8:-1.5489000082015991 9:0.13503545522689819 10:0.68433505296707153 11:0.56421232223510742 12:-0.42848801612854004 13:-0.018336394801735878 14:-0.19189460575580597 15:0.010404167696833611 16:0.41355922818183899 17:-0.10771071165800095 18:0.42704993486404419 19:-0.22207614779472351 20:-0.61421990394592285 21:-0.15856888890266418 22:0.32931959629058838 23:-0.63578540086746216 24:-0.037901204079389572 25:0.40940549969673157 26:0.16079945862293243 27:-0.40807116031646729 28:-0.96301060914993286 29:0.22807566821575165 30:0.12053796648979187 31:-0.31293466687202454 32:0.17092253267765045 33:0.28423032164573669 34:0.14488637447357178 35:-0.22898344695568085 36:1.0369014739990234 37:-0.058853253722190857 38:-0.22417794167995453 39:0.88311076164245605 40:0.0519087053835392 41:-0.059676599 42:0.36429003 43:0.032328703 44:0.21317334 45:-0.32553592 46:0.22599727 47:-0.037548166 48:-0.13953444 49:0.21354544 50:-0.20223476 51:-0.093331568 52:0.16577838 53:-0.15364084 54:-0.11939657 55:0.44321066 56:0.18817712 57:0.66241956 58:-0.10786889 59:0.29866746 60:-0.589894  |EV|
1 |BT| (ROOT (S (NP (NNP Tocilizumab) (NN treatment)) (VP (VBD increased) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NN factor) (CD VIII)))) (PP (IN in) (NP (DT a) (JJ rapid) (CC and) (JJ sustained) (NN manner))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (DT the) (JJ prednisolone) (NN dose)))))))) (. .))) |ET| |BV| 1:-0.86115586757659912 2:0.28541219234466553 3:0.19052702188491821 4:0.2996622622013092 5:0.23198516666889191 6:-0.52643561363220215 7:-0.044808477163314819 8:-0.85596227645874023 9:0.014371099881827831 10:0.88446831703186035 11:0.27386927604675293 12:-0.20425532758235931 13:0.76129603385925293 14:-0.22965890169143677 15:-0.19001731276512146 16:0.42697900533676147 17:-0.95155835151672363 18:-0.71085143089294434 19:0.2538796067237854 20:0.33171182870864868 21:-0.68103639781475067 22:0.6905205100774765 23:0.33124778419733047 24:-0.32335158064961433 25:0.34961898252367973 26:-0.65285880863666534 27:0.21090873330831528 28:-0.45215766131877899 29:-0.2405739538371563 30:0.11513280868530273 31:-0.32448406424373388 32:-0.20304349809885025 33:0.55820858478546143 34:-0.11459027975797653 35:0.62634769082069397 36:0.13714280724525452 37:-0.77483606338500977 38:-0.47620786726474762 39:0.49472841620445251 40:0.55531629920005798 41:-0.5260402 42:0.040202778 43:-0.16155222 44:0.077654392 45:0.1007771 46:-0.26393121 47:0.019789228 48:-0.18529819 49:-0.15939566 50:0.2901181 51:0.2908119 52:-0.35136083 53:-0.1588743 54:-0.10575747 55:-0.024212973 56:0.096512109 57:0.57491863 58:0.31312901 59:0.13119067 60:0.19278426  |EV|
1 |BT| (ROOT (SINV (VP (VBG Using) (NP (DT the) (ADJP (ADJP (JJ intranigral) (JJ lipopolysaccharide)) (PRN (-LRB- -LRB-) (NP (NNP LPS)) (-RRB- -RRB-))) (NN rat) (NN model))) (PRN (, ,) (S (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NN meloxicam)) (, ,) (NP (DT a) (JJ preferential) (NN COX-2) (NN inhibitor)) (, ,)) (VP (VP (VBZ diminishes) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NNP OX-42-immunoreactive) (PRN (-LRB- -LRB-) (NP (NN ir)) (-RRB- -RRB-)) (NN microglia))))) (CC and) (VP (VBZ reduces) (NP (NP (DT the) (NN loss)) (PP (IN of) (NP (NP (JJ tyrosine) (NN hydroxylase)) (PRN (-LRB- -LRB-) (NP (NNP TH)) (-RRB- -RRB-))))))))))) (, -)) (VP (VBP ir) (NP (JJ dopamine) (PRN (-LRB- -LRB-) (NP (NNP DA)) (-RRB- -RRB-)) (NNS neurons)) (PP (IN in) (NP (DT the) (NN substantia) (NN nigra)))) (NP (NP (JJ pars) (NN compacta)) (PRN (-LRB- -LRB-) (NP (NNP SNpc)) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADVP (RB normally)) (VP (VBN induced) (PP (IN by) (NP (NN exposure))) (PP (TO to) (NP (NNP LPS)))))))) (. .))) |ET| |BV| 1:-0.68889814615249634 2:-0.29203572869300842 3:-0.091921061277389526 4:-0.85583287477493286 5:0.19028556346893311 6:-0.9728093147277832 7:-0.13513760268688202 8:0.43235838413238525 9:0.49013328552246094 10:0.22208227217197418 11:0.58568131923675537 12:-0.40404236316680908 13:0.49840709567070007 14:0.21775263547897339 15:0.46412289142608643 16:-0.10357712954282761 17:-0.17316554486751556 18:-0.5283350944519043 19:-0.10205205529928207 20:0.16675248742103577 21:0.22286020219326019 22:-0.36231246590614319 23:-0.039630386978387833 24:-0.2745974063873291 25:-0.51627016067504883 26:-0.25163805484771729 27:-0.69397962093353271 28:0.017182717099785805 29:0.6208527684211731 30:0.46506220102310181 31:-1.2651848793029785 32:-0.93857032060623169 33:-0.61381608247756958 34:0.33596032857894897 35:-0.24084118008613586 36:-0.22675506770610809 37:0.21916913986206055 38:-0.69940108060836792 39:0.60645192861557007 40:0.27172639966011047 41:-0.18622424 42:-0.81706423 43:0.084611282 44:0.081445038 45:0.0030053484 46:-0.19037405 47:0.43096572 48:-0.13220996 49:-0.02393645 50:0.39518321 51:0.68101358 52:0.13603069 53:0.23453447 54:-0.40553513 55:-0.25994229 56:0.53839463 57:0.46485466 58:0.11911035 59:-0.087702088 60:-0.27450597  |EV|
1 |BT| (ROOT (S (NP (NP (NNP Adenosine) (NNP A2A) (NN receptor) (NN activation)) (CC and) (NP (NN hyaluronan) (NN fragment) (NN inhibition))) (VP (VBP reduce) (NP (NN inflammation)) (PP (IN in) (NP (NP (NN mouse) (NN articular) (NNS chondrocytes)) (VP (VBN stimulated) (PP (IN with) (ADJP (JJ interleukin-1ß))))))) (. .))) |ET| |BV| 1:-0.70083105564117432 2:-0.48336687684059143 3:1.555108904838562 4:-0.66309350728988647 5:-0.27682679891586304 6:0.29311046004295349 7:0.97332656383514404 8:0.26250022649765015 9:0.66947346925735474 10:0.11007383465766907 11:0.12701353430747986 12:0.1888488382101059 13:2.0751087665557861 14:0.70770031213760376 15:0.70161557197570801 16:1.2508820295333862 17:1.0054638385772705 18:0.26610258221626282 19:0.17825436592102051 20:-0.33795878291130066 41:-0.055080209 42:0.17051971 43:0.24311967 44:-0.23639181 45:-0.057900582 46:-0.2191066 47:-0.28970817 48:-0.33767453 49:-0.02021179 50:0.38227299 51:0.31343594 52:0.055278443 53:0.19324942 54:-0.34066781 55:0.082516164 56:0.36719826 57:0.3030279 58:0.28605852 59:-0.31925508 60:-0.11240701  |EV|
1 |BT| (ROOT (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NNP Celecoxib)) (VP (MD can) (VP (VB be) (VP (VBN used) (ADVP (ADVP (RB effectively)) (CC and) (ADVP (RB safely))) (S (VP (TO to) (VP (VB prevent) (NP (JJ capecitabine-related) (NN HFS))))))))) (. .))) |ET| |BV| 1:-0.56679701805114746 2:-0.62543493509292603 3:-0.5860247015953064 4:-0.072349876165390015 5:0.29145419597625732 6:0.039748843759298325 7:0.12966907024383545 8:-0.46064525842666626 9:0.56549721956253052 10:0.089931420981884003 11:-0.20305611193180084 12:0.38930007815361023 13:0.12347035855054855 14:-0.012362192384898663 15:-0.31148207187652588 16:0.74294346570968628 17:0.21108853816986084 18:-0.9141501784324646 19:-0.47628018260002136 20:-1.0190287828445435 21:-0.32796666026115417 22:-0.25613048672676086 23:-0.52632725238800049 24:0.24094533920288086 25:-0.26407837867736816 26:-0.0081087350845336914 27:-0.255229651927948 28:-0.01429471280425787 29:0.88211840391159058 30:-0.31850835680961609 31:-0.75686383247375488 32:1.0172774791717529 33:0.68566596508026123 34:-0.85475629568099976 35:-0.31067046523094177 36:0.78766518831253052 37:0.16948181390762329 38:-1.0481270551681519 39:-0.16115592420101166 40:-0.68791288137435913 41:-0.22668482 42:0.12565137 43:-0.1324587 44:0.0024048779 45:0.26116794 46:-0.24280791 47:-0.20895852 48:-0.51180321 49:-0.079732776 50:0.092892893 51:0.31995887 52:-0.010705335 53:-0.14677839 54:0.42625371 55:0.28632826 56:-0.25836739 57:0.35476696 58:-0.16922681 59:-0.16634247 60:-0.11811004  |EV|
1 |BT| (ROOT (NP (NP (JJ Nicotine) (NN treatment)) (NP (-LRB- -LRB-) (JJ 0.4) (NN mg) (NN ·) (NN kg)) (. ?))) |ET| |BV| 1:-1.1741338968276978 2:-0.8037683367729187 3:0.73639500141143799 4:-1.3107953071594238 5:-0.5012480616569519 6:-0.7120283842086792 7:0.037885159254074097 8:0.024502340704202652 9:-0.62534022331237793 10:-1.0763078927993774 11:0.46874541044235229 12:0.8211359977722168 13:-0.54107004404067993 14:0.027600111439824104 15:-1.0784759521484375 16:0.68977898359298706 17:0.37871652841567993 18:0.36807838082313538 19:0.72015947103500366 20:0.38100522756576538 21:-0.31161078810691833 22:-0.36281344294548035 23:0.18907669186592102 24:0.0857047438621521 25:-0.025418208912014961 26:-0.14755964279174805 27:0.024619143456220627 28:-0.21351070702075958 29:1.1228067874908447 30:0.19449490308761597 31:0.71831655502319336 32:-0.6476479172706604 33:-0.32324349880218506 34:-0.11913424730300903 35:-0.39324352145195007 36:1.1804386377334595 37:0.10067534446716309 38:0.44076952338218689 39:-0.16835710406303406 40:0.32567781209945679 41:-0.26463479 42:-0.55324954 43:0.27039886 44:-0.26796728 45:0.18832435 46:0.26036689 47:-0.47951382 48:-0.13806488 49:-0.56894797 50:0.37010613 51:0.48502937 52:0.11663242 53:0.49399641 54:0.028105782 55:-0.23181823 56:0.22351535 57:0.63156885 58:0.1119284 59:0.25994405 60:-0.43358517  |EV|
1 |BT| (ROOT (S (NP (NP (DT An) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN quinine)))))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN drug)) (VP (VBZ is) (ADJP (JJ co-administered) (PP (IN with) (NP (NN nevirapine))))))))) (. .))) |ET| |BV| 1:0.57349073886871338 2:-0.62114441394805908 3:0.13733120262622833 4:-0.73294895887374878 5:0.94155579805374146 6:0.42877951264381409 7:-0.40418940782546997 8:1.1755208969116211 9:0.16499815881252289 10:-0.06225140392780304 11:-0.092863604426383972 12:-0.43411082029342651 13:0.85699158906936646 14:-0.1865602433681488 15:-1.3612602949142456 16:1.4078652858734131 17:-0.13748873770236969 18:-0.29962924122810364 19:1.3479722738265991 20:0.83568090200424194 21:0.069912061095237732 22:-0.10778003185987473 23:-0.88023275136947632 24:0.29654455184936523 25:-0.059729181230068207 26:-0.49629133939743042 27:0.47862133383750916 28:0.022943072021007538 29:0.58010441064834595 30:0.012288450263440609 31:-0.18734775483608246 32:-0.036213595420122147 33:-0.25611776113510132 34:-0.91316807270050049 35:-0.33024159073829651 36:-0.21044041216373444 37:0.23369637131690979 38:0.029738567769527435 39:0.29810675978660583 40:-0.48655638098716736 41:-0.3004795 42:0.39136875 43:0.30683371 44:-0.019175682 45:0.057783317 46:-0.13880754 47:0.31635532 48:-0.2154997 49:-0.58690673 50:0.26825139 51:-0.043800626 52:-0.09825433 53:0.36857939 54:-0.060938723 55:-0.066977113 56:-0.02944928 57:-0.16560057 58:0.32706708 59:0.2795074 60:0.20782381  |EV|
1 |BT| (ROOT (S (NP (DT A) (JJ recent) (NN study)) (VP (VBD reported) (SBAR (IN that) (S (NP (NN resveratrol)) (VP (VP (ADVP (RB directly)) (VBZ inhibits) (NP (JJ cyclic) (JJ adenosine) (JJ monophosphate-specific) (NNS phosphodiesterases))) (CC and) (VP (ADVP (RB then)) (VBZ activates) (NP (JJ 5cyclic) (JJ adenosine) (JJ monophosphate-specific) (NNS phosphodiesterases))))))))) |ET| |BV| 1:-0.58411967754364014 2:-0.47265872359275818 3:-0.15236552059650421 4:-0.015359037555754185 5:0.10891268402338028 6:-1.0250097513198853 7:-1.6109727621078491 8:1.0500451326370239 9:0.052163530141115189 10:0.89534938335418701 11:-0.62225812673568726 12:-0.0080696651712059975 13:0.035750679671764374 14:1.3001171350479126 15:-1.4801602363586426 16:0.88950949907302856 17:-0.50203561782836914 18:-0.24404615163803101 19:-0.24035544693470001 20:-1.4877289533615112 21:-0.308309406042099 22:-0.31597813963890076 23:-0.25802623853087425 24:-0.078292949125170708 25:-0.31885256618261337 26:-0.063564442098140717 27:0.36135384440422058 28:0.2976071685552597 29:0.16068317741155624 30:-0.050796912983059883 31:0.11653322726488113 32:-0.021431386470794678 33:0.75684660673141479 34:0.10787388309836388 35:-0.20611053705215454 36:-0.029026400297880173 37:0.26027099788188934 38:0.034744299948215485 39:0.19359428435564041 40:0.22078773379325867 41:0.0084029417 42:0.017400514 43:0.012152082 44:-0.020999137 45:0.014177808 46:0.020954652 47:-0.0048795589 48:-0.0010717437 49:-0.0050756452 50:-0.011515853 51:0.01602816 52:0.018754518 53:-0.023977019 54:0.0090801353 55:-0.0075581134 56:0.022889582 57:0.0042083976 58:0.017112264 59:-0.00077992986 60:-0.021568734  |EV|
1 |BT| (ROOT (FRAG (NP (NNP CONCLUSION)) (: :) (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN aspirin)) (VP (VP (VBZ inhibits) (NP (NP (DT the) (NN proliferation)) (PP (IN of) (NP (JJ gemcitabine-resistant) (JJ pancreatic) (NN cancer) (NNS cells))))) (CC and) (VP (VBZ augments) (NP (NP (DT the) (JJ antisurvival) (NN effect)) (PP (IN of) (NP (NN gemcitabine))))) (, ,) (PP (ADVP (RB probably)) (IN by) (S (VP (VBG suppressing) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (NNS GSK-3beta)) (CC and) (NP (PRP$ its) (JJ downstream) (NN gene) (NNS products))))))))))))) (. .))) |ET| |BV| 1:-1.0761337280273438 2:-0.72653055191040039 3:-0.047030564397573471 4:-0.095044218003749847 5:0.87921142578125 6:0.14182645082473755 7:0.56299537420272827 8:0.3043750524520874 9:0.050402730703353882 10:0.2984650731086731 11:-0.08135475218296051 12:0.20232106745243073 13:0.73375540971755981 14:-0.26733201742172241 15:-0.2360379695892334 16:0.81133437156677246 17:-0.324349045753479 18:-1.4542429447174072 19:-0.42247280478477478 20:-0.82956928014755249 21:-0.45031630992889404 22:0.15654109418392181 23:-0.1405574232339859 24:0.57517284154891968 25:0.19980970025062561 26:-0.0032609140034765005 27:-0.33045914769172668 28:-0.79845482110977173 29:0.21623410284519196 30:-0.19117653369903564 31:-0.26789900660514832 32:0.13184972107410431 33:0.56898230314254761 34:-0.53675496578216553 35:-0.2580471932888031 36:0.65332514047622681 37:-0.48971584439277649 38:-0.86091041564941406 39:0.14939133822917938 40:-0.010001880116760731 41:-0.096336924 42:-0.027791424 43:0.039164212 44:0.2517575 45:-0.13067243 46:-0.096702948 47:-0.49028218 48:0.26716644 49:0.2047739 50:0.40549722 51:0.10614941 52:0.43307978 53:0.20852001 54:-0.16296774 55:0.17101906 56:0.39294994 57:-0.20900437 58:-0.28422031 59:0.13200566 60:-0.072639398  |EV|
1 |BT| (ROOT (NP (NP (NNP DISCUSSION)) (: :) (NP (NP (NNP Addition)) (PP (IN of) (NP (NP (NN magnesium) (NN lidocaine)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (NP (JJ upper) (JJ extremity) (JJ orthopedic) (NNS operations)) (VP (VBG using) (S (S (NP (NNP IVRA)) (VP (VBZ decreases) (ADVP (RB significantly)) (NP (NP (NP (DT the) (NN time) (NN gap)) (PP (IN between) (NP (NN drug) (NN administration)))) (CC and) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (DT the) (NN block))))))) (: ;) (S (ADVP (RB also)) (, ,) (NP (DT this) (NN drug) (NN combination)) (VP (VBZ increases) (NP (DT the) (NNP IVRA) (NN block) (NN length)) (, ,) (SBAR (IN while) (S (NP (NNP paracetamol)) (VP (VBZ does) (RB not) (VP (VB have) (NP (PDT such) (DT a) (JJ significant) (NN effect))))))))))))))))) (. .))) |ET| |BV| 1:-0.69870471954345703 2:-0.24796676635742188 3:-0.81360667943954468 4:-0.01056311558932066 5:0.23021408915519714 6:-0.49103528261184692 7:-0.12774047255516052 8:0.32772007584571838 9:-0.10109277069568634 10:0.37758281826972961 11:-0.10246789455413818 12:-0.1783854216337204 13:-0.4138738214969635 14:-0.30004423856735229 15:-0.1044161394238472 16:0.11705338954925537 17:-0.51407170295715332 18:0.68735867738723755 19:0.66774976253509521 20:-0.36981764435768127 21:-0.18326178193092346 22:-0.63327020406723022 23:-1.2221074104309082 24:-0.77608859539031982 25:0.18754744529724121 26:-0.082618378102779388 27:-0.14242550730705261 28:0.073615573346614838 29:-0.11079295724630356 30:-0.012629220262169838 31:0.16777820885181427 32:0.12226185202598572 33:-0.07135232537984848 34:-0.55858153104782104 35:-0.28625985980033875 36:0.31376615166664124 37:0.34146344661712646 38:0.47314885258674622 39:-0.37956538796424866 40:-0.51146042346954346 41:-0.14086781 42:0.30037495 43:-0.097284853 44:0.1301499 45:0.42104021 46:-0.30829734 47:-0.041039914 48:-0.34421268 49:0.020515801 50:-0.25443634 51:-0.26521 52:0.020620639 53:0.20517096 54:-0.1703351 55:0.13005041 56:-0.066182412 57:0.26216039 58:0.31447414 59:0.11923023 60:-0.080269575  |EV|
1 |BT| (ROOT (S (ADVP (RB Finally)) (, ,) (NP (NP (DT the) (NN noradrenalin) (NN transporter)) (PP (ADVP (RB together)) (IN with) (NP (JJ dopamine) (NN transporter) (NN blocker) (NN bupropion)))) (VP (VBD was) (ADJP (RBR more) (JJ effective) (PP (IN in) (S (VP (VBG decreasing) (NP (NP (DT the) (NN stress)) (PP (IN of) (NP (NP (DT an) (NN injection)) (PP (IN in) (NP (JJ SERT) (PRN (-LRB- -LRB-) (FRAG (ADJP (RB -) (JJ /)) (: -)) (-RRB- -RRB-)) (NNS rats)))))) (PP (IN than) (PP (IN in) (NP (JJ SERT) (PRN (-LRB- -LRB-) (NP (NNP +) (NNP /) (NNP +)) (-RRB- -RRB-)) (NNS rats))))))))) (. .))) |ET| |BV| 1:-0.43928695097565651 2:-0.056595359928905964 3:0.0809200843796134 4:-0.55128292739391327 5:-0.23415082693099976 6:-0.65561532974243164 7:0.89014655351638794 8:1.0537023544311523 9:1.1572905778884888 10:0.81946077942848206 11:0.24070235341787338 12:-0.6853669285774231 13:0.80484870076179504 14:0.47524851560592651 15:-0.47601757943630219 16:0.36912289261817932 17:-0.8705255538225174 18:0.28288738033734262 19:0.39863422513008118 20:-0.079362049698829651 21:0.43385875225067139 22:-0.70879608392715454 23:-0.15121306478977203 24:-0.49849820137023926 25:0.25945013761520386 26:-0.21913771331310272 27:-0.7705080509185791 28:-0.65597772598266602 29:0.77728211879730225 30:0.75117897987365723 31:0.26791933178901672 32:0.098864078521728516 33:0.040396872907876968 34:0.34282582998275757 35:-0.63833892345428467 36:0.37242758274078369 37:-0.52486193180084229 38:-0.3926006555557251 39:0.14577914774417877 40:0.077141791582107544 41:-0.30710801 42:-0.11094452 43:0.46930155 44:0.14255986 45:0.19020131 46:-0.64546072 47:-0.18757522 48:0.043041289 49:-0.098300159 50:-0.067231648 51:0.56252474 52:0.035957605 53:0.60373741 54:-0.19733548 55:-0.17642644 56:-0.070108272 57:-0.038676135 58:-0.1489349 59:0.06508337 60:-0.017799556  |EV|
1 |BT| (ROOT (S (NP (NP (DT The) (NN attenuation)) (PP (IN of) (NP (NP (JJ mossy) (NN fiber) (NN LTP)) (PP (IN by) (NP (JJ tail) (NN suspension)))))) (VP (VBD was) (ADVP (RB completely)) (VP (VBN restored) (SBAR (WHADVP (WRB when)) (S (NP (NNS rats)) (VP (VBD were) (VP (VBN pretreated) (PP (IN with) (NP (NN clioquinol) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mg/kg)) (-RRB- -RRB-)) (S (VP (TO to) (VP (VB block) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (JJ chelatable) (NN zinc))))))))))))))) (. .))) |ET| |BV| 1:-0.097933709621429443 2:-0.6052822470664978 3:-0.024483999237418175 4:-0.40964469313621521 5:0.93276751041412354 6:-0.79760658740997314 7:0.40149950981140137 8:0.029675951227545738 9:0.12886705994606018 10:0.73275822401046753 11:-0.0099219996482133865 12:0.40133649110794067 13:-0.091869987547397614 14:-0.28844568133354187 15:-0.39580073952674866 16:-0.78840023279190063 17:0.068280048668384552 18:0.14598976075649261 19:0.33837887644767761 20:0.084088556468486786 21:0.11782391369342804 22:-0.1132638230919838 23:-0.45559829473495483 24:0.2364472895860672 25:0.76049387454986572 26:-0.59329843521118164 27:0.54228013753890991 28:0.41613417863845825 29:0.04001135379076004 30:-0.32132768630981445 31:0.92303711175918579 32:0.70906955003738403 33:-0.073625802993774414 34:0.061595749109983444 35:0.56586366891860962 36:0.75466644763946533 37:-0.81484872102737427 38:-0.17582589387893677 39:0.64058375358581543 40:-0.051477093249559402 41:-0.44955367 42:-0.30030286 43:0.11882168 44:-0.45189169 45:0.010749685 46:-0.8219229 47:-0.029807638 48:-0.17772147 49:-0.25201723 50:0.24559647 51:0.016874924 52:0.083186172 53:0.3055582 54:-0.30730185 55:-0.28739202 56:-0.17966278 57:-0.56990087 58:0.10578173 59:-0.00016746538 60:0.014165998  |EV|
1 |BT| (ROOT (S (NP (JJ Ethanol) (NN abuse)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (CD >) (ADJP (NP (CD 50) (NN %)) (JJR lower)) (JJ cumulative) (NN dose)) (PP (IN of) (NP (NP (JJ morphine) (NNS equivalents)) (PRN (-LRB- -LRB-) (NP (NP (NN ratio) (CD 0.47)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NNP CI)) (NP (CD 0.25-0) (CD .87)))) (-RRB- -RRB-)))))))) (. .))) |ET| |BV| 1:-0.45263946056365967 2:-0.44811126589775085 3:-0.40243950486183167 4:-0.3595319390296936 5:0.29140186309814453 6:-0.3102668821811676 7:-0.16002285480499268 8:0.027013452723622322 9:0.46951276063919067 10:0.70688903331756592 11:0.51139503717422485 12:-0.31645745038986206 13:0.28384193778038025 14:-0.14880067110061646 15:-0.087615728378295898 16:-0.37213057279586792 17:0.33573028445243835 18:0.14914470911026001 19:-0.28276950120925903 20:0.36941593885421753 21:-0.18262425065040588 22:-0.27455565333366394 23:-0.63187038898468018 24:-0.20303082466125488 25:-0.49805775284767151 26:-0.36358526349067688 27:-0.67585134506225586 28:-0.18507486581802368 29:0.57143604755401611 30:-0.13132448494434357 31:0.033105544745922089 32:0.3947727382183075 33:0.014030230231583118 34:-0.085290499031543732 35:0.069696143269538879 36:0.078646555542945862 37:-0.25420689582824707 38:-0.09992583841085434 39:0.4503624439239502 40:0.5757184624671936 41:0.20964836 42:0.21594174 43:0.14140192 44:0.047380116 45:0.10607688 46:-0.07651335 47:0.005253105 48:-0.25008866 49:-0.47941738 50:-0.24737062 51:-0.050675459 52:0.29840505 53:0.044068847 54:-0.10152492 55:0.1286649 56:0.44614688 57:0.4337557 58:-0.39313215 59:-0.091315329 60:0.18066423  |EV|
1 |BT| (ROOT (FRAG (NP (NNP CONCLUSIONS)) (: :) (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NP (NN dexamethasone)) (PP (TO to) (NP (NN mepivacaine)))))) (VP (VP (VBZ prolongs) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NN analgesia))))) (CC but) (VP (VBZ does) (RB not) (VP (VB reduce) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (JJ sensory) (CC and) (NN motor) (NN blockade)) (PP (IN after) (NP (JJ ultrasound-guided) (NN supraclavicular) (NN block)))))) (PP (VBN compared) (PP (IN with) (NP (NN mepivacaine)) (ADVP (RB alone)))))))) (. .))) |ET| |BV| 1:-0.10846969485282898 2:-1.1248966455459595 3:-2.2123501300811768 4:-0.45427525043487549 5:-0.0025391362141817808 6:-0.71694999933242798 7:0.98120748996734619 8:0.085808828473091125 9:-0.01811661384999752 10:0.24273000657558441 11:0.28299728035926819 12:0.87854862213134766 13:0.55519455671310425 14:-0.51021361351013184 15:0.35845407843589783 16:0.48307442665100098 17:1.243505597114563 18:0.47536060214042664 19:0.85673850774765015 20:0.015080234967172146 21:-0.37860354781150818 22:-0.77694696187973022 23:0.15381135046482086 24:-0.30914473533630371 25:0.17392580211162567 26:-0.03874872624874115 27:-0.12139929831027985 28:-0.30365684628486633 29:-0.37887203693389893 30:0.9753606915473938 31:-0.1092710867524147 32:-0.26525720953941345 33:0.15702246129512787 34:-0.080765247344970703 35:0.040583889931440353 36:0.4782106876373291 37:-0.29756030440330505 38:-0.32002869248390198 39:-0.079881735146045685 40:0.0094199497252702713 41:-0.0069700577 42:0.62894666 43:-0.11931515 44:-0.095916934 45:0.6696977 46:-0.52859932 47:-0.38847485 48:-0.2709077 49:-0.022042869 50:0.079710484 51:-0.27185559 52:-0.3044467 53:-0.33029908 54:-0.063711867 55:-0.30507949 56:0.09436854 57:0.46872929 58:-0.17002775 59:-0.27465081 60:0.083312295  |EV|
1 |BT| (ROOT (S (S (NP (NNP MEASUREMENTS) (CC AND) (NNP MAIN)) (VP (VBZ RESULTS))) (: :) (S (NP (PRP$ Our) (NN study)) (VP (VBZ demonstrates) (SBAR (IN that) (S (S (LST (LS 1) (-RRB- -RRB-)) (NP (JJ proteasomal) (JJ glucocorticoid) (NN receptor) (NNS degradation)) (VP (VBZ is) (VP (VBN established) (PP (IN in) (NP (NN brain) (NN endothelial) (NNS cells))) (PP (IN after) (NP (NP (JJ traumatic) (NN brain) (NN injury)) (PP (IN as) (NP (NP (DT a) (NN form)) (PP (IN of) (NP (JJ posttranslational) (JJ glucocorticoid) (NN receptor) (NN modification)))))))))) (: ;) (S (NP (NP (LST (LS 2) (-RRB- -RRB-)) (NP (NN inhibition)) (PP (IN of) (NP (NP (DT the) (JJ proteasomal) (NN degradation) (NN pathway)) (PP (IN with) (NP (NN bortezomib)))))) (PRN (-LRB- -LRB-) (NP (CD 0.2) (NN mg/kg)) (-RRB- -RRB-)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NP (DT the) (JJ glucocorticoid) (NN dexamethasone)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-))) (PP (IN by) (NP (JJ subcutaneous) (NN injection))))) (NP-TMP (CD 30) (NNS minutes))))) (VP (VP (ADVP (RB postinjury)) (VBZ restores) (NP (NP (NNS levels)) (PP (IN of) (NP (NP (NN barrier)) (VP (VBG sealing) (NP (NP (JJ glucocorticoid) (NN receptor) (NN target) (NN occludin)) (PP (IN in) (NP (NN brain) (NN endothelial) (NNS cells))))))))) (, ,) (VP (VBZ improves) (NP (JJ blood-brain) (NN barrier) (NN integrity))) (, ,) (VP (VBZ reduces) (NP (NN edema) (NN formation))) (, ,) (CC and) (VP (VBZ limits) (NP (JJ neuronal) (NN damage)) (PP (IN after) (NP (NN brain) (NN trauma)))))))))) (. .))) |ET| |BV| 1:-0.50815683603286743 2:-0.81141805648803711 3:0.69089633226394653 4:0.50509023666381836 5:0.87124818563461304 6:-0.40051931142807007 7:0.20089279115200043 8:-0.34843119978904724 9:-0.84581851959228516 10:1.0982402563095093 11:-0.055473688989877701 12:0.25731325149536133 13:0.77957820892333984 14:0.46582648158073425 15:0.6419638991355896 16:0.82395142316818237 17:0.15897981822490692 18:-0.82585740089416504 19:0.24042521417140961 20:-0.81440454721450806 21:-0.37860354781150818 22:-0.77694696187973022 23:0.15381135046482086 24:-0.30914473533630371 25:0.17392580211162567 26:-0.03874872624874115 27:-0.12139929831027985 28:-0.30365684628486633 29:-0.37887203693389893 30:0.9753606915473938 31:-0.1092710867524147 32:-0.26525720953941345 33:0.15702246129512787 34:-0.080765247344970703 35:0.040583889931440353 36:0.4782106876373291 37:-0.29756030440330505 38:-0.32002869248390198 39:-0.079881735146045685 40:0.0094199497252702713 41:-0.98713988 42:-0.7381556 43:-0.3788994 44:-0.68624175 45:-0.33139229 46:-0.16791049 47:0.070695803 48:-0.076030038 49:0.18732956 50:-0.04925666 51:0.28003922 52:-0.49605626 53:0.41498891 54:-0.11530301 55:0.13957149 56:0.39291275 57:0.22017333 58:-0.049427692 59:-0.29047385 60:0.054481585  |EV|
1 |BT| (ROOT (S (NP (NP (NP (NNP Low) (NNS doses)) (PP (IN of) (NP (NN oxybutynin)))) (, ,) (NP (NP (DT an) (JJ anticholinergic) (NN medication)) (SBAR (WHNP (WDT that)) (S (ADVP (RB competitively)) (VP (VBZ antagonizes) (NP (DT the) (JJ muscarinic) (NN acetylcholine) (NN receptor)))))) (, ,)) (VP (MD can) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NN palmar) (NNS hyperhidrosis)) (PP (IN with) (NP (JJR fewer) (NN side) (NNS effects))))))))) (. .))) |ET| |BV| 1:-0.51880121231079102 2:0.17045455705374479 3:0.85412108898162842 4:-0.69963857531547546 5:-0.2943166047334671 6:-0.34126417338848114 7:0.62195433676242828 8:0.2749420553445816 9:0.82437688112258911 10:0.068378299474716187 11:0.80219161510467529 12:-0.45784677565097809 13:1.1120889782905579 14:0.20851708203554153 15:-0.052710539312101901 16:0.37089569866657257 17:0.32535319030284882 18:-0.068557709455490112 19:0.57967972755432129 20:-0.22693540155887604 21:-1.5915744304656982 22:0.28387871384620667 23:0.70781689882278442 24:-0.82616466283798218 25:0.52297723293304443 26:0.27328887581825256 27:0.61876070499420166 28:0.99428755044937134 29:1.2780674695968628 30:1.2075725793838501 31:-0.96468573808670044 32:0.52205604314804077 33:-0.58593368530273438 34:-0.49952518939971924 35:-0.72520172595977783 36:-0.030002571642398834 37:0.50635254383087158 38:-0.38588538765907288 39:0.90383446216583252 40:-1.0607157945632935 41:-0.17759308 42:0.096929029 43:0.31493446 44:-0.035304289 45:0.26120454 46:0.21718191 47:0.0020539106 48:-0.48884836 49:-0.062609412 50:0.26391169 51:0.29302233 52:0.086325034 53:-0.45860323 54:-0.089275755 55:0.31635192 56:-0.32018757 57:-0.10573237 58:-0.14954974 59:-0.19930482 60:0.018251302  |EV|
1 |BT| (ROOT (S (NP (NNP Selenium)) (VP (VBZ attenuates) (NP (NP (JJ adriamycin-induced) (JJ cardiac) (NN dysfunction)) (PP (IN via) (S (VP (VBG restoring) (NP (NP (NN expression)) (PP (IN of) (NP (JJ ATP-sensitive) (NN potassium) (NNS channels)))) (PP (IN in) (NP (NNS rats)))))))) (. .))) |ET| |BV| 1:-0.074493646621704102 2:0.71976464986801147 3:-0.21396432816982269 4:-0.26380324363708496 5:0.042501077055931091 6:0.15227691829204559 7:-0.046447642147541046 8:-0.41188600659370422 9:1.0815731287002563 10:-0.58426511287689209 11:-0.46673494577407837 12:-0.78133094310760498 13:0.31379315257072449 14:0.83311575651168823 15:0.56302767992019653 16:-0.89255762100219727 17:-0.16943435370922089 18:-0.20200319588184357 19:-0.26159819960594177 20:0.71667402982711792 21:-0.84095442295074463 22:-0.26002046465873718 23:0.35422635078430176 24:-0.41506358981132507 25:0.24434551596641541 26:0.33636441826820374 27:-0.098769396543502808 28:-0.43478909134864807 29:0.19588550925254822 30:0.27329164743423462 31:-0.76377040147781372 32:-0.82083845138549805 33:0.18110927939414978 34:0.284563809633255 35:-0.040204130113124847 36:-0.0043880525045096874 37:-0.53718525171279907 38:-0.6499214768409729 39:-0.46033313870429993 40:0.28226664662361145 41:-0.72913688 42:-0.20518996 43:0.16337502 44:-0.39143226 45:-0.094706923 46:-0.031286705 47:0.26639876 48:-0.15889025 49:0.039190017 50:-0.022993386 51:0.12730381 52:-0.41042995 53:0.23311917 54:0.15098602 55:0.02116636 56:0.12731932 57:0.12481887 58:0.19910228 59:0.10648496 60:0.17767385  |EV|
1 |BT| (ROOT (S (S (VP (VBN Randomized))) (, ,) (NP (JJ double-blind) (NNS studies)) (VP (VBD demonstrated) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NP (NN neostigmine)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ increases) (NP (JJ cholinergic) (NN tone)))))))) (, ,) (PP (VBN combined) (PP (IN with) (NP (NP (NN glycopyrrolate)) (, ,) (NP (NP (DT an) (JJ anticholinergic) (NN agent)) (PP (IN with) (NP (NP (JJ minimal) (NN activity)) (PP (IN in) (NP (NP (DT the) (NN colon)) (SBAR (WHNP (WDT that)) (S (VP (VBZ reduces) (NP (JJ extracolonic) (NNS side-effects)))))))))))))) (. .))) |ET| |BV| 1:-0.73282301425933838 2:-0.62496715784072876 3:-0.55196630954742432 4:-0.59960639476776123 5:0.041034616529941559 6:-0.34943714737892151 7:0.12115459144115448 8:0.74872982501983643 9:0.71173536777496338 10:-0.54305732250213623 11:0.92430597543716431 12:-0.20378845930099487 13:0.71527504920959473 14:-0.89005416631698608 15:-1.0758097171783447 16:1.0591765642166138 17:-0.083953075110912323 18:0.84651631116867065 19:-0.49481835961341858 20:-0.20741775631904602 21:-0.59328508377075195 22:-0.55294811725616455 23:-0.57597559690475464 24:-1.1223059892654419 25:0.67643135786056519 26:0.43415868282318115 27:0.1625148206949234 28:-0.11341550946235657 29:0.31060078740119934 30:0.75220131874084473 31:-0.15621031820774078 32:0.58801215887069702 33:-0.26563930511474609 34:-0.96827411651611328 35:0.25380414724349976 36:-0.24970884621143341 37:0.34735751152038574 38:-0.56714379787445068 39:-0.07748924195766449 40:-0.7113153338432312 41:-0.49468029 42:0.51294333 43:0.37286428 44:0.11083341 45:-0.022975842 46:0.073579207 47:-0.13125758 48:-0.83527756 49:0.0052624461 50:0.27846742 51:0.63454539 52:0.16527042 53:-0.27842113 54:-0.026566118 55:-0.41302904 56:-0.19662595 57:0.04714008 58:-0.20998394 59:0.25194424 60:0.039853305  |EV|
1 |BT| (ROOT (S (SBAR (IN As) (S (NP (DT the) (NN TOFR)) (VP (VBD was) (NP (NP (CD 1.44)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN surgery)) (VP (VBD completed)))))))) (, ,) (NP (DT the) (NN trachea)) (VP (VBD was) (VP (VBN extubated) (PP (IN without) (S (VP (VBG giving) (ADJP (JJ neostigmine) (S (VP (TO to) (VP (VB antagonize) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN vecuronium))))))))))))) (. .))) |ET| |BV| 1:-0.73282301425933838 2:-0.62496715784072876 3:-0.55196630954742432 4:-0.59960639476776123 5:0.041034616529941559 6:-0.34943714737892151 7:0.12115459144115448 8:0.74872982501983643 9:0.71173536777496338 10:-0.54305732250213623 11:0.92430597543716431 12:-0.20378845930099487 13:0.71527504920959473 14:-0.89005416631698608 15:-1.0758097171783447 16:1.0591765642166138 17:-0.083953075110912323 18:0.84651631116867065 19:-0.49481835961341858 20:-0.20741775631904602 21:-0.68614113330841064 22:-0.65829485654830933 23:-0.00013987022975925356 24:-0.69458353519439697 25:0.96579355001449585 26:-0.39681914448738098 27:0.070516727864742279 28:0.88442426919937134 29:2.4594264030456543 30:0.64080500602722168 31:-0.21193583309650421 32:0.462291419506073 33:-0.40535548329353333 34:-1.1348872184753418 35:-0.20699724555015564 36:0.71404099464416504 37:0.092942588031291962 38:1.1456378698348999 39:0.64754295349121094 40:0.24682903289794922 41:-0.39083207 42:0.25195426 43:0.088800497 44:-0.087418184 45:0.35853833 46:0.13507693 47:-0.085344456 48:-0.06275928 49:-0.059664588 50:0.45961237 51:0.08794494 52:0.11617428 53:-0.28607452 54:-0.26028624 55:-0.46931139 56:-0.28569847 57:0.084914111 58:-0.12482747 59:-0.0028960989 60:-0.42502385  |EV|
1 |BT| (ROOT (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NNP Genistein)) (VP (MD can) (VP (VP (VB reduce) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NNS TGF-beta1))))) (CC and) (VP (VB block) (NP (NP (DT the) (NN accumulation)) (PP (IN of) (NP (NP (NN intracellular) (JJ free) (NN calcium)) (VP (VBN induced) (PP (IN by) (NP (NN growth) (NNS factors))))))))))) (. .))) |ET| |BV| 1:-0.76733154058456421 2:0.24607940018177032 3:-0.3637290894985199 4:-0.26238524913787842 5:-0.33067521452903748 6:-0.33500140905380249 7:-0.08953440934419632 8:0.13414254784584045 9:0.37700408697128296 10:0.26008978486061096 11:-0.075949981808662415 12:-0.24670501053333282 13:0.17961160838603973 14:-0.15187470614910126 15:-1.0580264329910278 16:-0.25400683283805847 17:-0.31937047839164734 18:0.033552780747413635 19:0.48308485746383667 20:-0.69982004165649414 21:-0.88100749254226685 22:-0.82609057426452637 23:-1.0307251214981079 24:-0.55634868144989014 25:-0.26797688007354736 26:-0.31451919674873352 27:0.50074118375778198 28:0.95685005187988281 29:-1.155311107635498 30:0.057921607047319412 31:0.56989318132400513 32:-0.15794640779495239 33:1.2393218278884888 34:0.034051261842250824 35:0.38033518195152283 36:1.0104743242263794 37:0.24098911881446838 38:-0.438519686460495 39:0.26584595441818237 40:-0.64438432455062866 41:0.16321167 42:-0.28958035 43:-0.059644565 44:0.0074298442 45:0.30851322 46:-0.50210363 47:-0.029710406 48:-0.0061491807 49:-0.08498773 50:0.258744 51:-0.31173491 52:-0.29327375 53:-0.031276263 54:0.016536172 55:-0.088501006 56:0.29832447 57:0.66238058 58:0.039773043 59:-0.022565685 60:0.2259912  |EV|
-1 |BT| (ROOT (FRAG (NP (NNP CONCLUSION)) (: :) (S (NP (PRP$ Our) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ canakinumab) (CD 150) (NN mg)) (VP (VP (VBZ provides) (NP (JJ rapid) (CC and) (JJ sustained) (NN pain) (NN relief)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ acute) (JJ gouty) (NN arthritis)))))) (, ,) (CC and) (VP (ADVP (RB significantly)) (VBZ reduces) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (JJ recurrent) (NNS flares)) (PP (VBN compared) (PP (IN with) (NP (JJ triamcinolone) (NN acetonide))))))))))))) (. .))) |ET| |BV| 1:-0.70107084512710571 2:-0.67142343521118164 3:-0.99821794033050537 4:-0.27082878351211548 5:0.96723514795303345 6:-0.90341013669967651 7:-0.21741242706775665 8:0.17161171138286591 9:0.18283897638320923 10:0.35798311233520508 11:-0.34145879745483398 12:-0.28059735894203186 13:-0.21575036644935608 14:0.80553984642028809 15:-0.29131484031677246 16:0.31853765249252319 17:-0.014064249582588673 18:-0.62460803985595703 19:-2.1282365322113037 20:-0.86754268407821655 21:-0.50730270147323608 22:-0.46654549241065979 23:-0.19207969307899475 24:-0.18477006256580353 25:0.48602673411369324 26:0.0095923962071537971 27:-0.15957985818386078 28:-0.66272211074829102 29:-0.11714134365320206 30:-0.083451218903064728 31:-0.29273140430450439 32:-0.0025909750256687403 33:0.99936646223068237 34:0.77390444278717041 35:0.61782747507095337 36:0.65482217073440552 37:0.43461203575134277 38:-0.63503080606460571 39:0.77378171682357788 40:0.27871394157409668 41:-0.23816001 42:0.49596485 43:0.24029925 44:0.34273428 45:-0.10382351 46:0.1243526 47:0.22147045 48:-0.12639189 49:0.085527204 50:0.10854711 51:-0.05201349 52:0.33668953 53:-0.027487827 54:0.24325944 55:-0.12473096 56:-0.14732218 57:0.414942 58:0.085233316 59:0.43200132 60:-0.074566804  |EV|
-1 |BT| (ROOT (S (NP (DT The) (NN plasma) (NN lipid) (NN peroxidation)) (VP (VP (VBD was) (VP (VBN determined) (CC and) (VBN reported) (PP (IN as) (NP (JJ thiobarbituric) (NN acid) (NN reactive) (NN substance))))) (CC and) (VP (VBD was) (ADJP (ADJP (ADJP (RB significantly) (JJ increased)) (PRN (-LRB- -LRB-) (NP (CD +21) (NN %)) (-RRB- -RRB-))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (NNS activities)) (PP (IN of) (NP (NP (DT the) (JJ erythrocyte) (JJ antioxidant) (NNS enzymes) (NN glutathione)) (ADJP (JJ peroxidase) (, ,) (JJ catalase) (, ,) (CC and) (JJ superoxide) (JJ dismutase))))) (VP (VBD were) (ADVP (RB significantly)) (VP (VBN decreased) (PRN (-LRB- -LRB-) (NP (NP (NP (CD -32) (NN %)) (, ,) (NP (CD -14) (NN %)) (CC and) (NP (CD -31) (NN %))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))))))) (PP (IN in) (NP (JJ amphetamine) (NNS users))))) (. .))) |ET| |BV| 1:-0.51009583473205566 2:-0.56838345527648926 3:0.018959643319249153 4:-0.8073391318321228 5:-0.028113126754760742 6:-0.51623201370239258 7:0.14834246039390564 8:-0.50347131490707397 9:0.91042083501815796 10:0.16682194173336029 11:0.37457370758056641 12:-0.095307551324367523 13:0.23110786080360413 14:-0.50809144973754883 15:-0.55485570430755615 16:-0.40123346447944641 17:0.6509438157081604 18:-0.029162149876356125 19:0.42906674742698669 20:1.1775617599487305 21:-2.131966233253479 22:1.0506795942783356 23:0.86121746897697449 24:-0.52978295087814331 25:-0.8402726948261261 26:-0.48896053433418274 27:-0.34385865926742554 28:0.59534968435764313 29:-0.29902796074748039 30:0.96731510758399963 31:0.075172229669988155 32:0.12474464997649193 33:1.6130535006523132 34:0.37658464908599854 35:-0.24996968731284142 36:-1.5141645669937134 37:-1.6431140899658203 38:-0.34250835329294205 39:0.28368517756462097 40:-1.1796204149723053 41:0.36493894 42:-0.12623131 43:0.23646332 44:-0.0021588178 45:-0.22519679 46:-0.017826512 47:-0.76105434 48:-0.16577321 49:0.093279012 50:-0.21217889 51:0.42986286 52:0.47051576 53:0.11429661 54:-0.94374698 55:-0.17818514 56:0.49227211 57:0.39937896 58:0.26278988 59:-0.57860619 60:0.089267962  |EV|
-1 |BT| (ROOT (S (NP (NP (NNS Millions)) (PP (IN of) (NP (NNS individuals)))) (VP (VBP are) (VP (VBN prescribed) (S (NP (NP (JJ platelet) (NNS inhibitors)) (, ,) (PP (JJ such) (IN as) (NP (NN aspirin) (CC and) (NN clopidogrel))) (, ,)) (VP (TO to) (VP (VB reduce) (NP (NP (PRP$ their) (NN risk)) (PP (IN of) (NP (JJ thrombosis-related) (JJ clinical) (NNS events))))))))) (. .))) |ET| |BV| 1:-0.15856888890266418 2:0.32931959629058838 3:-0.63578540086746216 4:-0.037901204079389572 5:0.40940549969673157 6:0.16079945862293243 7:-0.40807116031646729 8:-0.96301060914993286 9:0.22807566821575165 10:0.12053796648979187 11:-0.31293466687202454 12:0.17092253267765045 13:0.28423032164573669 14:0.14488637447357178 15:-0.22898344695568085 16:1.0369014739990234 17:-0.058853253722190857 18:-0.22417794167995453 19:0.88311076164245605 20:0.0519087053835392 21:-0.45031630992889404 22:0.15654109418392181 23:-0.1405574232339859 24:0.57517284154891968 25:0.19980970025062561 26:-0.0032609140034765005 27:-0.33045914769172668 28:-0.79845482110977173 29:0.21623410284519196 30:-0.19117653369903564 31:-0.26789900660514832 32:0.13184972107410431 33:0.56898230314254761 34:-0.53675496578216553 35:-0.2580471932888031 36:0.65332514047622681 37:-0.48971584439277649 38:-0.86091041564941406 39:0.14939133822917938 40:-0.010001880116760731 41:-0.13894668 42:0.14867257 43:0.25275663 44:-0.074380524 45:0.30145276 46:0.16982481 47:-0.15957671 48:-0.15784621 49:0.24943964 50:0.31978816 51:0.12373658 52:0.019082075 53:-0.40232769 54:-0.062541299 55:0.2235852 56:0.38597289 57:0.33574659 58:0.14232403 59:0.31984273 60:-0.35995016  |EV|
-1 |BT| (ROOT (S (S (NP (DT The) (JJ cyclooxygenase) (NN inhibitor) (NN indomethacin)) (VP (VBD normalized) (NP (DT this) (NN response)))) (, ,) (CC and) (S (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NP (DT the) (JJ stable) (NN metabolite)) (PP (IN of) (NP (NP (NN prostacyclin)) (PP (IN in) (NP (NP (DT the) (NN aorta)) (PP (IN of) (NP (NNP CLP) (NNS rats)))))))))) (VP (VBD increased) (PP (PP (IN in) (NP (JJ basal) (NNS conditions))) (CC and) (PP (IN after) (NP (NN stimulation)))) (PP (IN with) (NP (NN acetylcholine))))) (. .))) |ET| |BV| 1:-0.69642180204391479 2:0.36328217387199402 3:0.83913600444793701 4:-0.91466933488845825 5:-0.27204117178916931 6:-0.37875962257385254 7:0.44033417105674744 8:0.29511433839797974 9:0.89047360420227051 10:-0.26710110902786255 11:0.88625317811965942 12:-0.29589822888374329 13:0.9739459753036499 14:-0.12877832353115082 15:-0.10586167126893997 16:0.56494545936584473 17:0.29423040151596069 18:0.27486869692802429 19:0.55836880207061768 20:-0.16265568137168884 21:-0.26775088906288147 22:-0.17085112631320953 23:-0.28042009472846985 24:-0.11034965515136719 25:-0.097754493355751038 26:0.26364117860794067 27:0.064379073679447174 28:-0.10352087765932083 29:0.47721406817436218 30:0.89500260353088379 31:-0.43930518627166748 32:-0.32465222477912903 33:-0.036774005740880966 34:-0.4443260133266449 35:-0.21733295917510986 36:-0.36880412697792053 37:-0.047921027988195419 38:-0.76586854457855225 39:-0.049508597701787949 40:0.055001813918352127 41:-0.42306143 42:-0.21677443 43:0.13826723 44:-0.37169611 45:0.14014922 46:-0.23866676 47:-0.11636898 48:-0.23296531 49:0.15913241 50:0.11641513 51:0.020793764 52:-0.3296493 53:0.1054501 54:-0.60931742 55:0.15935853 56:0.15040198 57:-0.23283552 58:-0.036179513 59:-0.10597014 60:0.35070109  |EV|
-1 |BT| (ROOT (S (S (NP (NNP Plasma) (NNP calcium)) (VP (VBD did) (RB not) (VP (VB change)))) (, ,) (CC but) (S (NP (NNS concentrations)) (VP (ADVP (IN of)) (VBZ insulin) (-LRB- -LRB-) (NP (NNP P)))) (. ?))) |ET| |BV| 1:-0.76733154058456421 2:0.24607940018177032 3:-0.3637290894985199 4:-0.26238524913787842 5:-0.33067521452903748 6:-0.33500140905380249 7:-0.08953440934419632 8:0.13414254784584045 9:0.37700408697128296 10:0.26008978486061096 11:-0.075949981808662415 12:-0.24670501053333282 13:0.17961160838603973 14:-0.15187470614910126 15:-1.0580264329910278 16:-0.25400683283805847 17:-0.31937047839164734 18:0.033552780747413635 19:0.48308485746383667 20:-0.69982004165649414 21:0.11782391369342804 22:-0.1132638230919838 23:-0.45559829473495483 24:0.2364472895860672 25:0.76049387454986572 26:-0.59329843521118164 27:0.54228013753890991 28:0.41613417863845825 29:0.04001135379076004 30:-0.32132768630981445 31:0.92303711175918579 32:0.70906955003738403 33:-0.073625802993774414 34:0.061595749109983444 35:0.56586366891860962 36:0.75466644763946533 37:-0.81484872102737427 38:-0.17582589387893677 39:0.64058375358581543 40:-0.051477093249559402 41:-0.16284072 42:-0.36576149 43:0.41856998 44:0.28824455 45:-0.011221407 46:0.47739005 47:-0.45349297 48:-0.14012027 49:-0.14517677 50:-0.03136408 51:0.28500482 52:-0.091129169 53:0.27687401 54:-0.34755701 55:-0.0070933066 56:0.38126776 57:0.81831282 58:0.048237447 59:0.50520217 60:0.33657447  |EV|
-1 |BT| (ROOT (S (NP (DT The) (NP (NNP Nicotrol) (NNP ®) (PRN (-LRB- -LRB-) (NP (NNP Pfizer)) (, ,) (NP (NNP USA)) (-RRB- -RRB-)) (NNP nicotine)) (NN inhaler)) (VP (VBZ reduces) (NP (NN craving)) (PP (IN by) (S (VP (VP (VBG mimicking) (NP (NP (DT the) (JJ behavioural) (NN component)) (PP (IN of) (NP (NNS cigarettes))))) (CC and) (VP (VBG delivering) (NP (NP (JJ controlled) (NNS doses)) (PP (IN of) (NP (NP (NN nicotine)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ binds) (PP (TO to) (NP (NP (DT the) (JJ beta-2) (JJ subunit-containing) (JJ nicotinic) (NN acetylcholine) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NP (JJ ß2) (NNS *)) (: -) (NP (NNS nAChRs))) (-RRB- -RRB-))))))))))))))) (. .))) |ET| |BV| 1:-0.31161078810691833 2:-0.36281344294548035 3:0.18907669186592102 4:0.0857047438621521 5:-0.025418208912014961 6:-0.14755964279174805 7:0.024619143456220627 8:-0.21351070702075958 9:1.1228067874908447 10:0.19449490308761597 11:0.71831655502319336 12:-0.6476479172706604 13:-0.32324349880218506 14:-0.11913424730300903 15:-0.39324352145195007 16:1.1804386377334595 17:0.10067534446716309 18:0.44076952338218689 19:-0.16835710406303406 20:0.32567781209945679 21:-0.69642180204391479 22:0.36328217387199402 23:0.83913600444793701 24:-0.91466933488845825 25:-0.27204117178916931 26:-0.37875962257385254 27:0.44033417105674744 28:0.29511433839797974 29:0.89047360420227051 30:-0.26710110902786255 31:0.88625317811965942 32:-0.29589822888374329 33:0.9739459753036499 34:-0.12877832353115082 35:-0.10586167126893997 36:0.56494545936584473 37:0.29423040151596069 38:0.27486869692802429 39:0.55836880207061768 40:-0.16265568137168884 41:-0.13013077 42:-0.25981644 43:0.093551666 44:-0.32276356 45:0.052727435 46:0.046370339 47:-0.5112021 48:-0.42461124 49:-0.21455133 50:0.35746774 51:0.67682666 52:0.1710259 53:-0.10439385 54:0.0082091782 55:-0.1243705 56:0.39434627 57:0.20973958 58:0.18682955 59:-0.062972702 60:-0.22990212  |EV|
-1 |BT| (ROOT (S (NP (NP (DT The) (NN breast) (NN cancer) (NN cell) (NN line) (NN MCF7)) (CC and) (NP (DT the) (NN lung) (NN cancer) (NN cell) (NN line) (NN H1299))) (VP (VBD were) (VP (VBN treated) (PP (IN with) (NP (JJ usnic) (NN acid) (CD 29) (NN microM))) (PP (IN for) (NP (NP (NP (CD 24) (NNS hours)) (CC and) (NP (CD two) (JJ positive) (NNS controls))) (: :) (NP (NP (NN vincristine)) (PRN (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (VP (VBZ prevents) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NNS microtubules))))))) (-RRB- -RRB-))) (CC or) (NP (NP (NN taxol)) (PRN (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (VP (VBZ stabilizes) (NP (NNS microtubules))))) (-RRB- -RRB-))))))) (. .))) |ET| |BV| 1:-0.23953434824943542 2:-0.57552444934844971 3:-0.091918863356113434 4:0.54840689897537231 5:-0.1715116947889328 6:-0.2273714691400528 7:0.78435564041137695 8:-0.81545114517211914 9:-0.18066610395908356 10:0.7449570894241333 11:-0.3430122435092926 12:-0.20670248568058014 13:-0.20429329574108124 14:-0.043390769511461258 15:0.5533795952796936 16:0.3697935938835144 17:-0.11731836199760437 18:-0.15539655089378357 19:0.69868940114974976 20:0.17335754632949829 21:0.10806208848953247 22:-0.73798894882202148 23:1.6558136940002441 24:0.51094293594360352 25:0.81971055269241333 26:-1.1616857051849365 27:1.1428647041320801 28:-0.1101008728146553 29:-0.050751615315675735 30:-0.44537079334259033 31:1.1681331396102905 32:0.33287894725799561 33:-0.79483717679977417 34:0.031246200203895569 35:0.29051205515861511 36:0.28662109375 37:-0.33912843465805054 38:-1.6960805654525757 39:-0.73355275392532349 40:-0.39573019742965698 41:-0.068689667 42:-0.26722994 43:-0.62467772 44:0.80861115 45:-0.16673295 46:-0.5172134 47:-0.26220453 48:-0.089695491 49:0.13679996 50:-0.016236933 51:0.740749 52:0.0048364378 53:0.053002104 54:0.41280836 55:0.0089981183 56:0.2014052 57:0.10079674 58:0.01941967 59:0.68656081 60:0.35450247  |EV|
-1 |BT| (ROOT (S (ADVP (RB Recently)) (NP (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (NNS mutations)) (PP (IN in) (NP (NNP KRAS)))) (VP (VBP predict) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NN panitumumab) (CC and) (NN cetuximab)))) (, ,) (S (VP (VP (VBG limiting) (NP (PRP$ their) (NN use) (S (VP (TO to) (VP (VB CRC) (NP (NNS patients)) (PP (IN with) (NP (JJ wild-type) (NNS KRAS)))))))) (, ,) (CC and) (VP (VBG moving) (NP (NP (DT the) (JJ clinical) (NN field)) (PP (IN towards) (NP (VBN personalized) (NN cancer) (NN care))))))))))))) (. .))) |ET| |BV| 1:0.60125124454498291 2:-0.76545882225036621 3:1.1888238191604614 4:0.45946463942527771 5:0.63420009613037109 6:-0.044119510799646378 7:0.73391872644424438 8:0.13165163993835449 9:0.66971921920776367 10:0.89429110288619995 11:-0.68757224082946777 12:0.64582759141921997 13:0.27450233697891235 14:1.323746919631958 15:-0.39306837320327759 16:0.21697030961513519 17:-0.37259691953659058 18:-0.66445273160934448 19:0.4482596218585968 20:-0.88031834363937378 21:-0.2816181480884552 22:-0.68261337280273438 23:0.44740390777587891 24:0.29308760166168213 25:0.5837702751159668 26:0.37423157691955566 27:0.70943683385848999 28:-0.085498526692390442 29:0.86710089445114136 30:0.58071637153625488 31:0.063820101320743561 32:-0.0067333667539060116 33:0.2699408233165741 34:0.39133661985397339 35:-0.3362809419631958 36:1.5841424465179443 37:-0.76286178827285767 38:-0.42525660991668701 39:-0.71097695827484131 40:-0.94073945283889771 41:0.17530411 42:-0.14159285 43:0.10548896 44:-0.18714178 45:-0.094075002 46:-0.13974254 47:0.095271334 48:-0.31400967 49:0.37932444 50:0.38600287 51:0.097688533 52:0.08405342 53:-0.035385132 54:0.40623608 55:0.017745996 56:0.10302187 57:-0.046429336 58:0.41667458 59:-0.062408935 60:0.13697022  |EV|
-1 |BT| (ROOT (S (NP (DT These) (NNS results)) (VP (VP (VBP indicate) (NP (NP (DT a) (JJ major) (NN role)) (PP (IN of) (NP (NP (NN acetylcholine)) (PP (IN in) (NP (JJ airway) (NN inflammation) (CC and) (NN remodelling))))) (PP (IN in) (NP (DT a) (NNP GORD) (NN model))))) (, ,) (CC and) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NN tiotropium) (CC and) (NN atropine)) (VP (MD can) (VP (VB prevent) (NP (NN lung) (NN inflammation)) (PP (IN with) (NP (NP (DT an) (NN effectiveness)) (ADJP (JJ similar) (PP (TO to) (NP (JJ intraperitoneal) (NN dexamethasone)))))) (, ,) (S (VP (VBG providing) (NP (JJ additional) (NN evidence)) (SBAR (IN that) (S (NP (NNS anticholinergics)) (VP (MD might) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NP (JJ inflammatory) (NNS processes)) (PP (IN in) (NP (JJ airway) (NNS diseases))))))))))))))))))) (. .))) |ET| |BV| 1:-0.67935633659362793 2:-0.76576101779937744 3:-0.22106757760047913 4:-0.57372367382049561 5:0.28197568655014038 6:0.208147332072258 7:0.15986424684524536 8:-0.027409208938479424 9:0.26356154680252075 10:0.08958183228969574 11:0.42520076036453247 12:-0.090538851916790009 13:0.23981952667236328 14:-0.41005590558052063 15:-0.60331243276596069 16:0.26125708222389221 17:0.019843308255076408 18:-0.055050365626811981 19:-0.095602601766586304 20:-0.014820318669080734 21:-0.37860354781150818 22:-0.77694696187973022 23:0.15381135046482086 24:-0.30914473533630371 25:0.17392580211162567 26:-0.03874872624874115 27:-0.12139929831027985 28:-0.30365684628486633 29:-0.37887203693389893 30:0.9753606915473938 31:-0.1092710867524147 32:-0.26525720953941345 33:0.15702246129512787 34:-0.080765247344970703 35:0.040583889931440353 36:0.4782106876373291 37:-0.29756030440330505 38:-0.32002869248390198 39:-0.079881735146045685 40:0.0094199497252702713 41:-0.25554961 42:-0.066803969 43:-0.041934393 44:-0.024751531 45:0.63210422 46:-0.54006594 47:-0.031161059 48:-0.71179026 49:0.11188504 50:0.12862749 51:0.33247223 52:-0.27847508 53:0.21757856 54:0.28733116 55:0.24617992 56:0.20327522 57:0.26331401 58:-0.05941309 59:-0.069137335 60:0.070984431  |EV|
-1 |BT| (ROOT (S (NP (NP (NP (NNP Tolvaptan)) (PRN (-LRB- -LRB-) (NP (NP (NNP TOL)) (: ;) (NP (JJ selective) (NN V2) (NN antagonist))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Conivaptan)) (PRN (-LRB- -LRB-) (NP (NP (NNP CON)) (: ;) (NP (JJ dual) (JJ V1a/V2) (NN antagonist))) (-RRB- -RRB-)))) (VP (VBP are) (NP (NP (CD two) (NNP AVP) (NNS antagonists)) (SBAR (WHNP (WDT that)) (S (VP (VB counteract) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NNP AVP)))) (PP (IN with) (NP (JJ distinct) (NNS profiles)))))))) (. .))) |ET| |BV| 1:-0.099199011921882629 2:-0.59156978130340576 3:1.3558156490325928 4:-1.102553129196167 5:0.3752683699131012 6:-0.27797397971153259 7:0.70420801639556885 8:1.389860987663269 9:0.94101846218109131 10:-0.49985513091087341 11:0.72899067401885986 12:0.424012690782547 13:-0.083025023341178894 14:0.33309704065322876 15:-0.41587144136428833 16:0.44663920998573303 17:1.0212160348892212 18:-1.3189735412597656 19:-0.14416024088859558 20:-0.66059714555740356 21:0.4752143919467926 22:-0.46435663104057312 23:1.2071205377578735 24:-1.2103272676467896 25:0.12324187159538269 26:-0.33217537403106689 27:0.83428329229354858 28:0.99301606416702271 29:0.28150647878646851 30:-0.17493747174739838 31:0.71685445308685303 32:0.19261352717876434 33:-0.25161030888557434 34:-0.12366971373558044 35:-0.3902687132358551 36:0.56242197751998901 37:0.36128464341163635 38:-0.9156070351600647 39:-0.22868570685386658 40:-0.40150341391563416 41:-0.15018162 42:-0.51398051 43:0.18935935 44:0.041888025 45:0.15456265 46:-0.25415865 47:0.30340156 48:-0.045860093 49:-0.61562616 50:-0.072516426 51:0.67239285 52:0.047182575 53:-0.057147928 54:-0.2689198 55:-0.052209131 56:0.83301347 57:-0.018257987 58:-0.036308259 59:-0.30328986 60:0.059476748  |EV|
-1 |BT| (ROOT (FRAG (NP (NNP CONCLUSION)) (: :) (S (NP (DT The) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (S (VP (VBG lowering) (NP (NN sodium) (NN intake)) (PP (IN while) (S (VP (VBG maintaining) (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (JJ dietary) (NN calcium) (CC and) (NN magnesium))))))))) (VP (MD may) (VP (VB help) (VP (VB prevent) (NP (JJ ischemic) (NN stroke)) (PP (IN in) (NP (JJ southern) (JJ Chinese) (NNS adults)))))))))) (. .))) |ET| |BV| 1:-0.76733154058456421 2:0.24607940018177032 3:-0.3637290894985199 4:-0.26238524913787842 5:-0.33067521452903748 6:-0.33500140905380249 7:-0.08953440934419632 8:0.13414254784584045 9:0.37700408697128296 10:0.26008978486061096 11:-0.075949981808662415 12:-0.24670501053333282 13:0.17961160838603973 14:-0.15187470614910126 15:-1.0580264329910278 16:-0.25400683283805847 17:-0.31937047839164734 18:0.033552780747413635 19:0.48308485746383667 20:-0.69982004165649414 21:-0.69870471954345703 22:-0.24796676635742188 23:-0.81360667943954468 24:-0.01056311558932066 25:0.23021408915519714 26:-0.49103528261184692 27:-0.12774047255516052 28:0.32772007584571838 29:-0.10109277069568634 30:0.37758281826972961 31:-0.10246789455413818 32:-0.1783854216337204 33:-0.4138738214969635 34:-0.30004423856735229 35:-0.1044161394238472 36:0.11705338954925537 37:-0.51407170295715332 38:0.68735867738723755 39:0.66774976253509521 40:-0.36981764435768127 41:0.12490097 42:-0.24122033 43:0.364043 44:0.27269372 45:-0.020926356 46:0.099756584 47:-0.20888409 48:-0.52222663 49:0.25905439 50:0.23447201 51:-0.53805071 52:-0.010039113 53:-0.51783282 54:-0.27206084 55:-0.020578245 56:-0.09236417 57:0.2175418 58:0.24771287 59:-0.18901238 60:-0.20950763  |EV|
-1 |BT| (ROOT (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (S (NP (NP (JJ dihydropyridine) (NN calcium) (NN channel) (NNS blockers)) (, ,) (PP (JJ such) (IN as) (NP (NN amlodipine))) (, ,)) (VP (VBP have) (VP (VBN been) (VP (VBN proven) (S (VP (TO to) (VP (VB lower) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NN stroke))))))))))) (CC but) (S (NP (PRP$ their) (NN use)) (VP (VBZ seems) (S (VP (TO to) (VP (VB be) (ADJP (JJ effective) (PP (IN in) (S (VP (VP (VBG relieving) (NP (NP (NNS symptoms)) (PP (IN of) (NP (JJ coronary) (NN artery) (NN disease))))) (CC and) (VP (VBG reducing) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NN revascularisation) (NNS procedures)))))))))))))) (. .))) |ET| |BV| 1:0.025097215548157692 2:0.68531781435012817 3:-0.80269664525985718 4:0.0019880877807736397 5:0.91691410541534424 6:0.021895760670304298 7:-0.22288580238819122 8:0.38498020172119141 9:0.99198967218399048 10:0.45172032713890076 11:-0.71133583784103394 12:-0.37961366772651672 13:0.20876647531986237 14:0.1851770430803299 15:-0.78236562013626099 16:0.67130273580551147 17:0.0048903967253863811 18:0.15368357300758362 19:0.60696160793304443 20:-0.013395466841757298 21:-0.76733154058456421 22:0.24607940018177032 23:-0.3637290894985199 24:-0.26238524913787842 25:-0.33067521452903748 26:-0.33500140905380249 27:-0.08953440934419632 28:0.13414254784584045 29:0.37700408697128296 30:0.26008978486061096 31:-0.075949981808662415 32:-0.24670501053333282 33:0.17961160838603973 34:-0.15187470614910126 35:-1.0580264329910278 36:-0.25400683283805847 37:-0.31937047839164734 38:0.033552780747413635 39:0.48308485746383667 40:-0.69982004165649414 41:-0.55360216 42:0.69416606 43:0.14143132 44:-0.012109168 45:0.060778696 46:0.042874884 47:-0.017658187 48:-0.1254151 49:0.015170814 50:-0.049119953 51:0.056066599 52:0.30813375 53:-0.48535234 54:0.17965734 55:0.10110472 56:-0.21423033 57:-0.37189919 58:-0.078309715 59:0.50929612 60:0.14844044  |EV|
-1 |BT| (ROOT (S (NP (PRP$ Our) (NNS studies)) (ADVP (RB further)) (VP (VBP support) (NP (DT the) (NN notion)) (SBAR (SBAR (IN that) (S (NP (NP (JJ 1-phenylpropane-1) (CD ,2)) (: -) (NP (NP (NN dione)) (CC and) (NP (-LRB- -LRB-) (NNP S) (-RRB- -RRB-))) (: -)) (ADVP (RB cathinone)) (VP (VBP are) (NP (NP (JJ biosynthetic) (NNS precursors)) (PP (IN of) (NP (NP (DT the) (JJ ephedrine) (NNS alkaloids)) (PP (IN in) (NP (NP (NNP E.) (NNP sinica)) (VP (VBZ stems)))))))))) (CC and) (SBAR (IN that) (S (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (-LRB- -LRB-) (NNP S) (-RRB- -RRB-)) (: -) (NP (JJ cathinone) (NNS reductases))))) (VP (VBZ directs) (CC and) (VBZ determines) (NP (NP (DT the) (JJ stereochemical) (NN branching)) (PP (IN of) (NP (DT the) (NN pathway))))))))) (. .))) |ET| |BV| 21:-1.1082639694213867 22:-0.6469154953956604 23:-0.76749938726425171 24:-0.76419538259506226 25:0.58523952960968018 26:0.084061302244663239 27:0.76048016548156738 28:0.2280670553445816 29:-0.064313508570194244 30:0.57709318399429321 31:0.20533080399036407 32:0.34237214922904968 33:-0.79073208570480347 34:0.29531130194664001 35:-0.21772186458110809 36:0.9417344331741333 37:0.24663670361042023 38:-0.031097013503313065 39:-0.45997047424316406 40:-0.41981825232505798 41:-0.35839799 42:-0.06994307 43:0.079077519 44:0.19737177 45:-0.23435576 46:-0.01649498 47:0.033517227 48:-0.02881957 49:0.1992152 50:0.069139674 51:0.24089955 52:0.13287215 53:0.15652777 54:0.034178816 55:-0.47532448 56:0.3159157 57:-0.011261834 58:-0.26447919 59:0.40172455 60:-0.061112583  |EV|
-1 |BT| (ROOT (S (PP (X (NP (NNS CONCLUSIONS)) (: :) (PP (IN In) (NP (NNS patients)))) (IN with) (S (NP (NN diabetes) (NNS mellitus)) (VP (VBG presenting) (PP (IN with) (S (NP (NNP STEMI)) (VP (VBG undergoing) (NP (JJ primary) (NN PCI)))))))) (, ,) (NP (NP (JJ anticoagulant) (NN therapy)) (PP (IN with) (NP (NP (NN bivalirudin)) (PP (VBN compared) (PP (IN with) (NP (NNP heparin) (CC plus) (NNP GPI))))))) (VP (VP (VBZ is) (ADJP (JJ safe) (CC and) (JJ effective))) (CC and) (VP (MD might) (VP (VB reduce) (NP (JJ cardiac) (NN mortality)) (PP (IN at) (NP (NP (CD 30) (NNS days)) (CC and) (NP (CD 1) (NN year))))))) (. .))) |ET| |BV| 1:-1.0991220474243164 2:-0.36827781796455383 3:-0.22745463252067566 4:0.79862171411514282 5:1.1189055442810059 6:-0.31402871012687683 7:0.78748995065689087 8:-1.43687903881073 9:0.31192052364349365 10:0.86474186182022095 11:0.19004239141941071 12:-0.21946680545806885 13:-0.23166942596435547 14:-0.094983436167240143 15:-0.052418749779462814 16:1.0033584833145142 17:-0.59131497144699097 18:-0.25575783848762512 19:-0.77031677961349487 20:-1.1225936412811279 21:-0.4122677743434906 22:-0.46324244141578674 23:0.073631599545478821 24:-0.10951337963342667 25:0.16933341324329376 26:-0.27944037318229675 27:-0.18100021779537201 28:-0.50181663036346436 29:0.24505071341991425 30:0.34632956981658936 31:-0.46979761123657227 32:0.0045941001735627651 33:-0.65328466892242432 34:-0.18240880966186523 35:0.043888773769140244 36:0.63524508476257324 37:-0.069035768508911133 38:0.38571858406066895 39:0.22889822721481323 40:-0.57725471258163452 41:0.07721018 42:0.53104848 43:0.41290727 44:0.29133421 45:0.10447101 46:0.053088009 47:-0.21406367 48:-0.20055093 49:0.20370208 50:0.15551409 51:0.10436682 52:-0.10512314 53:-0.4236657 54:0.15486327 55:-0.18560886 56:0.0064896429 57:0.1893428 58:0.36462119 59:-0.28561786 60:0.069616042  |EV|
-1 |BT| (ROOT (S (SBAR (IN As) (S (NP (NP (PDT both) (DT the) (NN response)) (SBAR (S (VP (TO to) (VP (VB prednisolone) (PP (IN in) (NP (NP (ADJP (NN vitro) (CC and) (JJ prednisone))) (PP (IN in) (NP (NN vivo)))))))))) (VP (VBP are) (VP (VBG predictive) (PP (IN for) (NP (JJ clinical) (NN outcome))))))) (, ,) (S (VP (VBG understanding) (CC and) (VBG overcoming) (NP (JJ glucocorticoid) (NN resistance)))) (VP (VBZ remains) (NP (DT an) (JJ essential) (NN step)) (PP (IN towards) (S (VP (VBG improving) (NP (NN prognosis)))))) (. .))) |ET| |BV| 1:-0.25088974833488464 2:-0.2241760790348053 3:-0.23734773695468903 4:0.15524609386920929 5:-0.19554200768470764 6:-0.68985354900360107 7:-0.11541075259447098 8:-0.0034374147653579712 9:-0.091236963868141174 10:0.71780586242675781 11:-0.60373032093048096 12:-0.4882625937461853 13:-0.32568597793579102 14:0.51839214563369751 15:-0.4992041289806366 16:0.075583301484584808 17:-0.023438317701220512 18:0.37608864903450012 19:0.045492861419916153 20:0.31782379746437073 21:-0.2168390154838562 22:-0.5827181339263916 23:-0.37737980484962463 24:0.31495052576065063 25:-0.075841523706912994 26:-0.1366657167673111 27:-0.077723585069179535 28:-0.39503255486488342 29:0.067886330187320709 30:0.4634937047958374 31:-0.58181411027908325 32:0.057384632527828217 33:0.24518060684204102 34:0.18402077257633209 35:-0.60698193311691284 36:-0.26682448387145996 37:0.12457526475191116 38:-0.72550779581069946 39:0.078947603702545166 40:-0.5998038649559021 41:-0.058952384 42:-0.34687319 43:-0.10381656 44:0.079854757 45:0.18420377 46:-0.20589992 47:-0.13227901 48:-0.028267972 49:0.44925666 50:-0.093968749 51:0.25786161 52:0.091424741 53:-0.39672804 54:-0.16570562 55:0.24398781 56:0.50884503 57:0.010939389 58:0.34082115 59:-0.10389297 60:0.051601786  |EV|
-1 |BT| (ROOT (S (PP (IN During) (NP (NP (DT the) (NN period)) (PP (IN of) (NP (NN retention))))) (NP (NP (DT the) (NN chlorine) (NN content)) (PP (IN of) (NP (DT the) (NN blood)))) (VP (VBZ is) (ADJP (RB distinctly) (JJR lower)) (SBAR (IN than) (S (S (ADVP (RB normally)) (, ,) (NP (DT the) (NN calcium) (NN content)) (VP (VBZ is) (ADVP (RB apparently)) (ADJP (RB slightly) (JJR lower)))) (, ,) (CC and) (S (NP (DT the) (NN magnesium) (NN content)) (VP (VBZ tends) (ADVP (RB also)) (S (VP (TO to) (VP (VB be) (ADJP (NP (DT a) (RB little)) (JJR lower)))))))))) (. .))) |ET| |BV| 1:-0.76733154058456421 2:0.24607940018177032 3:-0.3637290894985199 4:-0.26238524913787842 5:-0.33067521452903748 6:-0.33500140905380249 7:-0.08953440934419632 8:0.13414254784584045 9:0.37700408697128296 10:0.26008978486061096 11:-0.075949981808662415 12:-0.24670501053333282 13:0.17961160838603973 14:-0.15187470614910126 15:-1.0580264329910278 16:-0.25400683283805847 17:-0.31937047839164734 18:0.033552780747413635 19:0.48308485746383667 20:-0.69982004165649414 21:-0.69870471954345703 22:-0.24796676635742188 23:-0.81360667943954468 24:-0.01056311558932066 25:0.23021408915519714 26:-0.49103528261184692 27:-0.12774047255516052 28:0.32772007584571838 29:-0.10109277069568634 30:0.37758281826972961 31:-0.10246789455413818 32:-0.1783854216337204 33:-0.4138738214969635 34:-0.30004423856735229 35:-0.1044161394238472 36:0.11705338954925537 37:-0.51407170295715332 38:0.68735867738723755 39:0.66774976253509521 40:-0.36981764435768127 41:-0.33053035 42:0.32286009 43:-0.31099394 44:-0.041827079 45:-0.089347117 46:0.24733691 47:-0.19805221 48:-0.01455935 49:0.14183567 50:-0.12761287 51:0.18701932 52:-0.47131419 53:0.40048292 54:-0.44303295 55:0.38636225 56:0.11848532 57:0.25722757 58:0.085567869 59:0.30996332 60:0.12313284  |EV|
-1 |BT| (ROOT (S (NP (NP (NP (NNP AUTHORS) (POS ')) (NNS CONCLUSIONS)) (: :) (NP (NP (NNP Sublingual) (NNP nitroglycerin)) (, ,) (VP (VBN given) (SBAR (WHADVP (WRB when)) (S (NP (NN oxytocin)) (VP (VBZ fails)))))) (, ,)) (VP (VBZ seems) (S (VP (TO to) (VP (VB reduce) (NP (NP (PDT both) (DT the) (NN need)) (PP (IN for) (NP (NP (JJ manual) (NN removal)) (PP (IN of) (NP (NN placenta) (CC and) (NN blood) (NN loss)))))) (PP (IN during) (NP (NP (DT the) (JJ third) (NN stage)) (PP (IN of) (NP (NN labour))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NN placebo)))))))))) (. .))) |ET| |BV| 1:-0.73396551609039307 2:-0.035638149827718735 3:-0.47762554883956909 4:-1.1443393230438232 5:-0.29404604434967041 6:-1.2843784093856812 7:0.24934539198875427 8:-0.11478795856237411 9:0.55850881338119507 10:0.73228472471237183 11:0.35990875959396362 12:0.18292009830474854 13:-0.37143382430076599 14:-0.65031296014785767 15:0.24407632648944855 16:0.39379450678825378 17:-0.66080558300018311 18:0.79185009002685547 19:1.0224575996398926 20:-0.68803888559341431 21:-0.75388216972351074 22:0.026484988629817963 23:-0.93423944711685181 24:-0.8040388822555542 25:0.15034288167953491 26:-0.057772785425186157 27:0.20338556170463562 28:-0.69750761985778809 29:0.11853725463151932 30:-0.19391100108623505 31:0.63666027784347534 32:-0.52382642030715942 33:-0.066916093230247498 34:-0.7816234827041626 35:-0.40303850173950195 36:-0.30153197050094604 37:0.27281329035758972 38:0.071324415504932404 39:0.16258467733860016 40:-0.37367284297943115 41:-0.14025825 42:0.1799354 43:0.28692123 44:0.16866462 45:0.13340171 46:-0.17866249 47:-0.44523141 48:-0.65965497 49:-0.42149514 50:-0.57263017 51:0.50604087 52:0.08195658 53:-0.087305821 54:0.016588148 55:0.5200491 56:0.051870335 57:0.42822832 58:-0.16960782 59:-0.22868252 60:-0.1605612  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Recent) (NNS initiatives)) (VP (VBG using) (NP (NP (NP (JJR lower) (NNS doses)) (PP (IN of) (NP (NN capecitabine) (CC and) (NN irinotecan)))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ alternative) (NN dosing) (NNS schedules))))) (, ,) (VP (VBP have) (VP (VBN resulted) (PP (PP (IN in) (NP (NP (ADJP (RBR more) (JJ favorable)) (NNS outcomes)) (PRN (-LRB- -LRB-) (NP (JJ efficacy) (CC and) (JJ tolerability)) (-RRB- -RRB-)))) (, ,) (RB even) (PP (IN in) (NP (NN combination)))) (PP (IN with) (NP (NP (NNS targeted-agents)) (PP (JJ such) (IN as) (NP (NN bevacizumab))))))) (. .))) |ET| |BV| 1:-0.46881800889968872 2:-0.46444794535636902 3:-0.26888450980186462 4:-0.15217959880828857 5:1.5136512517929077 6:0.85400742292404175 7:1.0441439151763916 8:-0.89196044206619263 9:-0.1493084579706192 10:0.63301414251327515 11:0.40352672338485718 12:0.23101969063282013 13:0.76615053415298462 14:0.10990569740533829 15:-0.71746057271957397 16:1.3965064287185669 17:-0.45881772041320801 18:-0.66644859313964844 19:-0.70927691459655762 20:-0.94010508060455322 21:-1.3908823728561401 22:-0.11869227141141891 23:0.23167699575424194 24:0.20158879458904266 25:0.51931130886077881 26:0.15928104519844055 27:-0.9472196102142334 28:-0.71603250503540039 29:0.5303729772567749 30:0.30137166380882263 31:-1.0751276016235352 32:0.034899134188890457 33:0.29326963424682617 34:0.060902319848537445 35:-0.11565397679805756 36:0.021296026185154915 37:0.44529137015342712 38:-0.70981979370117188 39:-0.15477675199508667 40:-1.3002903461456299 41:-0.42334145 42:0.053204302 43:0.14373149 44:0.098878093 45:0.50184149 46:0.24694282 47:-0.10846069 48:0.045926113 49:-0.027187824 50:0.26369774 51:0.34348264 52:-0.14971417 53:-0.11164189 54:0.21436319 55:0.21167266 56:-0.033072136 57:0.056870934 58:-0.19191745 59:0.047568329 60:-0.08281666  |EV|
-1 |BT| (ROOT (FRAG (NP (NNP CONCLUSION)) (: :) (S (NP (DT These) (NNS data)) (VP (VBP do) (RB not) (VP (VB support) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP NMDA) (NN receptor) (NNS antagonists) (, ,) (NN ketamine) (CC and) (NN magnesium) (NNS sulfate)))) (S (VP (TO to) (VP (VB prevent) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ remifentanil-induced) (NN postoperative) (NN hyperalgesia) (CC and) (NN tolerance)))))))))) (. .))) |ET| |BV| 1:-1.043468713760376 2:-0.48374432325363159 3:-2.1462996006011963 4:-0.59154266119003296 5:1.3453140258789062 6:0.0023006133269518614 7:-0.0087117943912744522 8:0.089628852903842926 9:-0.58979570865631104 10:0.58092844486236572 11:-0.062513589859008789 12:-0.19914944469928741 13:-0.13309690356254578 14:-0.49067828059196472 15:0.58802539110183716 16:1.4150663614273071 17:-0.094051860272884369 18:0.91224408149719238 19:-0.72598648071289062 20:-0.4579339325428009 21:-0.69870471954345703 22:-0.24796676635742188 23:-0.81360667943954468 24:-0.01056311558932066 25:0.23021408915519714 26:-0.49103528261184692 27:-0.12774047255516052 28:0.32772007584571838 29:-0.10109277069568634 30:0.37758281826972961 31:-0.10246789455413818 32:-0.1783854216337204 33:-0.4138738214969635 34:-0.30004423856735229 35:-0.1044161394238472 36:0.11705338954925537 37:-0.51407170295715332 38:0.68735867738723755 39:0.66774976253509521 40:-0.36981764435768127 41:0.12311483 42:-0.17266284 43:0.54261172 44:0.073040731 45:0.34987366 46:-0.15822597 47:0.16371936 48:-0.34874821 49:-0.13257727 50:0.055886976 51:-0.079014599 52:0.47449544 53:0.019402876 54:0.096627094 55:0.12965058 56:0.089846835 57:0.29744983 58:-0.37044382 59:-0.3985568 60:-0.064133599  |EV|
-1 |BT| (ROOT (S (NP (NP (NNP Ribavirin)) (CC and) (NP (JJ 6-aza-uridine))) (VP (VBD were) (ADJP (JJ able) (S (VP (TO to) (VP (VP (VB delay)) (CC but) (RB not) (VP (VB prevent) (NP (JJ NiV-induced) (NN mortality)) (PP (IN in) (NP (NNS hamsters))))))))) (. .))) |ET| |BV| 1:-0.16825023293495178 2:-0.1773214191198349 3:-0.11057192832231522 4:0.47006824612617493 5:0.55146330595016479 6:-0.91474908590316772 7:-0.12150086462497711 8:-0.21713793277740479 9:-0.14340105652809143 10:0.15220862627029419 11:-0.67543905973434448 12:-0.43896740674972534 13:-0.13286592066287994 14:1.2378125190734863 15:-1.2088123559951782 16:0.45170077681541443 17:-0.13367460668087006 18:-1.0689737796783447 19:0.244657963514328 20:0.28939124941825867 21:-1.1302647590637207 22:-0.87816238403320312 23:0.87777018547058105 24:0.91256284713745117 25:-0.11664555966854095 26:-0.26310652494430542 27:1.2942240238189697 28:1.330219030380249 29:0.36540096998214722 30:-0.1702829897403717 31:-1.0839082002639771 32:0.46411004662513733 33:-0.57737272977828979 34:1.5671377182006836 35:0.0090304119512438774 36:0.50075417757034302 37:0.95782428979873657 38:1.131172776222229 39:0.68107181787490845 40:0.7444005012512207 41:0.0037732667 42:-0.14265953 43:0.032184314 44:0.042804223 45:0.10987251 46:-0.17220221 47:0.26723441 48:-0.15407398 49:-0.13954736 50:-0.00076337677 51:0.19204888 52:0.1135656 53:0.14836071 54:0.3701047 55:0.37077254 56:0.27281705 57:0.32126915 58:0.70471555 59:-0.076927483 60:0.15218115  |EV|
-1 |BT| (ROOT (S (NP (NP (NNS CONCLUSIONS)) (: :) (NP (NP (NNP Administration)) (PP (IN of) (NP (JJ oral) (NN cholecalciferol))) (UCP (PP (TO to) (NP (JJ HIV-infected) (NNS children))) (CC and) (VP (VBG adolescents) (PP (IN at) (NP (NP (DT a) (NN dosage)) (PP (IN of) (NP (CD 100,000) (NN IU)))))) (NP (DT every) (CD 2) (NNS months)) (, ,) (ADVP (RB together) (PP (IN with) (NP (CD 1) (JJ g/day) (NN calcium)))))) (, ,)) (VP (VP (VBZ is) (ADJP (JJ safe))) (CC and) (VP (VBZ results) (PP (IN in) (NP (NP (JJ significant) (NNS increases)) (PP (IN in) (NP (JJ serum) (JJ 25-hydroxyvitamin) (NNP D) (NNS concentrations))))))) (. .))) |ET| |BV| 1:-0.76733154058456421 2:0.24607940018177032 3:-0.3637290894985199 4:-0.26238524913787842 5:-0.33067521452903748 6:-0.33500140905380249 7:-0.08953440934419632 8:0.13414254784584045 9:0.37700408697128296 10:0.26008978486061096 11:-0.075949981808662415 12:-0.24670501053333282 13:0.17961160838603973 14:-0.15187470614910126 15:-1.0580264329910278 16:-0.25400683283805847 17:-0.31937047839164734 18:0.033552780747413635 19:0.48308485746383667 20:-0.69982004165649414 21:-0.096292294561862946 22:-1.5551949739456177 23:-0.98769670724868774 24:0.35432729125022888 25:0.84567105770111084 26:-0.51499336957931519 27:-0.18037846684455872 28:-0.64571470022201538 29:0.15408337116241455 30:0.89624559879302979 31:0.17549346387386322 32:0.44203722476959229 33:-0.59305566549301147 34:0.53062897920608521 35:-0.32494696974754333 36:1.0898079872131348 37:-0.023833915591239929 38:-0.084314443171024323 39:1.4496328830718994 40:-0.97434145212173462 41:0.1874679 42:0.10865168 43:-0.2795662 44:0.30078739 45:0.18772158 46:0.43481719 47:-0.29426977 48:-0.29693085 49:-0.42093197 50:0.24895035 51:-0.0053882585 52:-0.17340101 53:0.35578895 54:0.094016381 55:0.16182128 56:-0.098656625 57:-0.0032122619 58:0.54385775 59:0.30633852 60:-0.044400193  |EV|
-1 |BT| (ROOT (S (ADVP (RB However)) (, ,) (PP (IN at) (NP (JJ 0.63) (NN mg/kg))) (, ,) (NP (NP (NNP F15063)) (VP (VBN induced) (NP (NP (DT a) (JJR lower) (NN degree)) (PP (IN of) (NP (JJ striatal) (NNP IEG) (NNP mRNA) (NN expression)))) (PP (IN than) (NP (NN haloperidol) (CC and) (NN pretreatment))) (PP (IN with) (NP (NP (NP (NP (NP (DT the) (ADJP (JJ serotonin) (NP-TMP (CD 5-HT))) (PRN (-LRB- -LRB-) (NP (CD 1A)) (-RRB- -RRB-)) (NN receptor)) (NP (NNP antagonist) (NNP N))) (: -) (NP (NP (NP (QP (CD -LSB-) (CD 2))) (PRN (: -) (NP (QP (CD -LSB-) (CD 4))) (: -))) (PRN (-LRB- -LRB-) (ADJP (JJ 2-methoxyphenyl)) (-RRB- -RRB-)) (NP-TMP (CD -1))) (: -) (NP (NP (JJ piperazinyl) (NNS -RSB-)) (NP (NN ethyl-N))) (: -) (NP (NP (PRN (-LRB- -LRB-) (ADJP (JJ 2-pyridinyl)) (-RRB- -RRB-)) (JJ cyclohexane) (NN carboxamide)) (NP (NN trihydrochloride)))) (PRN (-LRB- -LRB-) (NP (NNP WAY100635)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (QP (CD 0.63) (CD mg/kg))) (-RRB- -RRB-)))))) (VP (VBD increased) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NNP IEG) (NN mRNA) (NN induction)))) (PP (IN by) (NP (NNP F15063)))) (. .))) |ET| |BV| 1:-0.53704452514648438 2:-0.12204218655824661 3:0.84530586004257202 4:-0.62675082683563232 5:-0.92522335052490234 6:0.035758636891841888 7:0.87108439207077026 8:0.58559095859527588 9:-1.1690226793289185 10:-1.857342004776001 11:0.25633057951927185 12:0.35471615195274353 13:-0.65178722143173218 14:0.58234232664108276 15:0.36624380946159363 16:-0.45924550294876099 17:0.5733916163444519 18:-1.0607194900512695 19:1.3023651838302612 20:-0.84165275096893311 21:-0.028838174417614937 22:-0.19995279610157013 23:-0.23261217772960663 24:-0.71930772066116333 25:0.47374251484870911 26:-0.10928840935230255 27:0.10452057421207428 28:0.003772262716665864 29:0.53051584959030151 30:0.3882269561290741 31:0.940998375415802 32:0.33176013827323914 33:0.12136629223823547 34:0.31366530060768127 35:-0.79584586620330811 36:-0.020856441929936409 37:0.28518173098564148 38:-0.066591188311576843 39:0.3175196647644043 40:0.35279625654220581 41:-0.38618639 42:-0.93829429 43:0.38555783 44:-0.77534562 45:0.35856313 46:-0.21710774 47:-0.11740205 48:-0.39984682 49:-0.36120972 50:-0.14159638 51:0.032128744 52:-0.010269973 53:0.079882212 54:-0.19202092 55:-0.15700236 56:-0.069073133 57:0.46875384 58:-0.011727256 59:0.40354019 60:0.34818971  |EV|
-1 |BT| (ROOT (S (NP (NP (NNP Pretreatment)) (PP (IN of) (NP (NP (NNS rats)) (PP (IN with) (NP (NN hexamethonium) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg/kg/day)) (-RRB- -RRB-)) (S (VP (TO to) (VP (VB antagonize) (NP (JJ peripheral) (JJ nicotinic) (NNS receptors)) (PP (IN except) (PP (IN for) (NP (NP (JJ a7) (JJ nicotinic) (NN acetylcholine) (NN receptor)) (PRN (-LRB- -LRB-) (ADJP (JJ a7-nAChR)) (-RRB- -RRB-))))))))))))) (VP (VBD had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN insulin) (VBG sensitizing) (NN effect)) (PP (IN of) (NP (NN nicotine))))))) (. .))) |ET| |BV| 1:-0.69642180204391479 2:0.36328217387199402 3:0.83913600444793701 4:-0.91466933488845825 5:-0.27204117178916931 6:-0.37875962257385254 7:0.44033417105674744 8:0.29511433839797974 9:0.89047360420227051 10:-0.26710110902786255 11:0.88625317811965942 12:-0.29589822888374329 13:0.9739459753036499 14:-0.12877832353115082 15:-0.10586167126893997 16:0.56494545936584473 17:0.29423040151596069 18:0.27486869692802429 19:0.55836880207061768 20:-0.16265568137168884 21:-0.31161078810691833 22:-0.36281344294548035 23:0.18907669186592102 24:0.0857047438621521 25:-0.025418208912014961 26:-0.14755964279174805 27:0.024619143456220627 28:-0.21351070702075958 29:1.1228067874908447 30:0.19449490308761597 31:0.71831655502319336 32:-0.6476479172706604 33:-0.32324349880218506 34:-0.11913424730300903 35:-0.39324352145195007 36:1.1804386377334595 37:0.10067534446716309 38:0.44076952338218689 39:-0.16835710406303406 40:0.32567781209945679 41:-0.42557269 42:-0.44162837 43:0.070636481 44:-0.14707261 45:0.4170531 46:0.21429317 47:-0.14757098 48:0.1515376 49:-0.73837423 50:0.67230415 51:0.044768557 52:-0.10559467 53:0.085499734 54:-0.0026796774 55:-0.25354201 56:0.13665839 57:-0.072767481 58:0.066548817 59:0.32274595 60:0.11894938  |EV|
-1 |BT| (ROOT (FRAG (NP (NNP CONCLUSION)) (: :) (S (NP (NP (DT Both)) (ADJP (JJ atropine) (CC and) (JJ labetalol))) (VP (VBD were) (ADJP (JJ able) (S (VP (TO to) (VP (VB lower) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NN bradycardia)))))))))) (. .))) |ET| |BV| 1:-0.67935633659362793 2:-0.76576101779937744 3:-0.22106757760047913 4:-0.57372367382049561 5:0.28197568655014038 6:0.208147332072258 7:0.15986424684524536 8:-0.027409208938479424 9:0.26356154680252075 10:0.08958183228969574 11:0.42520076036453247 12:-0.090538851916790009 13:0.23981952667236328 14:-0.41005590558052063 15:-0.60331243276596069 16:0.26125708222389221 17:0.019843308255076408 18:-0.055050365626811981 19:-0.095602601766586304 20:-0.014820318669080734 21:-0.58098125457763672 22:-0.40042358636856079 23:-1.5038908720016479 24:-0.86171507835388184 25:-0.4934094250202179 26:0.017316615208983421 27:0.43960094451904297 28:-0.049376938492059708 29:0.362833172082901 30:0.74861335754394531 31:0.40210619568824768 32:-0.69954502582550049 33:0.42344731092453003 34:-0.44488522410392761 35:-0.40955182909965515 36:0.91399258375167847 37:-0.059419192373752594 38:0.32290282845497131 39:0.011256273835897446 40:-0.64895021915435791 41:-0.33024085 42:0.095193006 43:0.13546225 44:0.10700334 45:-0.020409832 46:-0.27642927 47:-0.40872547 48:-0.34815118 49:0.047458958 50:-0.034340546 51:0.090304479 52:0.013966616 53:-0.33480132 54:-0.064863056 55:-0.24053223 56:-0.16270885 57:0.16170947 58:0.17324926 59:-0.15239599 60:-0.17294192  |EV|
-1 |BT| (ROOT (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (S (PP (IN under) (NP (NP (DT the) (JJ same) (NN dose) (NN level)) (PP (IN of) (NP (NN mefloquine))))) (, ,) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (JJ single) (NN dose)))) (VP (VBZ is) (ADJP (JJ superior) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (JJ multiple) (JJ daily) (NNS doses)))))))) (: ;) (S (NP (NP (NN mefloquine)) (VP (VBN combined) (PP (IN with) (NP (NN artesunate) (CC or) (NN artemether))) (PP (IN at) (NP (DT an) (ADJP (JJ invalid) (CC or) (JJ moderate)) (JJ effective) (NN dose))))) (VP (MD may) (VP (VB show) (NP (NP (JJ synergistic) (NN effect)) (, ,) (RB especially) (NP (NP (DT the) (NN effect)) (PP (IN against) (NP (JJ female) (NNS worms)))))))) (: ;) (S (NP (DT no) (JJ prominent) (JJ synergistic) (NN effect)) (VP (VBZ is) (ADJP (JJ observed)) (, ,) (SBAR (WHADVP (WRB when)) (FRAG (NP (NP (DT the) (JJ similar) (NN dose) (NN level)) (PP (IN of) (NP (NN mefloquine))) (PP (IN in) (NP (NN combination)))))) (PP (IN with) (NP (NN praziquantel)))))))) (. .))) |ET| |BV| 1:-0.56343692541122437 2:-0.35159784555435181 3:-0.14530688524246216 4:0.41392627358436584 5:0.43864274024963379 6:-0.62473142147064209 7:-0.74550020694732666 8:0.1065661758184433 9:0.38636046648025513 10:1.0745468139648438 11:-0.93271833658218384 12:0.50037240982055664 13:-0.11474588513374329 14:-0.72066718339920044 15:-0.34713095426559448 16:1.3505288362503052 17:-0.14346741139888763 18:-0.084357351064682007 19:-0.1347251832485199 20:-0.72076880931854248 21:-0.93005985021591187 22:-0.30919522047042847 23:0.31470483541488647 24:0.076104596257209778 25:0.72613853216171265 26:1.0984203815460205 27:0.33448243141174316 28:-1.0921666622161865 29:-0.30778869986534119 30:2.2662880420684814 31:0.17608442902565002 32:0.30545121431350708 33:-1.0081551074981689 34:-0.26120167970657349 35:0.1207587793469429 36:0.30791527032852173 37:-0.13103453814983368 38:-0.74474751949310303 39:0.014664151705801487 40:-0.36352622509002686 41:-0.69996119 42:-0.16134493 43:0.13931625 44:0.086392276 45:0.35147309 46:0.12523282 47:0.58646411 48:-0.37716371 49:-0.0075372397 50:0.51305377 51:0.42101899 52:0.14617337 53:-0.062068481 54:0.43490702 55:0.13152415 56:-0.69503963 57:0.33024818 58:0.089715101 59:0.23025621 60:0.54238826  |EV|
-1 |BT| (ROOT (S (S (NP (DT Some) (ADJP (RB clinically) (JJ important)) (NNS exceptions)) (, ,) (ADVP (RB however)) (, ,) (VP (VBD were) (ADJP (JJ apparent)))) (: :) (S (NP (NNS women)) (VP (VBD experienced) (NP (ADJP (RB substantially) (JJR lower)) (NN response) (NNS rates)) (PP (IN with) (NP (NP (JJR newer) (NNS antiemetics)) (PP (IN than) (NP (NP (NNS men)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 45) (NN %)) (PP (IN vs.) (NP (CD 58) (NN %)))) (: ;) (NP (NP (JJ relative) (NN risk) (NNS 1.49)) (, ,) (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval)))) (NP (CD 1.35-1) (CD .64))) (-RRB- -RRB-)))))))) (: ;) (S (NP (NNS men)) (VP (VBD had) (NP (NP (JJR higher) (NNS rates)) (PP (IN of) (NP (JJ sexual) (NN dysfunction)))) (PP (IN than) (NP (NP (NNS women) (NN while)) (PP (IN on) (NP (NP (NN paroxetine)) (PP (IN for) (NP (JJ major) (NN depressive) (NN disorder))))))))) (: ;) (S (NP (NNS women)) (VP (VBN discontinued) (NP (NN lovastatin)) (PP (ADVP (RBR more) (RB frequently)) (IN than) (NP (NP (NNS men)) (PP (RB because) (IN of) (NP (JJ adverse) (NNS events))))))) (. .))) |ET| |BV| 1:0.50952249765396118 2:0.44653409719467163 3:-0.42117476463317871 4:-0.31547650694847107 5:0.94188535213470459 6:-0.87366014719009399 7:0.0058062556199729443 8:0.31431654095649719 9:0.28069150447845459 10:1.0075365304946899 11:-0.33895000815391541 12:-0.26962867379188538 13:0.99218714237213135 14:-0.40420466661453247 15:-0.64567238092422485 16:0.22010013461112976 17:0.14331115782260895 18:-1.0680099725723267 19:2.1103479862213135 20:-0.1815706193447113 21:0.40516424179077148 22:-0.34817230701446533 23:-0.21981067955493927 24:0.67711430788040161 25:0.8423309326171875 26:0.27862197160720825 27:-0.19206374883651733 28:-0.02439386211335659 29:-0.0233762226998806 30:0.9987872838973999 31:-1.1819034814834595 32:0.31121748685836792 33:-0.04303300753235817 34:-0.55655074119567871 35:-1.3637564182281494 36:0.078063137829303741 37:0.20712907612323761 38:0.049719754606485367 39:1.4825402498245239 40:-0.26617380976676941 41:-0.031649016 42:0.22462671 43:-0.16766463 44:0.20247023 45:0.2385591 46:0.37477896 47:-0.49243805 48:-0.67391932 49:0.16632746 50:-0.10955181 51:0.047606394 52:0.41431329 53:-0.84957355 54:-0.091051146 55:0.31255504 56:0.52172166 57:0.47119716 58:0.30716452 59:0.4766213 60:0.012856621  |EV|
-1 |BT| (ROOT (S (NP (NP (DT The) (NNS pharmacokinetics) (CC and) (NNS pharmacodynamics)) (PP (IN of) (NP (JJ porcine) (NN insulin) (NN zinc) (NN suspension)))) (VP (VBD were) (VP (VP (VBN studied) (PP (IN in) (NP (NP (NP (CD eight) (NNS dogs)) (PP (IN with) (NP (JJ spontaneous) (NN diabetes) (NNS mellitus)))) (CC and) (NP (NP (DT a) (NN lack)) (PP (IN of) (NP (JJ endogenous) (NN insulin))))))) (, ,) (VP (VBN demonstrated) (PP (IN by) (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (NN insulin) (NN secretion))))) (PP (IN after) (NP (NP (DT an) (NN injection)) (PP (IN of) (NP (NN glucagon)))))) (CC and) (VP (VBN confirmed) (PP (IN by) (NP (NP (NN measurement)) (PP (IN of) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NNP C-peptide))))))) (PP (IN during) (NP (DT the) (JJ pharmacokinetic) (NNS assessments)))))) (. .))) |ET| |BV| 1:0.20189295709133148 2:0.27777375529209775 3:-0.6038479208946228 4:0.37231352366507053 5:0.19332364201545715 6:-0.32141239196062088 7:0.44214948515097302 8:0.12248312433560689 9:0.49692559490601224 10:0.21804627776145935 11:0.72888734936714172 12:0.63714908560117089 13:-0.18561435552934805 14:0.35771164670586586 15:-0.11597318450609843 16:0.55502705276012421 17:-0.78332587083180749 18:-0.25377185146013898 19:0.27052856485048932 20:-0.13939533258477846 21:-1.406773567199707 22:0.40916508436203003 23:-0.93048185110092163 24:-0.90124398469924927 25:-1.1390219926834106 26:-0.90997916460037231 27:-0.13679330050945282 28:-0.4585670530796051 29:0.20126998424530029 30:0.44320374727249146 31:0.17076015472412109 32:0.13942185044288635 33:0.59822404384613037 34:0.28471127152442932 35:0.47598883509635925 36:-0.066112466156482697 37:-1.2346280813217163 38:0.26826265454292297 39:0.56514877080917358 40:-0.9385371208190918 41:-0.24873205 42:-0.37741387 43:-0.13749911 44:-0.16866711 45:-0.02013343 46:-0.26543555 47:-0.11520155 48:-0.60198617 49:-0.21114011 50:0.502029 51:-0.20637487 52:-0.65794069 53:-0.16405942 54:-0.16070814 55:-0.26654825 56:0.12435222 57:0.47522637 58:0.022032019 59:0.42957374 60:-0.0071422169  |EV|
-1 |BT| (ROOT (S (ADVP (RB Secondly)) (, ,) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NP (NP (JJ targeted) (NN therapy) (NNS drugs)) (PP (JJ such) (IN as) (NP (NNP Cetuximab) (CC and) (NNP Erlotinib)))) (, ,) (CC or) (NP (NP (NN non)) (: -) (NP (NP (JJ targeted) (NNS agents)) (PP (JJ such) (IN as) (NP (NN temozolomide) (CC and) (NN nitrosourea)))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN influenced) (PP (IN by) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ certain) (JJ genetic) (CC or) (JJ epigenetic) (NNS markers))))) (PP (IN in) (NP (NNS tumors)))))) (. .))) |ET| |BV| 1:-0.6921430230140686 2:0.21240490674972534 3:0.00080377369886264205 4:0.36204692721366882 5:-0.15223251283168793 6:-0.30088230967521667 7:1.2508336305618286 8:0.25733453035354614 9:1.3072094917297363 10:0.98745745420455933 11:-0.83434855937957764 12:0.40237793326377869 13:-0.078595593571662903 14:0.077269963920116425 15:-0.65975505113601685 16:1.6260929107666016 17:-0.99955791234970093 18:-0.53161036968231201 19:1.0515879392623901 20:-0.45317563414573669 21:-0.28991279006004333 22:0.37629354000091553 23:0.42804348468780518 24:-0.22335901856422424 25:0.28749895095825195 26:0.5898507833480835 27:0.8052636981010437 28:-0.1943410187959671 29:1.3410344123840332 30:0.66071438789367676 31:0.48423975706100464 32:0.22147801518440247 33:0.3567124605178833 34:-0.28302618861198425 35:-0.63071799278259277 36:1.5842504501342773 37:-0.47079864144325256 38:0.025771930813789368 39:0.47316387295722961 40:-1.274549126625061 41:0.13066009 42:0.11461355 43:-0.24673337 44:0.24634486 45:-0.16579489 46:-0.27172568 47:-0.09005148 48:-0.12256122 49:0.24209523 50:0.43269047 51:0.70043033 52:0.32129848 53:0.21017855 54:0.32587168 55:0.043249562 56:0.20948215 57:0.20467678 58:0.41391915 59:0.24450508 60:0.2613984  |EV|
-1 |BT| (ROOT (FRAG (NP (NNP CONCLUSIONS)) (: :) (S (NP (NP (JJ Mucosal) (NN injury)) (PP (IN with) (NP (JJ diclofenac-K) (JJ liquid) (CD 25) (NN mg) (JJ liquid) (NNS capsules)))) (VP (VP (VBD was) (ADJP (JJ similar) (S (VP (TO to) (VP (VB diclofenac-K) (NP (NP (CD 25) (NN mg) (NNS tablets)) (, ,) (NP (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN than) (NP (NNP ASA) (CD 1)))) (NN g) (NNS tablets)))))))) (CC and) (VP (VBD showed) (NP (DT some) (NN superiority)) (PP (IN over) (NP (NP (JJ ibuprofen) (ADJP (NP (CD 400) (NNS mg)) (JJ liquid)) (NNS capsules)) (PRN (-LRB- -LRB-) (NP (NNP EudraCT) (NNP Number) (NNP 2009-011278-14)) (-RRB- -RRB-))))))) (. .))) |ET| |BV| 1:0.2054855078458786 2:-0.35148143768310547 3:-0.4001162052154541 4:0.40772348642349243 5:0.97159826755523682 6:0.96807026863098145 7:0.39033049345016479 8:0.26300904154777527 9:-0.043818987905979156 10:0.94724470376968384 11:0.0028803297318518162 12:0.20844343304634094 13:0.25706103444099426 14:-0.13688749074935913 15:-1.4772655963897705 16:0.59102123975753784 17:-0.74126547574996948 18:-0.33666136860847473 19:1.1327501535415649 20:-0.021496839821338654 21:0.2490612119436264 22:-0.99049872159957886 23:-0.41239464282989502 24:-0.044612977653741837 25:0.39299872517585754 26:0.28446468710899353 27:0.3846886157989502 28:-0.28248655796051025 29:0.67045301198959351 30:0.5261768102645874 31:-0.22174780070781708 32:0.23442170023918152 33:-0.71098858118057251 34:-0.73123657703399658 35:-0.32787027955055237 36:0.053887158632278442 37:0.38661277294158936 38:0.071346871554851532 39:0.66734158992767334 40:0.3804037868976593 41:0.059913151 42:0.26468921 43:-0.20027205 44:-0.24251381 45:0.032195982 46:-0.070126399 47:-0.061050329 48:-0.45855877 49:0.079036959 50:-0.20999974 51:0.60368371 52:-0.11027312 53:0.2444479 54:0.19429779 55:0.17067111 56:-0.2064845 57:-0.10443541 58:-0.25243422 59:-0.22681965 60:0.63085324  |EV|
-1 |BT| (ROOT (S (NP (NP (DT The) (JJ cysteine) (NN prodrug) (NN N-acetylcysteine)) (PRN (-LRB- -LRB-) (NP (NNP NAC)) (-RRB- -RRB-))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB reduce) (NP (NP (NN reinstatement)) (PP (IN of) (NP (NP (NN cocaine)) (VP (VBG seeking) (PP (IN by) (NP (NP (NN normalization)) (PP (IN of) (NP (JJ glutamatergic) (NN tone))))))))))))))) (. .))) |ET| |BV| 1:0.04645971953868866 2:-0.24341200292110443 3:-0.12847506999969482 4:-0.020735494792461395 5:0.046708986163139343 6:-0.63118833303451538 7:-0.37865597009658813 8:-0.7709348201751709 9:0.74587637186050415 10:-0.46059706807136536 11:0.0066282842308282852 12:-0.22267381846904755 13:-0.17692463099956512 14:-0.36518228054046631 15:-0.20190101861953735 16:0.29322820901870728 17:-0.080923497676849365 18:-0.1887049674987793 19:0.15922586619853973 20:0.54918378591537476 41:0.062842861 42:-0.33100313 43:0.066658333 44:-0.22510052 45:0.47421774 46:-0.48099273 47:-0.53954118 48:-0.15290162 49:0.10567547 50:0.27469495 51:0.12800848 52:-0.040627558 53:0.053304292 54:0.30889568 55:0.15100461 56:0.25580519 57:0.25999257 58:-0.26079535 59:0.57520294 60:0.28164241  |EV|
-1 |BT| (ROOT (S (S (NP (NP (NNS Isoflavones)) (PP (JJ such) (IN as) (NP (NP (NP (NN genistein)) (PRN (-LRB- -LRB-) (NP (CD 10)) (-RRB- -RRB-))) (, ,) (NP (NP (NN biochanin) (NN A)) (PRN (-LRB- -LRB-) (NP (CD 11)) (-RRB- -RRB-))) (, ,) (NP (NP (NN tectorigenin)) (PRN (-LRB- -LRB-) (NP (CD 12)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NP (CD 2) (POS ')) (JJ -) (NN methoxyformononetin)) (PRN (-LRB- -LRB-) (NP (CD 13)) (-RRB- -RRB-)))))) (VP (VBN stimulated) (NP (NP (DT the) (NN proliferation)) (PP (IN of) (NP (DT both) (NNS cells)))))) (, ,) (CC and) (S (NP (NP (NNS concentrations)) (PP (IN of) (NP (NP (JJR lower)) (PP (IN than) (NP (NP (CD 1) (NN muM)) (PP (IN of) (NP (DT these) (NNS compounds)))))))) (VP (VBD showed) (NP (NN equivalent) (NN activity)) (PP (TO to) (NP (NP (CD 10) (NN pM)) (PP (IN of) (NP (NP (NN estradiol)) (PRN (-LRB- -LRB-) (NP (NNP E2)) (-RRB- -RRB-)))))))) (. .))) |ET| |BV| 1:-0.85465067625045776 2:-0.12238670140504837 3:0.039865396916866302 4:-0.019043626263737679 5:0.4582093358039856 6:-0.2334979772567749 7:-0.05501941591501236 8:-0.62751144170761108 9:0.28472161293029785 10:0.22962188720703125 11:0.65343540906906128 12:0.033011775463819504 13:0.56688863039016724 14:0.29359838366508484 15:0.41499623656272888 16:0.37236988544464111 17:-0.36746573448181152 18:0.17696653306484222 19:0.45934385061264038 20:0.7460099458694458 21:-0.88100749254226685 22:-0.82609057426452637 23:-1.0307251214981079 24:-0.55634868144989014 25:-0.26797688007354736 26:-0.31451919674873352 27:0.50074118375778198 28:0.95685005187988281 29:-1.155311107635498 30:0.057921607047319412 31:0.56989318132400513 32:-0.15794640779495239 33:1.2393218278884888 34:0.034051261842250824 35:0.38033518195152283 36:1.0104743242263794 37:0.24098911881446838 38:-0.438519686460495 39:0.26584595441818237 40:-0.64438432455062866 41:-0.34721544 42:-0.28512558 43:-0.1205713 44:-0.066602863 45:-0.11335639 46:0.21175855 47:0.13927993 48:0.067316324 49:-0.52382398 50:-0.059564061 51:1.0340816 52:0.21518214 53:-0.22543478 54:-0.43967858 55:0.11394088 56:0.66286886 57:-0.072008222 58:0.054320592 59:-0.17068936 60:0.26421162  |EV|
-1 |BT| (ROOT (S (S (NP (NP (NNP Canakinumab)) (, ,) (NP (DT a) (ADJP (RB fully) (JJ human)) (JJ anti-IL-1ß) (NN monoclonal) (NN antibody)) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB produce) (NP (JJ rapid) (CC and) (JJ sustained) (NN pain) (NN relief)) (PP (IN from) (NP (NP (JJ acute) (NNS flares)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ difficult-to-treat) (NN disease)))))))))))))) (, ,) (CC and) (S (NP (DT both) (NN rilonacept) (CC and) (NN canakinumab)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB reduce) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ recurrent) (NNS flares))))))))))) (. .))) |ET| |BV| 1:0.35391843318939209 2:0.98827540874481201 3:0.054008670151233673 4:-0.45917797088623047 5:2.2084741592407227 6:-0.56636929512023926 7:-0.38445305824279785 8:-0.79062223434448242 9:0.51143383979797363 10:-1.0457932949066162 11:-0.31809362769126892 12:0.33756449818611145 13:0.61053746938705444 14:0.44455498456954956 15:0.22267612814903259 16:0.47340533137321472 17:-0.7892339825630188 18:-0.43376311659812927 19:0.80812323093414307 20:-0.2465919703245163 21:-0.50730270147323608 22:-0.46654549241065979 23:-0.19207969307899475 24:-0.18477006256580353 25:0.48602673411369324 26:0.0095923962071537971 27:-0.15957985818386078 28:-0.66272211074829102 29:-0.11714134365320206 30:-0.083451218903064728 31:-0.29273140430450439 32:-0.0025909750256687403 33:0.99936646223068237 34:0.77390444278717041 35:0.61782747507095337 36:0.65482217073440552 37:0.43461203575134277 38:-0.63503080606460571 39:0.77378171682357788 40:0.27871394157409668 41:0.11323069 42:0.16544619 43:0.2637082 44:-0.43226707 45:-0.11066541 46:-0.4860363 47:0.32890567 48:-0.55256307 49:-0.21497095 50:0.24597266 51:0.13533719 52:0.35434499 53:-0.41450372 54:0.016823879 55:0.45240211 56:-0.093924113 57:0.41857487 58:0.0070602074 59:0.24038072 60:-0.10504531  |EV|
-1 |BT| (ROOT (S (ADVP (RB However)) (, ,) (NP (DT the) (NNS authors)) (VP (VBD were) (ADJP (JJ unable) (S (VP (TO to) (VP (VB reduce) (S (NP (NNP KAV)) (VP (VBG using) (NP (JJ adjunctive) (NN atropine) (CC or) (NN metoclopramide))))))))) (. .))) |ET| |BV| 1:-0.67935633659362793 2:-0.76576101779937744 3:-0.22106757760047913 4:-0.57372367382049561 5:0.28197568655014038 6:0.208147332072258 7:0.15986424684524536 8:-0.027409208938479424 9:0.26356154680252075 10:0.08958183228969574 11:0.42520076036453247 12:-0.090538851916790009 13:0.23981952667236328 14:-0.41005590558052063 15:-0.60331243276596069 16:0.26125708222389221 17:0.019843308255076408 18:-0.055050365626811981 19:-0.095602601766586304 20:-0.014820318669080734 21:-0.18249137699604034 22:-0.10426323115825653 23:-0.17040956020355225 24:-0.23240828514099121 25:1.2175657749176025 26:0.12161293625831604 27:-0.024821899831295013 28:-0.48099514842033386 29:0.19091956317424774 30:-0.18165458738803864 31:0.62016201019287109 32:-0.12164175510406494 33:0.44775670766830444 34:0.3097003698348999 35:-0.55052608251571655 36:0.18322083353996277 37:-0.037191644310951233 38:0.1758992075920105 39:0.136609748005867 40:-0.067096911370754242 41:-0.18703142 42:-0.11043822 43:0.049154583 44:0.10559073 45:0.32764149 46:-0.34180167 47:-0.089928105 48:-0.096381903 49:0.23679715 50:0.15417252 51:0.22425766 52:0.18542746 53:0.098555706 54:0.086516596 55:0.21475337 56:-0.22649337 57:0.36151773 58:-0.1460931 59:-0.26087633 60:-0.15423661  |EV|
-1 |BT| (ROOT (FRAG (NP (NNP CONCLUSION)) (: :) (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB prevent) (NP (NN rebound) (CC or) (NN relapse)))))) (, ,) (NP (JJ various) (NNS approaches)) (VP (VBP are) (ADJP (JJ available)) (, ,) (PP (VBG including) (NP (JJ cyclosporine) (, ,) (JJ methotrexate) (CC and) (JJ biologic) (NNS therapies))))) (. .))) |ET| |BV| 1:0.02481439895927906 2:-0.24871031939983368 3:-0.10679193586111069 4:-0.10794007033109665 5:-0.5998653769493103 6:-0.27684015035629272 7:0.73448991775512695 8:-0.19402602314949036 9:-0.2889082133769989 10:0.75778615474700928 11:-0.25642815232276917 12:-0.42810559272766113 13:-0.66437232494354248 14:-0.12065994739532471 15:0.10851625353097916 16:0.92460924386978149 17:-0.29851534962654114 18:-0.2859988808631897 19:0.86515802145004272 20:-0.39470314979553223 21:0.22973515093326569 22:0.19648084044456482 23:0.55181854963302612 24:0.18758369982242584 25:0.38749653100967407 26:0.022247470915317535 27:0.3878440260887146 28:-0.22101809084415436 29:-0.25053679943084717 30:0.63505774736404419 31:-0.84504055976867676 32:-0.38331210613250732 33:-0.2815781831741333 34:0.26864224672317505 35:-0.59058409929275513 36:0.14444741606712341 37:0.25645807385444641 38:-0.067241907119750977 39:-0.22094772756099701 40:-0.84235155582427979 41:0.17405927 42:-0.20791538 43:0.18546791 44:0.12403602 45:0.27035078 46:-0.35232466 47:0.30350289 48:-0.31708738 49:0.19726326 50:0.11050511 51:0.29948801 52:0.050592054 53:-0.32458326 54:0.30495605 55:0.30676445 56:-0.087085158 57:0.20142482 58:-0.026089739 59:0.19592059 60:0.21563217  |EV|
-1 |BT| (ROOT (NP (NP (NNP CONCLUSION)) (: :) (S (PP (IN As) (PP (VBN compared) (PP (TO to) (NP (JJ norepinephrine-induced) (NN hypertension))))) (, ,) (NP (JJ dobutamine-induced) (JJ high) (NN CI)) (VP (VBD did) (RB not) (VP (VB reduce) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NN vasospasm)))) (PP (IN in) (NP (NNP SAH) (NNS patients)))))) (. .))) |ET| |BV| 1:-1.0374453067779541 2:0.85880064964294434 3:-0.24367348849773407 4:-1.0123558044433594 5:0.1485302597284317 6:0.064390242099761963 7:0.82503896951675415 8:0.057420235127210617 9:0.23259422183036804 10:0.22073723375797272 11:0.85523819923400879 12:-0.6310189962387085 13:0.38975125551223755 14:-0.61011910438537598 15:0.14520935714244843 16:0.3941006064414978 17:-0.23449532687664032 18:0.1393260657787323 19:0.37582126259803772 20:-0.082628250122070312 21:0.60882604122161865 22:-0.23329782485961914 23:-1.6974742412567139 24:-0.35691171884536743 25:-0.29879364371299744 26:-0.13806401193141937 27:0.25545862317085266 28:-0.36142683029174805 29:0.17044505476951599 30:-0.59444350004196167 31:0.24077467620372772 32:-0.20301823318004608 33:0.18098999559879303 34:-0.18655179440975189 35:0.019401097670197487 36:0.23374529182910919 37:-0.54920375347137451 38:-0.50025564432144165 39:-1.1375815868377686 40:0.18487530946731567 41:0.27587345 42:0.65306091 43:0.091484107 44:0.10153811 45:0.061800059 46:-0.014277156 47:-0.25318846 48:0.04884259 49:-0.054191679 50:-0.133063 51:0.053333018 52:-0.23034468 53:0.10888242 54:0.19153102 55:0.00062662078 56:0.20545039 57:0.23257196 58:-0.37533286 59:0.2309332 60:-0.020392369  |EV|
-1 |BT| (ROOT (FRAG (NP (NNP CONCLUSIONS)) (: :) (S (NP (NP (NNP Rituximab)) (CC and) (NP (NP (JJR lower) (NNS doses)) (PP (IN of) (NP (NN prednisone) (CC and) (NN calcineurin) (NNS inhibitors))))) (VP (VP (VBP are) (ADJP (JJ noninferior) (PP (TO to) (NP (NP (JJ standard) (NN therapy)) (PP (IN in) (S (VP (VBG maintaining) (S (NP (NP (JJ short-term) (NN remission)) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NNP INS)))))) (ADJP (JJ dependent) (PP (IN on) (NP (DT both) (NNS drugs)))))))))))) (CC and) (VP (VBP allow) (NP (PRP$ their) (JJ temporary) (NN withdrawal))))) (. .))) |ET| |BV| 1:-0.8092041015625 2:-0.19329148530960083 3:-0.70447874069213867 4:0.16662487387657166 5:0.29772061109542847 6:-0.64029854536056519 7:-0.70728737115859985 8:-0.16949117183685303 9:-0.54650425910949707 10:1.4144823551177979 11:-0.060322113335132599 12:0.17590384185314178 13:-0.13637727499008179 14:0.23657388985157013 15:-0.5770295262336731 16:1.4925574064254761 17:0.57485455274581909 18:-0.11306485533714294 19:0.70975369215011597 20:-1.2286081314086914 21:-0.2168390154838562 22:-0.5827181339263916 23:-0.37737980484962463 24:0.31495052576065063 25:-0.075841523706912994 26:-0.1366657167673111 27:-0.077723585069179535 28:-0.39503255486488342 29:0.067886330187320709 30:0.4634937047958374 31:-0.58181411027908325 32:0.057384632527828217 33:0.24518060684204102 34:0.18402077257633209 35:-0.60698193311691284 36:-0.26682448387145996 37:0.12457526475191116 38:-0.72550779581069946 39:0.078947603702545166 40:-0.5998038649559021 41:0.18605465 42:0.178432 43:0.066185363 44:0.30255163 45:0.036192015 46:-0.18028609 47:-0.076101005 48:-0.26996738 49:0.43288186 50:-0.11217209 51:0.067644887 52:-0.22861063 53:-0.29629922 54:-0.034416966 55:-0.032504879 56:-0.14814775 57:0.00098714139 58:0.50184435 59:0.32549354 60:-0.17926866  |EV|
-1 |BT| (ROOT (S (ADVP (RB Importantly)) (, ,) (NP (PRP we)) (VP (VBP report) (SBAR (IN that) (S (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (NNP AMPARs)) (PP (IN in) (NP (DT the) (NNP DMS)))))) (VP (VBZ attenuates) (NP (JJ operant) (NN self-administration)) (PP (PP (IN of) (NP (NN ethanol))) (, ,) (CC but) (RB not) (PP (IN of) (NP (NN sucrose)))))))) (. .))) |ET| |BV| 1:-0.9349932074546814 2:-0.84000343084335327 3:-0.41635552048683167 4:-0.3888784646987915 5:-0.25315806269645691 6:-0.15392397344112396 7:0.025107415392994881 8:0.56973457336425781 9:0.38532906770706177 10:0.37857183814048767 11:0.66472488641738892 12:0.96014046669006348 13:0.74786615371704102 14:-0.18957825005054474 15:-0.72223562002182007 16:-0.079844474792480469 17:-0.32539805769920349 18:0.89657247066497803 19:0.50971692800521851 20:0.36139878630638123 21:-0.18262425065040588 22:-0.27455565333366394 23:-0.63187038898468018 24:-0.20303082466125488 25:-0.49805775284767151 26:-0.36358526349067688 27:-0.67585134506225586 28:-0.18507486581802368 29:0.57143604755401611 30:-0.13132448494434357 31:0.033105544745922089 32:0.3947727382183075 33:0.014030230231583118 34:-0.085290499031543732 35:0.069696143269538879 36:0.078646555542945862 37:-0.25420689582824707 38:-0.09992583841085434 39:0.4503624439239502 40:0.5757184624671936 41:0.043245044 42:-0.21047522 43:0.16295318 44:-0.06986735 45:0.37599695 46:-0.36789513 47:-0.13689072 48:-0.10459423 49:-0.2404068 50:-0.21403892 51:-0.10588984 52:-0.29037097 53:0.23817398 54:-0.42229828 55:-0.1009757 56:0.19665396 57:0.38879347 58:-0.087785542 59:-0.037347183 60:-0.067421697  |EV|
-1 |BT| (ROOT (S (PP (IN In) (NP (NP (CD one) (JJ 36-month) (NN trial)) (PP (IN of) (NP (NP (JJ teriparatide) (NN vs) (NN alendronate)) (PP (IN for) (NP (NP (NNP GIOP)) (PP (IN in) (NP (NNS men) (CC and) (NNS women))))))))) (, ,) (NP (DT the) (JJ anabolic) (NN agent)) (VP (VP (VBD led) (PP (TO to) (NP (NP (DT a) (JJR greater) (NN increase)) (PP (IN in) (NP (NN bone) (NN density)))))) (CC and) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJR lower) (NN incidence)) (PP (IN of) (NP (JJ morphologic) (JJ vertebral) (NNS fractures)))))))) (. .))) |ET| |BV| 1:1.8555551767349243 2:-1.2722206115722656 3:-0.18031485378742218 4:-0.79166537523269653 5:-0.2276906818151474 6:1.095301628112793 7:0.30920225381851196 8:-0.21043385565280914 9:0.39473754167556763 10:0.42890214920043945 11:0.50850260257720947 12:0.30641096830368042 13:1.6130883693695068 14:0.42426800727844238 15:-0.67408519983291626 16:0.4287915825843811 17:-0.24680790305137634 18:-0.49778592586517334 19:-0.23895196616649628 20:-0.21471269428730011 21:0.14559665322303772 22:-0.96536797285079956 23:-0.04932079091668129 24:0.10797343403100967 25:0.30031579732894897 26:0.059898439794778824 27:-0.2060057520866394 28:-0.39199703931808472 29:0.19992817938327789 30:0.15507546067237854 31:-0.0048865796998143196 32:-0.33889412879943848 33:0.55883228778839111 34:-0.0016110739670693874 35:-0.50033372640609741 36:-0.1854834109544754 37:-0.46428102254867554 38:-0.25024151802062988 39:-0.046396352350711823 40:-0.3979354202747345 41:0.22779979 42:0.46281523 43:-0.13679771 44:0.27378795 45:0.13634209 46:0.070162185 47:0.0026049456 48:-0.30956495 49:-0.050599065 50:-0.0066138832 51:-0.036921434 52:-0.13931668 53:-0.062929444 54:0.18466379 55:0.16199456 56:-0.20060647 57:0.28610405 58:0.15790328 59:0.082400203 60:-0.14728466  |EV|
-1 |BT| (ROOT (S (NP (PRP It)) (ADVP (RB further)) (VP (VBD showed) (NP (DT that) (NN melatonin)) (ADVP (RB together)) (PP (IN with) (NP (NP (NN insulin)) (VP (ADVP (RB synergistically)) (VBN enhanced) (NP (DT the) (NN leptin) (NN synthesis)) (PP (IN by) (NP (JJ adipose) (NN tissue))) (PP (IN through) (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NP (JJ mitogen-activated) (NN protein) (NN kinase)) (PP (IN in) (NP (NNP C.) (NN sphinx))))))))))) (. .))) |ET| |BV| 1:-0.41765859723091125 2:-0.68634277582168579 3:-0.59409254789352417 4:0.4222644567489624 5:0.10007560253143311 6:-0.37648990750312805 7:-0.22770603001117706 8:0.20558573305606842 9:0.65462660789489746 10:0.6435583233833313 11:0.83729344606399536 12:-0.063424356281757355 13:0.33500063419342041 14:0.31329020857810974 15:0.52702087163925171 16:-0.65230077505111694 17:-0.26013901829719543 18:0.57008057832717896 19:-0.13120672106742859 20:0.10561328381299973 21:-1.192335844039917 22:0.36651092767715454 23:0.14956016838550568 24:-0.25442144274711609 25:-0.74738132953643799 26:0.29904133081436157 27:0.63527578115463257 28:0.27886191010475159 29:0.45418372750282288 30:0.062229525297880173 31:0.63828611373901367 32:-0.17143264412879944 33:0.40124374628067017 34:0.10097073018550873 35:0.77508127689361572 36:-0.084373779594898224 37:-1.0932121276855469 38:0.10228245705366135 39:1.046500563621521 40:-0.54566127061843872 41:0.10501792 42:-0.41132966 43:0.16034517 44:0.064595185 45:0.032805074 46:0.27733612 47:0.13718084 48:-0.052063465 49:-0.12556699 50:0.45286706 51:0.30769271 52:-0.47150424 53:-0.037359003 54:-0.69581383 55:0.18580177 56:0.004578359 57:0.62929893 58:-0.018739227 59:-0.025088396 60:0.24558863  |EV|
-1 |BT| (ROOT (S (S (NP (NP (NNS Analogues)) (PP (IN with) (NP (JJ 9-deazaguanine) (NN aglycone)))) (VP (VBP have) (NP (NP (JJR better) (NN anti-leukaemic) (CC and) (NN anti-lymphoma) (NNS activities)) (PP (VBN compared) (PP (TO to) (NP (DT the) (NN guanine) (CC and) (NN hypoxanthine) (NNS analogues))))))) (, ,) (CC and) (S (S (VP (VBN applied) (PP (IN in) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NP (CD 100) (NN mum)) (, ,) (VP (VBN caused) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN decrease)) (PP (IN in) (NP (DT the) (NN cell) (NN viability)))) (PP (IN in) (NP (NP (DT all) (JJ human) (NN leukaemia)) (CC and) (NP (NN lymphoma) (NNS cells))))))))))) (VP (VBD used))) (. .))) |ET| |BV| 1:-0.89806103706359863 2:-0.88740348815917969 3:0.66845309734344482 4:-0.726326584815979 5:-1.6517492532730103 6:-0.36108562350273132 7:0.26906853914260864 8:1.6386491060256958 9:0.22852036356925964 10:0.079020485281944275 11:0.19047874212265015 12:0.77491360902786255 13:0.37403875589370728 14:0.77928268909454346 15:-0.82996875047683716 16:0.47676581144332886 17:-0.69418495893478394 18:0.1101471409201622 19:-0.58469980955123901 20:-0.93877232074737549 21:-0.50943934917449951 22:-0.73875522613525391 23:0.061298321932554245 24:-0.25966426730155945 25:-0.96637290716171265 26:-1.054210901260376 27:0.518726646900177 28:1.7673639059066772 29:0.42409813404083252 30:-0.256416916847229 31:-0.35610869526863098 32:1.2766525745391846 33:0.54846912622451782 34:0.23720847070217133 35:-1.0828460454940796 36:0.23946470022201538 37:-1.0329642295837402 38:0.35627651214599609 39:-0.28181463479995728 40:-0.57772296667098999 41:-0.22328578 42:0.23710315 43:0.085840218 44:0.056551639 45:-0.14368555 46:0.042310908 47:-0.042670321 48:0.059921462 49:0.045837134 50:0.48710594 51:0.46052864 52:0.1620905 53:0.089402355 54:-0.18688795 55:-0.29084203 56:0.16001715 57:0.19617473 58:0.10502163 59:0.12059479 60:0.73291677  |EV|
-1 |BT| (ROOT (S (NP (NNP Naphazoline/antazoline)) (VP (VBD had) (NP (NP (JJR lower) (NN tolerability)) (PP (IN than) (NP (DT the) (JJ other) (NN study) (NNS treatments))))) (. .))) |ET| |BV| 1:-0.86237120628356934 2:0.76710021495819092 3:-0.38122648000717163 4:-0.79891812801361084 5:0.33592528104782104 6:-0.83879488706588745 7:1.3031260967254639 8:0.50441795587539673 9:0.92010998725891113 10:0.12217025458812714 11:1.3788343667984009 12:-0.79902410507202148 13:-0.51619488000869751 14:0.32232093811035156 15:-0.96453553438186646 16:0.87845307588577271 17:1.0339964628219604 18:1.140389084815979 19:0.49555647373199463 20:0.44571399688720703 41:0.095250353 42:0.11562728 43:0.42178336 44:0.16357337 45:0.36177072 46:0.27381998 47:-0.21962748 48:-0.29974627 49:-0.17445591 50:-0.067788847 51:0.1052556 52:-0.38929647 53:0.0018837682 54:0.3526127 55:0.0099860216 56:0.086867087 57:0.12770666 58:-0.26723984 59:-0.20702082 60:0.19667321  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Dexmedetomidine) (NN infusion)) (PP (IN without) (NP (DT a) (NNS bolus)))) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (NP (DT an) (JJ effective) (NN adjunct) (S (VP (TO to) (VP (VB fentanyl) (NP (NP (NN anesthesia)) (PP (IN in) (NP (NP (NN control)) (PP (IN of) (NP (JJ hemodynamic) (NNS responses)))))) (PP (TO to) (NP (NP (NN surgery)) (PP (IN for) (NP (NP (NN repair)) (PP (IN of) (NP (NNP CHD))))))) (PP (IN in) (NP (NNS children))))))))))) (. .))) |ET| |BV| 1:-0.77053290605545044 2:-0.48575147986412048 3:-0.84432661533355713 4:-1.0948235988616943 5:0.79077690839767456 6:-0.38421624898910522 7:-0.094402462244033813 8:-0.7633662223815918 9:-0.38017043471336365 10:0.042292214930057526 11:-0.44345054030418396 12:-0.75959682464599609 13:-0.44020324945449829 14:-0.11750142276287079 15:0.36356458067893982 16:1.1747187376022339 17:0.36346834897994995 18:0.23654294013977051 19:-0.10545375198125839 20:-0.92121630907058716 21:-0.59656029939651489 22:-0.6017303466796875 23:-0.56371450424194336 24:-0.7424049973487854 25:0.11047245562076569 26:-0.63334363698959351 27:-0.39095228910446167 28:-0.11231482774019241 29:0.080785229802131653 30:0.339478999376297 31:0.24232865869998932 32:-0.48895210027694702 33:0.044322166591882706 34:-0.77776569128036499 35:-0.32153224945068359 36:0.49588650465011597 37:0.62831389904022217 38:-0.01203435193747282 39:-0.66721820831298828 40:-1.0869570970535278 41:0.034788929 42:0.1428165 43:-0.15560913 44:0.034237575 45:0.36357898 46:-0.43612674 47:-0.54494858 48:-0.4042058 49:0.23585364 50:0.0031713275 51:-0.4113718 52:-0.087790638 53:-0.45852062 54:0.012386788 55:-0.44590914 56:-0.43328649 57:0.41290116 58:-0.16389251 59:-0.031090358 60:-0.19744091  |EV|
-1 |BT| (ROOT (S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (JJ monomeric) (NN rituximab)) (, ,) (PP (IN at) (NP (NP (DT the) (JJ high) (NNS concentrations)) (VP (VBN found) (PP (IN in) (NP (NP (NN plasma) (VBG following) (NN infusion)) (PP (IN of) (NP (JJ therapeutic) (NNS doses)))))))) (, ,)) (VP (VP (VBZ induces) (NP (NP (JJ prolonged) (JJ low-amplitude) (NN release)) (PP (IN of) (NP (NN calcium)))) (PP (IN from) (NP (JJ thapsigargin-sensitive) (NN intracellular) (NNS stores)))) (CC and) (VP (VBZ reduces) (NP (NP (DT the) (NN growth)) (PP (IN of) (NP (NNP Ramos) (NNP B) (NNS cells)))) (PP (IN in) (NP (NN culture)))))))) (. .))) |ET| |BV| 1:-0.8092041015625 2:-0.19329148530960083 3:-0.70447874069213867 4:0.16662487387657166 5:0.29772061109542847 6:-0.64029854536056519 7:-0.70728737115859985 8:-0.16949117183685303 9:-0.54650425910949707 10:1.4144823551177979 11:-0.060322113335132599 12:0.17590384185314178 13:-0.13637727499008179 14:0.23657388985157013 15:-0.5770295262336731 16:1.4925574064254761 17:0.57485455274581909 18:-0.11306485533714294 19:0.70975369215011597 20:-1.2286081314086914 21:-0.76733154058456421 22:0.24607940018177032 23:-0.3637290894985199 24:-0.26238524913787842 25:-0.33067521452903748 26:-0.33500140905380249 27:-0.08953440934419632 28:0.13414254784584045 29:0.37700408697128296 30:0.26008978486061096 31:-0.075949981808662415 32:-0.24670501053333282 33:0.17961160838603973 34:-0.15187470614910126 35:-1.0580264329910278 36:-0.25400683283805847 37:-0.31937047839164734 38:0.033552780747413635 39:0.48308485746383667 40:-0.69982004165649414 41:-0.27599439 42:-0.26065519 43:0.30075505 44:-0.04619623 45:-0.060590416 46:-0.18635866 47:0.24706767 48:-0.41342449 49:0.13261177 50:0.00053175585 51:0.11162081 52:-0.34493485 53:0.19853544 54:-0.53599483 55:0.1525014 56:-0.0047129244 57:0.37931886 58:-0.1014578 59:0.47082669 60:-0.037061524  |EV|
-1 |BT| (ROOT (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (DT the) (JJ antihypertensive) (NN drug) (NN Prazosin)) (VP (VBZ inhibits) (NP (JJ endocytic) (VBG sorting)) (PP (IN by) (NP (NP (DT an) (JJ off-target) (NN perturbation)) (PP (IN of) (NP (NP (NP (DT the) (NNP G) (JJ protein-coupled) (NN receptor) (NN dopamine) (NN receptor) (NNP D)) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NNP DRD3)) (-RRB- -RRB-)))))))))) (. .))) |ET| |BV| 1:-0.14506223797798157 2:-0.28481072187423706 3:-0.59362673759460449 4:-0.25439375638961792 5:0.38625630736351013 6:-0.046137731522321701 7:-0.35386601090431213 8:0.65320384502410889 9:-0.16809134185314178 10:0.57964813709259033 11:0.13037890195846558 12:-0.61583757400512695 13:0.31949564814567566 14:0.45095747709274292 15:-0.93978142738342285 16:0.63066709041595459 17:0.063957802951335907 18:-0.89659082889556885 19:0.36688527464866638 20:-0.13719877600669861 21:-0.52288627624511719 22:0.064634568989276886 23:0.43291720747947693 24:-0.59934920072555542 25:0.067319102585315704 26:-0.54065132141113281 27:0.75569421052932739 28:0.22499477863311768 29:0.75093740224838257 30:0.50299102067947388 31:0.66871351003646851 32:-0.46396654844284058 33:0.70376694202423096 34:0.35963043570518494 35:0.027474602684378624 36:0.40848967432975769 37:0.32412928342819214 38:-0.051923949271440506 39:0.47423961758613586 40:0.30214890837669373 41:-0.082409658 42:-0.15337348 43:0.12433288 44:0.019588588 45:0.12490033 46:-0.20622849 47:-0.27082387 48:-0.16096747 49:-0.17234598 50:0.13388297 51:0.34869686 52:-0.39368239 53:0.12837291 54:-0.28345147 55:-0.074015379 56:0.18608488 57:0.29153109 58:0.25861481 59:0.11662579 60:-0.46507797  |EV|
-1 |BT| (ROOT (S (NP (NP (DT The) (NN influence)) (PP (IN of) (NP (NN angiostatin) (NN K1-4) (CD .5))) (PRN (: --) (NP (NP (NP (DT a) (NN fragment)) (PP (IN of) (NP (NP (DT the) (JJ heavy) (NN chain)) (PP (IN of) (NP (NN plasmin)))))) (CC and) (NP (NP (DT a) (JJ powerful) (NN inhibitor)) (PP (IN of) (NP (NNS angiogenesis))))) (: --)) (PP (IN on) (NP (NP (NP (JJ kinetic) (NNS parameters)) (-LRB- -LRB-) (NP (NP (NP (NN k)) (PRN (-LRB- -LRB-) (NP (NNP Pg)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP K)) (PRN (-LRB- -LRB-) (NP (NNP Pg)) (-RRB- -RRB-)))) (-RRB- -RRB-)) (PP (IN of) (S (NP (NP (JJ human) (JJ Glu-plasminogen) (NN activation)) (PP (IN under) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NP (NN urokinase)) (PRN (-LRB- -LRB-) (NP (NN uPA)) (-RRB- -RRB-))))))) (RB not) (VP (VBG having) (NP (NN affinity)) (PP (IN for) (NP (NP (NN fibrin)) (CC and) (NP (JJ fibrin-specific) (NN tissue) (NN plasminogen) (NN activator))))))) (PRN (-LRB- -LRB-) (NP (NN tPA)) (-RRB- -RRB-))))) (VP (VBD was) (VP (VBN investigated))) (. .))) |ET| |BV| 1:-1.0772310495376587 2:-0.78749650716781616 3:0.38568541407585144 4:-1.0273858308792114 5:-0.73517733812332153 6:0.43055441975593567 7:1.2307174205780029 8:0.88914734125137329 9:-0.012340113520622253 10:0.39130142331123352 11:0.00087484990945085883 12:-0.34907984733581543 13:0.97235614061355591 14:1.1826136112213135 15:0.96312880516052246 16:-0.28996762633323669 17:0.24392388761043549 18:0.29467540979385376 19:1.5927048921585083 20:0.79999655485153198 21:-0.26211696863174438 22:-0.34698560833930969 23:1.5166832208633423 24:-0.88887870311737061 25:-0.70370286703109741 26:-0.96953868865966797 27:1.0129305124282837 28:0.60676825046539307 29:1.3489789962768555 30:0.4176056981086731 31:-0.6928972601890564 32:1.3752182722091675 33:-0.1590903252363205 34:1.2053062915802002 35:1.1177713871002197 36:1.2419295310974121 37:-1.2661890983581543 38:-0.27901464700698853 39:0.45664224028587341 40:-0.8036988377571106 41:-0.14090754 42:-0.45156783 43:0.13023336 44:-0.39831227 45:-0.44364297 46:-0.011735933 47:0.086790763 48:0.052822135 49:-0.088478528 50:0.1298715 51:0.66978848 52:-0.12746248 53:0.38101974 54:-0.18704313 55:-0.37873897 56:0.90354192 57:-0.22769904 58:0.22745048 59:0.37078217 60:0.41648433  |EV|
-1 |BT| (ROOT (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NN tenofovir-emtricitabine)) (PP (IN for) (NP (NP (QP (IN at) (JJS least) (CD 3)) (NNS weeks)) (PP (IN after) (NP (NN delivery)))))))) (VP (MD should) (VP (VB be) (VP (VBN considered) (S (VP (TO to) (VP (VB prevent) (NP (NP (DT the) (NN emergence)) (PP (IN of) (NP (ADJP (JJ resistant)) (NNS viruses)))))))))) (. .))) |ET| |BV| 21:0.17799820005893707 22:-0.27787178754806519 23:0.30854254961013794 24:0.62476873397827148 25:-0.30178850889205933 26:-0.72277116775512695 27:-0.20537346601486206 28:-0.059938192367553711 29:0.11513254791498184 30:0.025801291689276695 31:-1.0807256698608398 32:0.31774663925170898 33:-0.16543099284172058 34:1.4149730205535889 35:-0.72933727502822876 36:-0.079194381833076477 37:-0.81688737869262695 38:-0.25846809148788452 39:0.31218412518501282 40:-0.18701985478401184 41:-0.037113633 42:-0.089855231 43:-0.31068224 44:0.0015581683 45:0.06181572 46:-0.47191155 47:-0.28859434 48:-0.64450157 49:-0.11683331 50:0.43316478 51:0.27864674 52:0.59716046 53:-0.028225392 54:-0.15025483 55:0.30855858 56:0.059578165 57:0.51985157 58:0.015887072 59:-0.10807843 60:-0.32809609  |EV|
-1 |BT| (ROOT (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VP (VB evaluate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ atropine) (NN dose))))) (, ,) (VP (VB pyridostigmine) (S (NP (NP (NN bromide)) (PRN (-LRB- -LRB-) (NP (NNP PB)) (-RRB- -RRB-))) (ADJP (JJ pretreatment)))) (, ,) (CC and) (VP (VB oxime) (NP (NN selection)) (PP (IN on) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NNP SCP))))) (PP (IN as) (NP (DT an) (JJ adjunctive) (NN treatment))) (S (VP (TO to) (VP (VB enhance) (NP (NP (NN survival)) (PP (VBG following) (NP (NP (JJ lethal) (NN nerve) (NN agent) (NN exposure)) (PP (IN in) (NP (NN guinea) (NNS pigs)))))))))))))) (. .))) |ET| |BV| 1:-0.67935633659362793 2:-0.76576101779937744 3:-0.22106757760047913 4:-0.57372367382049561 5:0.28197568655014038 6:0.208147332072258 7:0.15986424684524536 8:-0.027409208938479424 9:0.26356154680252075 10:0.08958183228969574 11:0.42520076036453247 12:-0.090538851916790009 13:0.23981952667236328 14:-0.41005590558052063 15:-0.60331243276596069 16:0.26125708222389221 17:0.019843308255076408 18:-0.055050365626811981 19:-0.095602601766586304 20:-0.014820318669080734 21:-0.93410742282867432 22:-0.65373468399047852 23:-0.43406468629837036 24:-0.62340039014816284 25:-0.042419973760843277 26:-0.59540313482284546 27:0.050502300262451172 28:0.71034038066864014 29:0.8747403621673584 30:0.6111828088760376 31:1.0918377637863159 32:-0.079266086220741272 33:0.090141817927360535 34:-0.43119364976882935 35:0.71569561958312988 36:0.51479262113571167 37:-0.89098656177520752 38:-0.34835290908813477 39:1.2585413455963135 40:-0.80709505081176758 41:-0.26359537 42:-0.44234964 43:0.30599928 44:-0.017794991 45:0.18254153 46:0.23739402 47:0.19360054 48:-0.041642528 49:0.13987909 50:-0.024441687 51:0.039099436 52:-0.14512825 53:0.35809597 54:0.28925979 55:-0.30083889 56:0.12265188 57:-0.11060937 58:0.44460371 59:-0.38416731 60:-0.17028171  |EV|
-1 |BT| (ROOT (S (ADVP (RB Similarly)) (S (VP (TO to) (VP (VB paclitaxel) (PRN (-LRB- -LRB-) (NP (NNP Taxol)) (-RRB- -RRB-))))) (, ,) (VP (VP (VBP epothilone) (NP (DT A) (JJ inhibits) (NN cell) (NN proliferation))) (CC and) (VP (VBZ induces) (NP (NNS apoptosis)) (PP (IN by) (NP (VBG binding))) (PP (TO to) (NP (NP (NN tubulin) (CC and) (VBG stabilizing)) (PP (IN of) (NP (NNS microtubuli))))))) (. .))) |ET| |BV| 1:-0.25381281971931458 2:-0.39058360457420349 3:0.012394076213240623 4:-0.10967423021793365 5:0.096497513353824615 6:-0.41035369038581848 7:0.92843860387802124 8:-0.22448091208934784 9:-0.29918161034584045 10:1.0547025203704834 11:-0.002332854550331831 12:0.17811077833175659 13:0.36452794075012207 14:-0.053931765258312225 15:0.15668800473213196 16:0.72528845071792603 17:-0.048138551414012909 18:-1.1846963167190552 19:-0.57840800285339355 20:-0.21507517993450165 21:0.10806208848953247 22:-0.73798894882202148 23:1.6558136940002441 24:0.51094293594360352 25:0.81971055269241333 26:-1.1616857051849365 27:1.1428647041320801 28:-0.1101008728146553 29:-0.050751615315675735 30:-0.44537079334259033 31:1.1681331396102905 32:0.33287894725799561 33:-0.79483717679977417 34:0.031246200203895569 35:0.29051205515861511 36:0.28662109375 37:-0.33912843465805054 38:-1.6960805654525757 39:-0.73355275392532349 40:-0.39573019742965698 41:0.041133687 42:-0.36123791 43:-0.26177749 44:0.042678516 45:0.051704448 46:-0.4234786 47:-0.23021887 48:-0.21198164 49:0.063752249 50:0.50839698 51:0.40498763 52:-0.031887345 53:0.059205145 54:-0.24146071 55:-0.059601292 56:0.069364294 57:0.1582569 58:-0.068043143 59:-0.027889766 60:0.50526166  |EV|
-1 |BT| (ROOT (S (NP (DT The) (JJ optimal) (NN ritonavir) (NN dose) (S (VP (TO to) (VP (VB be) (VP (VBN given) (ADVP (RB together)) (PP (IN with) (NP (NN fosamprenavir)))))))) (VP (VBZ is) (ADVP (RB still)) (S (VP (TO to) (VP (VB be) (VP (VBN defined))))) (, ,) (SBAR (IN though) (S (NP (JJ available) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 100) (NN mg)))) (VP (MD may) (VP (VB be) (ADJP (JJ adequate) (SBAR (S (VP (VBD provided) (SBAR (IN that) (S (NP (DT no) (JJ protease) (NN inhibitor) (NN resistance)) (VP (VBZ is) (ADJP (JJ present))))))))))))))))) (. .))) |ET| |BV| 1:-1.4446250200271606 2:-0.4934391975402832 3:0.3028901219367981 4:0.098139896988868713 5:-0.084036901593208313 6:-0.60067528486251831 7:-0.045485895127058029 8:-0.20654243230819702 9:-0.25986936688423157 10:0.44161754846572876 11:-0.53373360633850098 12:-0.044802453368902206 13:0.69945645332336426 14:0.23874844610691071 15:-0.098392784595489502 16:0.19838865101337433 17:-0.83548247814178467 18:0.0063304346986114979 19:0.9234660267829895 20:-0.050698824226856232 21:-0.43200841546058655 22:-1.1393423080444336 23:-1.2164291143417358 24:0.24824608862400055 25:0.32690027356147766 26:-0.5405573844909668 27:-0.32841584086418152 28:-0.014385450631380081 29:0.37410014867782593 30:0.74537265300750732 31:-1.8347021341323853 32:0.63277041912078857 33:0.71766102313995361 34:-0.629780113697052 35:-0.2086031585931778 36:-0.1194966584444046 37:-0.51998025178909302 38:0.33431589603424072 39:-0.38128575682640076 40:-0.62202566862106323 41:-0.077343866 42:-0.024539631 43:0.093327776 44:-0.11456116 45:0.29569077 46:0.054075863 47:0.059512634 48:-0.54479396 49:0.2519896 50:0.043473069 51:0.10861761 52:0.4089101 53:-0.045286305 54:0.23647296 55:-0.17434925 56:-0.19584173 57:0.5338136 58:0.16138247 59:0.062433433 60:0.47094709  |EV|
-1 |BT| (ROOT (S (PP (IN As) (S (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (ADJP (ADVP (RB molecularly)) (JJ targeted)) (JJ anti-EGFR) (NNS therapies)) (PRN (-LRB- -LRB-) (ADJP (JJ cetuximab) (CC and) (JJ panitumumab)) (-RRB- -RRB-))))) (VP (VBG complementing) (ADVP (RB chemotherapy))))) (, ,) (NP (NN liver) (NNS metastases)) (VP (MD can) (VP (VP (VB reduce) (PP (IN in) (NP (NN size)))) (CC and) (VP (VB become) (NP (NP (JJ operable)) (PP (IN in) (NP (NP (JJ certain) (NNS patients)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (JJ complete) (NN recovery)) (PP (IN of) (NP (DT the) (NN patient))))))))))))))) (. .))) |ET| |BV| 1:0.60125124454498291 2:-0.76545882225036621 3:1.1888238191604614 4:0.45946463942527771 5:0.63420009613037109 6:-0.044119510799646378 7:0.73391872644424438 8:0.13165163993835449 9:0.66971921920776367 10:0.89429110288619995 11:-0.68757224082946777 12:0.64582759141921997 13:0.27450233697891235 14:1.323746919631958 15:-0.39306837320327759 16:0.21697030961513519 17:-0.37259691953659058 18:-0.66445273160934448 19:0.4482596218585968 20:-0.88031834363937378 21:-0.2816181480884552 22:-0.68261337280273438 23:0.44740390777587891 24:0.29308760166168213 25:0.5837702751159668 26:0.37423157691955566 27:0.70943683385848999 28:-0.085498526692390442 29:0.86710089445114136 30:0.58071637153625488 31:0.063820101320743561 32:-0.0067333667539060116 33:0.2699408233165741 34:0.39133661985397339 35:-0.3362809419631958 36:1.5841424465179443 37:-0.76286178827285767 38:-0.42525660991668701 39:-0.71097695827484131 40:-0.94073945283889771 41:0.55339426 42:0.025339678 43:0.10392881 44:-0.47433037 45:-0.051277269 46:-0.22727767 47:0.091562092 48:-0.10708047 49:0.60904169 50:0.40502673 51:0.20647898 52:-0.024519995 53:-0.2447584 54:-0.10245352 55:0.40801552 56:-0.28440028 57:0.48008108 58:0.20567422 59:0.35727257 60:-0.070227638  |EV|
-1 |BT| (ROOT (S (NP (DT This)) (VP (VBD was) (VP (VBN concomitant) (PP (IN with) (NP (NP (DT a) (NN decrease)) (PRN (-LRB- -LRB-) (NP (NNP P) (NNP <) (NNP 0.05)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (NNS enzymes)) (VP (VBN involved) (PP (IN in) (NP (NP (NP (IN de) (JJ novo) (NN fatty) (NN acid)) (PRN (-LRB- -LRB-) (NP (NNP FA)) (-RRB- -RRB-))) (NP (NP (NN synthesis)) (PRN (-LRB- -LRB-) (NP (NP (NNP FA) (NNP synthase)) (CC and) (NP (JJ glucose-6-phosphate) (NN dehydrogenase))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP FA) (NNP esterification)) (PRN (-LRB- -LRB-) (NP (JJ glycerol-3-phosphate) (NN dehydrogenase)) (-RRB- -RRB-)) (SBAR (WHADVP (WRB when)) (S (S (VP (VBN expressed) (PP (IN per) (NP (CD million) (NNS adipocytes))))) (, ,) (CC and) (S (VP (ADVP (IN with) (DT an)) (VB increase) (-LRB- -LRB-) (NP (NNP P)))))))))))))))) (. ?))) |ET| |BV| 1:-1.192335844039917 2:0.36651092767715454 3:0.14956016838550568 4:-0.25442144274711609 5:-0.74738132953643799 6:0.29904133081436157 7:0.63527578115463257 8:0.27886191010475159 9:0.45418372750282288 10:0.062229525297880173 11:0.63828611373901367 12:-0.17143264412879944 13:0.40124374628067017 14:0.10097073018550873 15:0.77508127689361572 16:-0.084373779594898224 17:-1.0932121276855469 18:0.10228245705366135 19:1.046500563621521 20:-0.54566127061843872 21:-1.8900908231735229 22:-0.95278626680374146 23:-0.10516618937253952 24:0.41801100969314575 25:-0.82989311218261719 26:-1.7642890214920044 27:0.72979474067687988 28:0.93331784009933472 29:0.77029907703399658 30:0.27786386013031006 31:0.93818867206573486 32:0.17773449420928955 33:0.43606042861938477 34:-0.56340086460113525 35:-0.88518381118774414 36:-0.66564178466796875 37:-0.10992545634508133 38:0.58030706644058228 39:0.83720535039901733 40:-0.24087898433208466 41:-0.23750593 42:0.0028952307 43:-0.01858812 44:-0.27196643 45:-0.18889652 46:-0.18162397 47:-0.077557489 48:0.40331829 49:0.020494709 50:0.091080956 51:0.85945529 52:0.33363289 53:0.041552924 54:-0.14560075 55:0.34892228 56:0.7493909 57:0.0088205449 58:0.41036832 59:0.11433691 60:0.50540876  |EV|
-1 |BT| (ROOT (FRAG (NP (NNP CONCLUSIONS)) (: :) (S (PP (IN Among) (NP (NP (NNS children)) (PP (NP (QP (CD 6) (TO to) (CD 23)) (NNS months)) (IN of) (NP (NN age))) (PP (IN with) (NP (JJ acute) (NNS otitis) (NNS media))))) (, ,) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NN amoxicillin-clavulanate)) (PP (IN for) (NP (CD 10) (NNS days)))))) (VP (VP (VBD tended) (S (VP (TO to) (VP (VB reduce) (NP (DT the) (NN time)) (PP (TO to) (NP (NP (NN resolution)) (PP (IN of) (NP (NNS symptoms))))))))) (CC and) (VP (VBD reduced) (NP (NP (DT the) (JJ overall) (NN symptom) (NN burden)) (CC and) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NP (JJ persistent) (NNS signs)) (PP (IN of) (NP (JJ acute) (NN infection))))))) (PP (IN on) (NP (JJ otoscopic) (NN examination)))))) (. .))) |ET| |BV| 1:0.35244706273078918 2:-0.53398048877716064 3:0.61924433708190918 4:-0.046414390206336975 5:0.014703782275319099 6:-0.15338265895843506 7:-0.1124558299779892 8:0.21922613680362701 9:1.1140474081039429 10:0.22506314516067505 11:-0.13748759031295776 12:-0.5041845440864563 13:0.055349297821521759 14:-0.4650251567363739 15:-0.59570586681365967 16:-0.5266871452331543 17:0.89103460311889648 18:-0.040526475757360458 19:0.81274670362472534 20:-0.76265352964401245 41:0.085949436 42:0.23730715 43:0.11128265 44:0.24194649 45:0.24496929 46:-0.16206677 47:-0.014506514 48:-0.032957513 49:-0.10342194 50:0.0016394954 51:0.0071134437 52:0.01312697 53:-0.13648118 54:-3.0848543e-05 55:0.45185885 56:-0.26350069 57:0.23227164 58:0.19531415 59:-0.007273118 60:0.051537462  |EV|
-1 |BT| (ROOT (S (ADVP (RB Interestingly)) (, ,) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN amiodarone)))) (VP (VBZ is) (ADJP (JJ additive) (PP (IN with) (NP (NP (DT the) (NN one)) (PP (IN of) (NP (NP (NN chloroquine)) (, ,) (NP (NP (DT a) (VBN known) (NN inhibitor)) (PP (IN of) (NP (NNP ABC-transporters)))))))))) (. .))) |ET| |BV| 1:-0.44465401768684387 2:-0.32230401039123535 3:-0.045599494129419327 4:0.39940434694290161 5:0.65570676326751709 6:-0.75953042507171631 7:-0.077495388686656952 8:0.46600577235221863 9:0.024262679740786552 10:0.39012047648429871 11:-1.4777908325195312 12:0.13325724005699158 13:0.47489362955093384 14:0.99156183004379272 15:-1.0308619737625122 16:0.12335151433944702 17:-0.30270707607269287 18:-0.059895068407058716 19:-0.040842503309249878 20:-0.32898730039596558 21:-0.16469965875148773 22:0.022516429424285889 23:-0.73193413019180298 24:0.045193154364824295 25:0.42221939563751221 26:0.036796849220991135 27:0.23524349927902222 28:-0.27031907439231873 29:0.41419598460197449 30:0.20313477516174316 31:-0.29296407103538513 32:-0.33279585838317871 33:0.23716504871845245 34:-0.2083229273557663 35:-0.14375141263008118 36:-0.043305229395627975 37:-0.10976047813892365 38:-0.43185728788375854 39:0.68558299541473389 40:0.1834789514541626 41:-0.10938887 42:-0.38245955 43:0.14321519 44:0.044857524 45:0.3669782 46:-0.29872188 47:0.23523457 48:0.17176935 49:0.098058701 50:0.28258982 51:0.40256479 52:0.017722167 53:-0.021063194 54:0.001281107 55:0.15073901 56:0.33263028 57:0.16956863 58:0.33415374 59:0.18496469 60:0.15551123  |EV|
-1 |BT| (ROOT (S (NP (DT The) (NN examination)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (CD 1) (NN %)) (VP (VBG acetic) (NP (CD acid/95) (NN %)) (PP (ADVP (NP (CD ethanol) (NN fixative)) (RB together)) (IN with) (NP (NN zinc) (NN staining))))) (VP (VBD provided) (NP (DT a) (JJ high) (NN contrast)) (NP (JJ micro-CT) (NN image)) (, ,) (S (VP (VBG enabling) (NP (NP (DT the) (NN segmentation)) (PP (IN of) (NP (JJ soft) (NNS tissues)))))))))) (. .))) |ET| |BV| 1:0.11782391369342804 2:-0.1132638230919838 3:-0.45559829473495483 4:0.2364472895860672 5:0.76049387454986572 6:-0.59329843521118164 7:0.54228013753890991 8:0.41613417863845825 9:0.04001135379076004 10:-0.32132768630981445 11:0.92303711175918579 12:0.70906955003738403 13:-0.073625802993774414 14:0.061595749109983444 15:0.56586366891860962 16:0.75466644763946533 17:-0.81484872102737427 18:-0.17582589387893677 19:0.64058375358581543 20:-0.051477093249559402 21:-0.18262425065040588 22:-0.27455565333366394 23:-0.63187038898468018 24:-0.20303082466125488 25:-0.49805775284767151 26:-0.36358526349067688 27:-0.67585134506225586 28:-0.18507486581802368 29:0.57143604755401611 30:-0.13132448494434357 31:0.033105544745922089 32:0.3947727382183075 33:0.014030230231583118 34:-0.085290499031543732 35:0.069696143269538879 36:0.078646555542945862 37:-0.25420689582824707 38:-0.09992583841085434 39:0.4503624439239502 40:0.5757184624671936 41:0.39236972 42:-0.00080840726 43:-0.49571657 44:0.21134223 45:0.42398912 46:-0.094265543 47:-0.46978244 48:-0.13828225 49:0.21080624 50:0.07591226 51:0.011811668 52:0.050475437 53:-0.12781434 54:-0.091617227 55:0.16044585 56:0.10710389 57:0.32368404 58:-0.008756551 59:-0.24492981 60:0.6281727  |EV|
-1 |BT| (ROOT (S (NP (JJ Toxicological) (NN examination)) (VP (VBD confirmed) (NP (NP (DT a) (JJ recent) (NN intake)) (PP (IN of) (NP (NN mefloquine)))) (PP (ADVP (RB together)) (IN with) (NP (NP (NN chloroquine)) (, ,) (NP (DT another) (JJ antimalarial) (NN drug))))) (. .))) |ET| |BV| 1:-0.44465401768684387 2:-0.32230401039123535 3:-0.045599494129419327 4:0.39940434694290161 5:0.65570676326751709 6:-0.75953042507171631 7:-0.077495388686656952 8:0.46600577235221863 9:0.024262679740786552 10:0.39012047648429871 11:-1.4777908325195312 12:0.13325724005699158 13:0.47489362955093384 14:0.99156183004379272 15:-1.0308619737625122 16:0.12335151433944702 17:-0.30270707607269287 18:-0.059895068407058716 19:-0.040842503309249878 20:-0.32898730039596558 21:-0.56343692541122437 22:-0.35159784555435181 23:-0.14530688524246216 24:0.41392627358436584 25:0.43864274024963379 26:-0.62473142147064209 27:-0.74550020694732666 28:0.1065661758184433 29:0.38636046648025513 30:1.0745468139648438 31:-0.93271833658218384 32:0.50037240982055664 33:-0.11474588513374329 34:-0.72066718339920044 35:-0.34713095426559448 36:1.3505288362503052 37:-0.14346741139888763 38:-0.084357351064682007 39:-0.1347251832485199 40:-0.72076880931854248 41:-0.094799429 42:0.028020205 43:0.069429196 44:0.061938088 45:0.26012227 46:0.051171158 47:0.41731721 48:-0.39252681 49:0.28055552 50:0.052727427 51:0.22744687 52:-0.095782071 53:-0.20767178 54:-0.068187743 55:0.334362 56:0.2492743 57:-0.27498114 58:0.28063262 59:0.14184166 60:0.44808555  |EV|
-1 |BT| (ROOT (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (DT the) (JJ chromogenic) (NN antifactor) (NN Xa)) (ADVP (RB assay)) (VP (VBD proved) (S (VP (TO to) (VP (VB be) (ADJP (JJ sensitive) (PP (TO to) (NP (NP (JJR lower) (NNS amounts)) (PP (IN of) (NP (NN rivaroxaban) (CC and) (NN apixaban)))))) (PP (IN with) (NP (JJR less) (NN variability))))))) (. .))) |ET| |BV| 1:-0.63687938451766968 2:-0.82367885112762451 3:-0.065637841820716858 4:-0.35780254006385803 5:0.60219275951385498 6:-0.13255666196346283 7:-0.33090624213218689 8:-0.14652448892593384 9:0.76032280921936035 10:0.47847583889961243 11:0.054607506841421127 12:1.1422563791275024 13:0.020491387695074081 14:-1.2595913410186768 15:-0.39662492275238037 16:0.89241385459899902 17:-1.4477484226226807 18:0.89069348573684692 19:-0.64151692390441895 20:-0.7832256555557251 21:-1.0708463191986084 22:-1.0190001726150513 23:-0.37221908569335938 24:-0.79612761735916138 25:1.1188668012619019 26:0.86109793186187744 27:0.14011245965957642 28:-0.33982381224632263 29:0.23061364889144897 30:0.82401549816131592 31:-0.16274262964725494 32:1.476293683052063 33:-0.018853453919291496 34:-1.4313775300979614 35:-0.30922985076904297 36:0.23932619392871857 37:-1.4855353832244873 38:1.1207211017608643 39:-0.090681008994579315 40:-0.46252664923667908 41:-0.41603047 42:-0.15366942 43:-0.039533544 44:0.25971389 45:0.083582051 46:0.2283562 47:0.25811633 48:0.053701136 49:-0.2005575 50:0.1264745 51:0.0032630756 52:0.190842 53:0.23908348 54:-0.37939921 55:-0.12541832 56:0.29845008 57:0.36831132 58:-0.0091973199 59:-0.048603486 60:0.59633225  |EV|
-1 |BT| (ROOT (S (NP (NP (NNP Tiagabine)) (PRN (-LRB- -LRB-) (NP (NNP Gabitril)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT an) (JJ anticonvulsive) (NN drug)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ binds) (ADVP (RB selectively)) (PP (TO to) (NP (NNP GABA) (CD transporter-1)))) (CC and) (VP (ADVP (RB thereby)) (VBZ inhibits) (NP (NNP GABA) (NN uptake)))))))) (. .))) |ET| |BV| 1:-0.8324161171913147 2:-1.1449341773986816 3:0.95080703496932983 4:-1.0274134874343872 5:0.22716926038265228 6:-0.14663307368755341 7:0.78738421201705933 8:-0.55017918348312378 9:2.0051949024200439 10:-0.043764743953943253 11:0.29244023561477661 12:0.74981307983398438 13:0.5796363353729248 14:-0.47093388438224792 15:0.61563384532928467 16:-0.25871527194976807 17:-0.69366621971130371 18:-1.0949746370315552 19:0.0025397066492587328 20:0.61486750841140747 21:-0.27307969331741333 22:-0.6343989372253418 23:0.67877787351608276 24:-0.37401637434959412 25:0.3066762387752533 26:0.0076121524907648563 27:0.36643663048744202 28:0.46619260311126709 29:0.96201419830322266 30:-0.15649326145648956 31:0.58691895008087158 32:0.85801345109939575 33:-0.23444062471389771 34:-0.29673784971237183 35:-0.33163401484489441 36:0.12373612821102142 37:-0.59513187408447266 38:-1.4145488739013672 39:0.45294952392578125 40:0.48181861639022827 41:0.13987552 42:-0.12864909 43:0.25546247 44:-0.28174827 45:-0.041111976 46:-0.32483268 47:-0.029574873 48:0.14357752 49:-0.061583485 50:0.24860196 51:0.01839046 52:0.12885794 53:0.30713049 54:-0.26737991 55:0.033892825 56:0.34236515 57:0.13177383 58:0.1335682 59:-0.26608232 60:-0.13616437  |EV|
-1 |BT| (ROOT (S (NP (ADJP (RB Minimally) (JJ invasive)) (NN aspiration)) (VP (VBD was) (VP (VBN applied) (PP (IN within) (NP (NP (CD 72) (NN h)) (PP (IN after) (NP (NN onset))))) (, ,) (S (ADVP (IN along) (PP (IN with) (NP (NN mannitol) (CC or) (NN furosemide)))) (VP (TO to) (VP (VB lower) (NP (NP (DT the) (JJ intracranial) (NN pressure)) (CC and) (NP (JJ symptomatic) (NN treatment)))))))) (. .))) |ET| |BV| 1:-0.62696892023086548 2:-0.36565166711807251 3:-0.11384069919586182 4:0.44427594542503357 5:0.45800435543060303 6:-0.26020354032516479 7:-0.19542311131954193 8:-0.98826760053634644 9:-0.10918805003166199 10:0.59983301162719727 11:-0.2770254909992218 12:-0.65473091602325439 13:0.58738785982131958 14:-0.20297446846961975 15:-0.17696739733219147 16:0.99944466352462769 17:0.34191957116127014 18:0.22632022202014923 19:-0.61622744798660278 20:-1.1697770357131958 21:-0.35126665234565735 22:-0.35966041684150696 23:-1.299602746963501 24:0.33869659900665283 25:0.57237958908081055 26:-0.45514419674873352 27:0.61909174919128418 28:-0.39228793978691101 29:-0.39884531497955322 30:0.13205176591873169 31:0.36984586715698242 32:-0.12144777923822403 33:0.32529017329216003 34:-1.1934534311294556 35:-0.072098195552825928 36:-0.35082137584686279 37:-0.55683654546737671 38:-0.31578785181045532 39:0.44719502329826355 40:-0.57014626264572144 41:0.0033704631 42:-0.22132783 43:-0.36639515 44:0.12309282 45:0.52829379 46:-0.14449844 47:-0.16318546 48:0.14585845 49:-0.060612865 50:0.52935928 51:0.15475383 52:-0.16273543 53:-0.28403702 54:-0.096480556 55:0.31771207 56:-0.15114406 57:0.22274947 58:-0.027484309 59:-0.39348614 60:-0.049821202  |EV|
-1 |BT| (ROOT (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ unknown)) (SBAR (IN whether) (S (NP (DT the) (NN glycosaminoglycan) (NN drug) (NN sulodexide)) (VP (VBZ interferes) (PP (IN with) (S (VP (VBG transforming) (NP (NN growth) (JJ factor-beta1))))) (: --) (NP (NP (NP (DT a) (NN member)) (PP (IN of) (NP (JJ heparin-binding) (NN family)))) (CC and) (NP (NP (DT a) (JJ potent) (NN regulator)) (PP (IN of) (NP (JJ human) (NN biology) (CC and) (NNS diseases))))))))) (. .))) |ET| |BV| 1:-0.4122677743434906 2:-0.46324244141578674 3:0.073631599545478821 4:-0.10951337963342667 5:0.16933341324329376 6:-0.27944037318229675 7:-0.18100021779537201 8:-0.50181663036346436 9:0.24505071341991425 10:0.34632956981658936 11:-0.46979761123657227 12:0.0045941001735627651 13:-0.65328466892242432 14:-0.18240880966186523 15:0.043888773769140244 16:0.63524508476257324 17:-0.069035768508911133 18:0.38571858406066895 19:0.22889822721481323 20:-0.57725471258163452 21:-0.65510368347167969 22:-0.52460598945617676 23:0.111061692237854 24:0.67898494005203247 25:0.13148628175258636 26:-0.83193159103393555 27:-0.15369746088981628 28:0.52105712890625 29:1.2081887722015381 30:-0.21189776062965393 31:-1.0272619724273682 32:-0.70817798376083374 33:0.71377503871917725 34:-0.12052490562200546 35:-0.096693187952041626 36:0.41423788666725159 37:-1.156403660774231 38:-0.4729708731174469 39:1.5090388059616089 40:0.57205814123153687 41:0.31216297 42:0.0074428972 43:0.33363277 44:-0.16067104 45:-0.22803342 46:-0.26304579 47:0.37227073 48:-0.50172383 49:0.084706403 50:0.44456699 51:0.11748976 52:0.44630286 53:-0.093320549 54:-0.12813094 55:0.18731081 56:0.36073723 57:0.016233841 58:-0.036993947 59:-0.24337633 60:-0.17992486  |EV|
-1 |BT| (ROOT (S (NP (PRP It)) (VP (MD may) (VP (VB be) (VP (VBN concluded) (SBAR (IN that) (S (NP (NP (CD 40) (NN mg) (NN enalapril)) (CC or) (NP (CD 200) (NN mg) (NN losartan))) (VP (VBP are) (RB not) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB reduce) (NP (NN proteinuria) (CC and) (NN blood) (NN pressure)) (ADVP (RB significantly)) (PP (IN in) (NP (NP (ADJP (NN type) (CD 2)) (JJ proteinuric) (NNS diabetics)) (PP (IN with) (NP (JJ renal) (NN dysfunction))))))))) (SBAR (IN although) (S (NP (DT both) (NNS drugs)) (VP (VBD were) (ADVP (RB well)) (VP (VBN tolerated) (PP (IN at) (NP (JJ high) (NNS doses))))))))))))) (. .))) |ET| |BV| 1:-0.44045794010162354 2:-0.20210637152194977 3:-0.6685832142829895 4:-0.20488084852695465 5:0.19160647690296173 6:-0.08557853102684021 7:-0.041856847703456879 8:0.21727310121059418 9:-0.22746990621089935 10:0.76215541362762451 11:-0.25301581621170044 12:-0.95776104927062988 13:0.62736779451370239 14:0.17984417080879211 15:-0.50206577777862549 16:-0.37004891037940979 17:-0.029559878632426262 18:-0.37207043170928955 19:0.013137033209204674 20:-0.36919876933097839 21:-0.11989373713731766 22:0.02275284007191658 23:0.096252784132957458 24:-0.10840993374586105 25:0.09111718088388443 26:0.54770022630691528 27:-0.28366002440452576 28:0.15614184737205505 29:-0.042302072048187256 30:1.2563320398330688 31:0.33538967370986938 32:-0.49246865510940552 33:0.067063368856906891 34:0.12273779511451721 35:-0.69925516843795776 36:0.54223620891571045 37:-1.0732444524765015 38:-0.16988180577754974 39:-0.29746478796005249 40:-0.29228118062019348 41:-0.4951438 42:-0.016866246 43:0.27956626 44:0.040818717 45:-0.14349174 46:-0.01564648 47:-0.48963043 48:0.21600883 49:0.1900941 50:0.14878403 51:0.19369347 52:-0.16875175 53:0.15268704 54:0.24139041 55:0.51968884 56:-0.28463146 57:-0.23024626 58:0.48723248 59:-0.22559986 60:-0.13642505  |EV|
-1 |BT| (ROOT (S (PP (IN After) (S (VP (VBG having) (VP (VBN experienced) (NP (DT a) (JJ significant) (NN stress)) (PP (IN on) (NP (DT a) (NN job))))))) (NP (DT the) (NN patient)) (VP (VBD ingested) (NP (NP (JJ huge) (NN amount)) (PP (IN of) (NP (NP (NN pregabalin)) (PRN (-LRB- -LRB-) (NP (QP (CD 4,2) (CD r))) (-RRB- -RRB-))))) (PP (ADVP (RB together)) (IN with) (NP (NP (NN bromazepam)) (PRN (-LRB- -LRB-) (NP (QP (CD 21) (CD mg))) (-RRB- -RRB-)) (CC and) (NP (NN chlorimipramine)) (PRN (-LRB- -LRB-) (NP (QP (CD 125) (CD mg))) (-RRB- -RRB-))))) (. .))) |ET| |BV| 1:-0.37152770161628723 2:0.87690615653991699 3:-0.67786133289337158 4:-1.0895817279815674 5:-0.32238093018531799 6:-0.30310103297233582 7:0.74545997381210327 8:1.0689115524291992 9:-0.084735177457332611 10:-0.13898903131484985 11:-0.45417901873588562 12:1.5356566905975342 13:-1.1514780521392822 14:0.39720049500465393 15:-0.16190478205680847 16:0.024553267285227776 17:-1.1329115629196167 18:0.32390153408050537 19:0.34227520227432251 20:-0.23198044300079346 21:-0.15756520628929138 22:-0.73500853776931763 23:0.27732077240943909 24:-1.1033922433853149 25:-0.84908270835876465 26:0.099410496652126312 27:0.61854541301727295 28:1.0471467971801758 29:-0.79155123233795166 30:1.0137994289398193 31:-0.16548819839954376 32:1.7841874361038208 33:-0.058538507670164108 34:-0.20666135847568512 35:0.24202348291873932 36:0.050779528915882111 37:-0.47508376836776733 38:0.21666744351387024 39:0.59299290180206299 40:-0.34812191128730774 41:-0.27601537 42:-0.008309924 43:-0.18264793 44:-0.086053051 45:0.19646661 46:0.1656806 47:0.096765384 48:0.44792366 49:-0.010487107 50:-0.45661753 51:0.11046581 52:0.48861441 53:0.10922129 54:-0.11300386 55:-0.073537484 56:-0.08435002 57:0.72861916 58:0.090702914 59:0.074953854 60:-0.16789076  |EV|
-1 |BT| (ROOT (S (NP (NNP Bosutinib)) (ADVP (RB effectively)) (VP (VBZ inhibits) (NP (NP (JJ wild-type) (NNS BCR-ABL)) (CC and) (NP (ADJP (RBS most) (JJ imatinib-resistant)) (JJ BCR-ABL) (NNS mutations))) (PP (IN except) (PP (IN for) (NP (NNP V299L) (CC and) (NNP T315I))))) (. .))) |ET| |BV| 1:-1.4150195121765137 2:-0.75379562377929688 3:-0.30274698138237 4:0.41086515784263611 5:0.87304496765136719 6:-0.13760939240455627 7:-0.11610860377550125 8:0.54664403200149536 9:0.41857829689979553 10:-1.0666376352310181 11:0.37693744897842407 12:0.044920638203620911 13:-0.5852544903755188 14:1.8035409450531006 15:-0.19468595087528229 16:0.43577274680137634 17:-0.24823987483978271 18:-0.38447585701942444 19:0.87542605400085449 20:-0.57449918985366821 21:-0.3385130763053894 22:-1.7168829441070557 23:0.14864605665206909 24:-0.79962551593780518 25:0.091452620923519135 26:0.71990466117858887 27:-0.19070912897586823 28:1.0048409700393677 29:0.15158902108669281 30:-0.040196452289819717 31:-0.73503422737121582 32:0.2474774569272995 33:1.0172499418258667 34:0.75858974456787109 35:0.045884404331445694 36:0.86002635955810547 37:-0.52672380208969116 38:0.35932794213294983 39:0.27222681045532227 40:-0.44760516285896301 41:-0.36382547 42:-0.41348338 43:0.14345749 44:-0.148377 45:0.22420827 46:0.0034748192 47:-0.12785278 48:-0.28102565 49:0.17195584 50:0.44904375 51:0.066136934 52:0.048695061 53:-0.46924067 54:0.35670757 55:-0.11258142 56:-0.0038496205 57:0.37719911 58:0.36941379 59:-0.39937991 60:0.34766871  |EV|
-1 |BT| (ROOT (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NP (NP (NN lamivudine)) (PRN (-LRB- -LRB-) (NP (NNP LAM)) (-RRB- -RRB-))) (PP (IN versus) (NP (NP (NN telbivudine)) (PRN (-LRB- -LRB-) (NP (NNP LdT)) (-RRB- -RRB-))))))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ chronic) (NNP hepatitis) (NNP B) (PRN (-LRB- -LRB-) (NP (NNP CHB)) (-RRB- -RRB-)))))))))) (. .))) |ET| |BV| 1:0.21777214109897614 2:-0.48387640714645386 3:-0.78525078296661377 4:0.066077396273612976 5:-0.24370560050010681 6:0.50630271434783936 7:0.45234659314155579 8:-0.72379815578460693 9:0.1120215430855751 10:1.3632782697677612 11:-0.27164024114608765 12:0.6232227087020874 13:-0.63029885292053223 14:1.0705798864364624 15:-0.82747238874435425 16:0.73803794384002686 17:-0.62852734327316284 18:-0.75331950187683105 19:-0.038409523665904999 20:-0.18720534443855286 21:0.23779198527336121 22:-1.6707587242126465 23:0.010241314768791199 24:-0.12289867550134659 25:-0.35425296425819397 26:1.0315036773681641 27:0.74759912490844727 28:0.13548201322555542 29:-0.56741869449615479 30:0.92076724767684937 31:0.26983118057250977 32:0.18860863149166107 33:-0.27637884020805359 34:0.73069202899932861 35:-1.1377899646759033 36:0.32787588238716125 37:-0.9437604546546936 38:-0.91430556774139404 39:0.36018893122673035 40:-1.216572642326355 41:-0.024095088 42:-0.20915298 43:0.26553917 44:-0.046438165 45:-0.22937129 46:-0.028843738 47:0.251798 48:-0.029212222 49:-0.14888071 50:-0.092224009 51:0.011975461 52:-0.32317951 53:-0.16132723 54:0.58817178 55:-0.19626126 56:0.41344604 57:0.2396934 58:0.19986278 59:-0.090092249 60:-0.12889434  |EV|
-1 |BT| (ROOT (NP (NP (NNS CONCLUSIONS)) (: :) (NP (NP (NNP Pegfilgrastim)) (VP (VBN prescribed) (PP (IN as) (NP (NP (NNS prophylaxis)) (VP (VBN resulted) (PP (IN in) (NP (NP (JJR lower) (NN risk)) (PP (IN of) (NP (JJ neutropenia-related) (CC and) (JJ all-cause) (NNS hospitalizations))))) (PP (VBN compared) (PP (TO to) (NP (NN filgrastim) (NNS prophylaxis))))))))) (. .))) |ET| |BV| 1:-0.59783238172531128 2:-0.21577467024326324 3:-1.3032203912734985 4:0.11277531087398529 5:0.15912826359272003 6:-0.558543860912323 7:-0.62208253145217896 8:-0.31364321708679199 9:-0.74878549575805664 10:1.5309748649597168 11:0.17169061303138733 12:0.36441716551780701 13:0.020225094631314278 14:0.087127074599266052 15:-0.041777066886425018 16:0.98396909236907959 17:0.29103648662567139 18:-0.33411052823066711 19:0.15795299410820007 20:0.19866879284381866 21:-0.84683191776275635 22:-0.12949369847774506 23:-0.33711621165275574 24:0.9023011326789856 25:0.44179549813270569 26:0.52285891771316528 27:-0.6604805588722229 28:-0.8284764289855957 29:0.018474340438842773 30:1.2685339450836182 31:-0.31697750091552734 32:0.76004558801651001 33:-0.85260289907455444 34:0.46231094002723694 35:-1.3743160963058472 36:1.1914694309234619 37:0.22807598114013672 38:0.37001562118530273 39:0.03324587270617485 40:0.38829821348190308 41:0.1475179 42:0.20781209 43:0.20133418 44:0.22575296 45:0.24077056 46:-0.1127293 47:-0.071849011 48:-0.22113422 49:0.042046204 50:-0.14211532 51:0.21430181 52:-0.25657484 53:-0.16298628 54:0.12978213 55:0.40566981 56:-0.076135136 57:0.32060182 58:-0.10927128 59:0.28213686 60:-0.22288972  |EV|
-1 |BT| (ROOT (S (NP (PRP It)) (VP (VBD was) (VP (VBN concluded) (SBAR (SBAR (IN that) (S (NP (DT all) (NNS protocols)) (VP (VBD provided) (NP (JJ adequate) (NN analgesia))))) (CC and) (SBAR (WHADVP (WRB when)) (S (S (VP (VBN used) (PP (IN with) (NP (NN midazolam-medetomidine-ketamine))))) (VP (VBP are) (ADJP (JJ effective) (PP (IN for) (NP (JJ routine) (JJ feline) (NN ovariohysterectomy)))))))))) (. .))) |ET| |BV| 1:-0.11668428778648376 2:-0.74165034294128418 3:-1.0241296291351318 4:-0.74730932712554932 5:0.10768051445484161 6:-0.027183696627616882 7:-0.37243309617042542 8:0.063145764172077179 9:0.61295735836029053 10:0.35496282577514648 11:0.77447646856307983 12:-0.233793705701828 13:0.25274378061294556 14:-0.15525589883327484 15:-0.4126114547252655 16:0.58029055595397949 17:0.033387862145900726 18:0.43734666705131531 19:-0.18863105773925781 20:-0.29837921261787415 21:-0.33319580554962158 22:-0.99600750207901001 23:-0.36023229360580444 24:-0.92181026935577393 25:0.70081371068954468 26:0.1302991509437561 27:-1.0233551263809204 28:-0.31179019808769226 29:-0.067936509847640991 30:-0.072507545351982117 31:0.083184622228145599 32:-0.4980456531047821 33:-0.090666599571704865 34:-0.080993279814720154 35:-0.4362177848815918 36:0.82062733173370361 37:-0.23244357109069824 38:-0.10020839422941208 39:0.24677145481109619 40:-1.4766076803207397 41:-0.54253477 42:-0.099288113 43:0.35640484 44:0.086138047 45:0.17721993 46:-0.15654343 47:-0.10916232 48:0.1159996 49:0.39309952 50:0.26952156 51:0.12959385 52:0.4050242 53:-0.15491019 54:0.25288731 55:-0.1877137 56:-0.47574008 57:0.037227448 58:0.02224724 59:-0.22766301 60:0.068437144  |EV|
-1 |BT| (ROOT (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP report) (SBAR (IN that) (S (NP (NP (NP (NP (JJ systemic) (CC or) (JJ local) (NN administration)) (PP (IN of) (NP (NN SB-277011A)))) (, ,) (NP (DT a) (ADJP (RB highly) (JJ selective)) (NNP D3) (NN R) (NN antagonist)) (, ,) (PP (IN into) (NP (NP (NP (DT the) (NN NAc)) (PRN (-LRB- -LRB-) (NP (JJ core) (CC and) (JJ shell)) (-RRB- -RRB-))) (CC or) (NP (DT the) (NN CeA))))) (, ,) (CONJP (CC but) (RB not)) (NP (DT the) (JJ dorsal) (NN striatum) (CC or) (NN basolateral) (NN amygdala)) (, ,)) (ADVP (RB significantly)) (VP (VP (VBZ inhibits) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NN incubation)) (PP (IN of) (NP (NP (NN cocaine) (NN craving)) (PP (IN in) (NP (NNS rats)))))))) (PP (IN after) (NP (NP (CD 2-30) (NNS days)) (PP (IN of) (NP (NP (NN withdrawal)) (PP (IN from) (NP (JJ previous) (NN cocaine) (NN self-administration)))))))) (CC but) (VP (VBD had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ sucrose-seeking) (NN behavior)) (PP (IN in) (NP (NNS rats)))))) (PP (IN after) (NP (NP (CD 10-30) (NNS days)) (PP (IN of) (NP (NN withdrawal)))))))))) (. .))) |ET| |BV| 1:0.04645971953868866 2:-0.24341200292110443 3:-0.12847506999969482 4:-0.020735494792461395 5:0.046708986163139343 6:-0.63118833303451538 7:-0.37865597009658813 8:-0.7709348201751709 9:0.74587637186050415 10:-0.46059706807136536 11:0.0066282842308282852 12:-0.22267381846904755 13:-0.17692463099956512 14:-0.36518228054046631 15:-0.20190101861953735 16:0.29322820901870728 17:-0.080923497676849365 18:-0.1887049674987793 19:0.15922586619853973 20:0.54918378591537476 21:-0.9349932074546814 22:-0.84000343084335327 23:-0.41635552048683167 24:-0.3888784646987915 25:-0.25315806269645691 26:-0.15392397344112396 27:0.025107415392994881 28:0.56973457336425781 29:0.38532906770706177 30:0.37857183814048767 31:0.66472488641738892 32:0.96014046669006348 33:0.74786615371704102 34:-0.18957825005054474 35:-0.72223562002182007 36:-0.079844474792480469 37:-0.32539805769920349 38:0.89657247066497803 39:0.50971692800521851 40:0.36139878630638123 41:-0.33865368 42:-0.24848591 43:0.3995091 44:-0.41769773 45:0.68927538 46:-0.26330471 47:-0.62767434 48:0.32440564 49:-0.06086744 50:-0.0041808765 51:0.37946677 52:0.17346567 53:0.77269131 54:-0.38428909 55:-0.28520402 56:-0.25364316 57:-0.3077842 58:-0.50354427 59:0.028540878 60:-0.70094997  |EV|
-1 |BT| (ROOT (S (PP (VBN Compared) (PP (TO to) (NP (NNP IDC)))) (, ,) (NP (NNP ILC)) (VP (VBD showed) (SBAR (S (NP (NP (DT a) (JJR larger) (NN tumor) (NN size)) (PRN (-LRB- -LRB-) (NP (NP (NNP =) (NNP T2)) (, ,) (NP (NP (CD 59.8) (NN %)) (PP (IN vs.) (NP (NP (CD 38.8) (NN %)) (, ,) (NP (NP (NNP P)) (SBAR (S (VP (SYM =) (NP (CD 0.001)))))))))) (-RRB- -RRB-)) (, ,) (NP (NP (DT a) (ADJP (JJR lower) (JJ histologic)) (NN grade)) (PRN (-LRB- -LRB-) (NP (NP (NNP HG) (CD 1/2)) (, ,) (NP (NP (CD 90.4) (NN %)) (PP (IN vs.) (NP (CD 64.4) (NN %)))) (, ,) (NP (NNP P) (NNP <) (NNP 0.001))) (-RRB- -RRB-))) (, ,) (NP (NP (JJR more) (JJ frequent) (NN estrogen) (NN receptor)) (ADJP (ADJP (JJ positive)) (PRN (-LRB- -LRB-) (NP (NP (CD 90.4) (NN %)) (PP (IN vs.) (NP (NP (CD 64.4) (NN %)) (, ,) (NP (NNP P) (NNP <) (NNP 0.001))))) (-RRB- -RRB-)))) (, ,)) (VP (VBP progesterone) (S (VP (VP (VBG receptor) (NP (NP (ADJP (ADJP (ADJP (JJ positive)) (PRN (-LRB- -LRB-) (NP (NP (CD 71.1) (NN %)) (PP (IN vs.) (NP (NP (CD 50.1) (NN %)) (, ,) (NP (NNP P) (NNP <) (NNP 0.001))))) (-RRB- -RRB-))) (CC and) (ADJP (ADJP (RB HER2) (JJ negative)) (PRN (-LRB- -LRB-) (NP (NP (CD 97.5) (NN %)) (PP (IN vs.) (NP (NP (CD 74.6) (NN %)) (, ,) (NP (NNP P) (NNP <) (NNP 0.001))))) (-RRB- -RRB-)))) (NN status)) (, ,) (CC and) (NP (NP (JJR lower) (NN Ki-67) (NN expression)) (PRN (-LRB- -LRB-) (NP (NP (CD 10.3) (NN %)) (NP (NP (QP (CD ±) (CD 10.6)) (NN %)) (PP (IN vs.) (NP (NP (NP (CD 20.6) (NN %)) (NP (QP (CD ±) (CD 19.8)) (NN %))) (, ,) (NP (NP (NNP P) (NNP <)) (NP (CD 0.001))))))) (-RRB- -RRB-))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (VP (VBG being) (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (VB be) (PP (IN of) (NP (DT the) (NN luminal)))))))) (NP (NP (DT A) (NN subtype)) (PRN (-LRB- -LRB-) (NP (NP (CD 91.4) (NN %)) (PP (IN vs.) (NP (NP (CD 51.2) (NN %)) (, ,) (NP (NNP P) (NNP <) (NNP 0.001))))) (-RRB- -RRB-))))))))) (. .))) |ET| |BV| 1:-1.0670901536941528 2:0.23203368484973907 3:0.71809619665145874 4:0.84020024538040161 5:-0.31951990723609924 6:0.41391420364379883 7:0.47330904006958008 8:0.02633211575448513 9:0.39720982313156128 10:-0.51868224143981934 11:0.00086135836318135262 12:-0.27064579725265503 13:0.27077051997184753 14:0.11533814668655396 15:-0.078596331179141998 16:0.25425335764884949 17:-0.81162267923355103 18:1.3172448873519897 19:0.24948108196258545 20:-0.41995546221733093 21:-0.70291984081268311 22:0.10596521198749542 23:0.40353924036026001 24:-0.0082024643197655678 25:0.51516556739807129 26:-0.42482960224151611 27:0.15003122389316559 28:0.12399149686098099 29:0.20275136828422546 30:0.48732560873031616 31:0.47781708836555481 32:-0.14894188940525055 33:0.51152008771896362 34:0.33163288235664368 35:-0.59081339836120605 36:0.57499492168426514 37:0.029747411608695984 38:0.1139160692691803 39:0.40241897106170654 40:0.63742589950561523 41:0.72959906 42:0.31645319 43:0.33957493 44:0.064995825 45:-0.087116443 46:-0.079077385 47:-0.43598956 48:0.006599939 49:0.11535599 50:-0.35353127 51:0.64523482 52:0.50717562 53:0.10426375 54:-0.30898896 55:0.35681897 56:0.80943263 57:0.85897726 58:0.77472395 59:-0.10712278 60:0.39021918  |EV|
-1 |BT| (ROOT (FRAG (NP (NNP CONCLUSION)) (: :) (S (NP (NNP Exenatide)) (VP (MD can) (VP (VB reduce) (NP (JJ glycemic) (NN variability)) (PP (VBN compared) (PP (IN with) (NP (NN glimepiride)))) (, ,) (S (VP (VBG providing) (NP (NP (JJ additional) (JJ beneficial) (NNS effects)) (PP (IN in) (NP (VBG controlling) (NN glucose) (NNS homeostasis))))))))) (. .))) |ET| |BV| 1:-0.93116724491119385 2:0.16165627539157867 3:-0.29050761461257935 4:0.41528582572937012 5:0.92106139659881592 6:0.96246242523193359 7:-0.4599493145942688 8:-0.49726834893226624 9:0.50690150260925293 10:1.0611228942871094 11:0.89072293043136597 12:1.0179568529129028 13:0.63718491792678833 14:-0.57090878486633301 15:-0.45598295331001282 16:0.94798737764358521 17:-0.31631407141685486 18:0.37501788139343262 19:-0.19825248420238495 20:0.23595334589481354 21:-0.8124687671661377 22:0.21673531830310822 23:-0.84179484844207764 24:-0.22898389399051666 25:0.0693511962890625 26:0.11475291103124619 27:-0.43084850907325745 28:-0.72749894857406616 29:-0.44754123687744141 30:1.1456862688064575 31:0.49666786193847656 32:0.32925325632095337 33:0.086216025054454803 34:0.78487759828567505 35:-0.070442803204059601 36:1.7741994857788086 37:-0.44247129559516907 38:-0.19110916554927826 39:-0.51957941055297852 40:-0.0753665491938591 41:-0.11285566 42:0.33559066 43:0.31283709 44:-0.093589649 45:0.060787041 46:-0.013190156 47:0.054832309 48:-0.85783446 49:0.038858727 50:-0.02937685 51:0.26014236 52:0.1090735 53:-0.091011293 54:-0.056013148 55:-0.099395066 56:0.46729338 57:0.30824614 58:0.16248286 59:0.2276943 60:0.404715  |EV|
-1 |BT| (ROOT (S (PP (IN On) (NP (DT the) (JJ seventh) (NN postoperative) (NN day))) (, ,) (NP (NP (DT the) (NNS amplitudes)) (PP (IN of) (NP (DT the) (NNP ERG) (NNS b-waves)))) (VP (VBD were) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN in) (NP (DT the) (NN vehicle) (NN group)))) (PP (IN than) (IN in) (NP (NP (DT the) (NNS groups)) (VP (VBN pretreated) (PP (IN with) (NP (NN captopril) (CC or) (NN candesartan))))))) (. .))) |ET| |BV| 1:-0.3854023814201355 2:-0.029400404542684555 3:-0.011971225962042809 4:-0.46540889143943787 5:-0.014149606227874756 6:-0.061438377946615219 7:-0.64122146368026733 8:0.0075905132107436657 9:0.17704339325428009 10:0.59466284513473511 11:-0.15140822529792786 12:-0.85643875598907471 13:-0.1154223307967186 14:0.19611437618732452 15:-1.1484330892562866 16:-0.58745360374450684 17:-0.36097177863121033 18:-0.085968799889087677 19:-0.069136999547481537 20:-0.47890177369117737 21:-0.23110723495483398 22:-1.7506664991378784 23:0.9853547215461731 24:-0.0243424903601408 25:-0.65138614177703857 26:0.09895922988653183 27:-0.30374383926391602 28:-0.28374430537223816 29:-0.38876917958259583 30:0.87318092584609985 31:-0.03287840262055397 32:-0.62267059087753296 33:0.7470775842666626 34:0.74080103635787964 35:-0.65818440914154053 36:-0.60471075773239136 37:-0.78161919116973877 38:0.47585368156433105 39:-0.29289764165878296 40:-0.58492201566696167 41:-0.16998658 42:-0.059208658 43:0.17626646 44:-0.17418414 45:0.2940405 46:0.074455582 47:-0.33273157 48:-0.25629267 49:0.24928108 50:-0.11851276 51:0.02406328 52:-0.084605463 53:0.20529212 54:-0.10385428 55:-0.021631127 56:-0.51458961 57:0.2339794 58:-0.041426707 59:-0.022182839 60:0.064581431  |EV|
-1 |BT| (ROOT (S (NP (NP (NNP Gefitinib)) (PRN (-LRB- -LRB-) (NP (NNP Iressa)) (, ,) (NP (NNP ZD1839)) (-RRB- -RRB-)) (, ,) (NP (NP (DT a) (JJ selective) (JJ epidermal) (NN growth) (NN factor) (NN receptor)) (NP (JJ tyrosine) (NN kinase) (NN inhibitor))) (, ,)) (VP (VBZ inhibits) (NP (NP (NN growth) (, ,) (NN invasion) (CC and) (NN colony) (NN formation)) (PP (IN of) (NP (JJ various) (NN cancer) (NNS cells))))) (. .))) |ET| |BV| 1:0.10216856002807617 2:-0.81429821252822876 3:1.1611762046813965 4:-0.40571942925453186 5:-0.45861449837684631 6:-0.340655118227005 7:-0.39178714156150818 8:2.1131851673126221 9:-0.1107584685087204 10:-1.6941170692443848 11:-0.048676334321498871 12:0.47019651532173157 13:0.37841218709945679 14:-0.057027876377105713 15:-0.33348977565765381 16:-0.2885817289352417 17:-0.27989533543586731 18:-0.32981866598129272 19:0.207241490483284 20:-0.91898322105407715 21:0.065595999360084534 22:-1.0159993171691895 23:1.6045340299606323 24:-0.35524636507034302 25:0.076724894344806671 26:-0.35726004838943481 27:-0.40416231751441956 28:2.2256073951721191 29:-0.80645549297332764 30:-1.041292667388916 31:0.1146354004740715 32:0.18742160499095917 33:0.68728649616241455 34:-0.35357695817947388 35:-0.31467437744140625 36:-0.64426547288894653 37:-1.1745643615722656 38:-0.24322222173213959 39:0.81377112865447998 40:-1.0585378408432007 41:-0.26250494 42:-0.12209284 43:0.17311475 44:-0.32206807 45:-0.052710257 46:-0.11155495 47:0.1030077 48:0.16907573 49:0.16935766 50:0.24108896 51:0.92404282 52:0.08721929 53:0.17738707 54:-0.082045339 55:0.32149088 56:0.10629202 57:0.25221282 58:-0.30146322 59:0.03583755 60:-0.34616727  |EV|
-1 |BT| (ROOT (FRAG (NP (NNP BACKGROUND)) (: :) (S (PP (JJ Due) (TO to) (NP (NP (DT the) (JJ limited) (NNS data)) (ADJP (JJ available) (PP (IN in) (NP (NN literature)))))) (, ,) (NP (NP (DT the) (NN aim)) (PP (IN of) (NP (DT this) (JJ multi-centre) (NN study)))) (VP (VBD was) (S (VP (TO to) (ADVP (RB prospectively)) (VP (VB compare) (PP (IN in) (NP (JJ thalassemia) (JJ major) (PRN (-LRB- -LRB-) (NP (NNP TM)) (-RRB- -RRB-)) (NNS patients))) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NP (NP (VBN combined) (NN deferiprone)) (PRN (-LRB- -LRB-) (NP (NNP DFP)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ deferoxamine) (PRN (-LRB- -LRB-) (NP (NNP DFO)) (-RRB- -RRB-)) (NN regimen)) (PP (IN versus) (NP (DT either) (NNP DFP) (CC and) (NNP DFO))) (PP (IN in) (NP (NN monotherapy)))))))))) (PP (IN by) (NP (NP (NP (JJ cardiovascular) (JJ magnetic) (NN resonance)) (PRN (-LRB- -LRB-) (NP (NNP CMR)) (-RRB- -RRB-))) (PP (IN over) (NP (NP (DT a) (VBG follow) (RP up)) (PP (IN of) (NP (CD 18) (NNS months))))))))) (. .))) |ET| |BV| 1:-0.59635317325592041 2:-0.73754423856735229 3:-0.22736442089080811 4:-0.18584974110126495 5:0.40085682272911072 6:-0.26287534832954407 7:0.23012420535087585 8:-0.55766993761062622 9:-0.70827299356460571 10:0.75369030237197876 11:-0.59109914302825928 12:0.43120390176773071 13:-0.069738186895847321 14:-0.21555620431900024 15:0.36373171210289001 16:0.44060203433036804 17:-0.78674417734146118 18:-0.53757834434509277 19:0.086989901959896088 20:-0.66096216440200806 21:-0.29204905033111572 22:-0.77387869358062744 23:-0.23356921970844269 24:-0.87999260425567627 25:0.30062583088874817 26:0.50936383008956909 27:0.74580115079879761 28:-0.86730086803436279 29:0.00043346901657059789 30:0.56914258003234863 31:0.090854264795780182 32:0.19427791237831116 33:-0.84593164920806885 34:0.0020033067557960749 35:0.53567260503768921 36:0.33451828360557556 37:-1.2774866819381714 38:-1.3302456140518188 39:-0.56758266687393188 40:-1.3697481155395508 41:0.27192444 42:-0.34477407 43:-0.036144745 44:-0.028823452 45:0.33378315 46:-0.21708131 47:-0.26402315 48:-0.14676255 49:0.25586542 50:-0.099953227 51:0.40094534 52:-0.033874787 53:-0.27203816 54:0.64172727 55:-0.12642813 56:-0.11062916 57:0.36570272 58:0.18812627 59:0.40082106 60:-0.53635865  |EV|
-1 |BT| (ROOT (S (NP (NP (DT A) (NN guanine)) (PRN (-LRB- -LRB-) (NP (NNP G)) (-RRB- -RRB-))) (VP (VBZ /) (NP (NP (NN adenine)) (PRN (-LRB- -LRB-) (NP (NNP A)) (-RRB- -RRB-)) (SBAR (S (NP (NP (JJ common) (JJ single) (NN nucleotide) (NN polymorphism)) (PP (IN at) (NP (NP (JJ first) (NN position)) (PP (IN of) (NP (NP (NN codon) (CD 589)) (PP (IN in) (NP (NNP Exo) (CD 1) (NN gene)))))))) (VP (VBZ determines) (NP (DT a) (JJ glutamic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NNP Glu)) (, ,) (NP (NNP E)) (-RRB- -RRB-)) (PP (TO to) (NP (NP (NP (NN lysine)) (PRN (-LRB- -LRB-) (NP (NNP Lys)) (, ,) (NP (NNP K)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NNP K589E)) (-RRB- -RRB-)))))))) (NP (NP (JJ aminoacidic) (NN substitution)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB alter) (NP (NN cancer) (NN risk)) (PP (IN by) (S (VP (VBG influencing) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NNP Exo) (CD 1) (NN protein))))))))))))) (. .))) |ET| |BV| 1:-0.89806103706359863 2:-0.88740348815917969 3:0.66845309734344482 4:-0.726326584815979 5:-1.6517492532730103 6:-0.36108562350273132 7:0.26906853914260864 8:1.6386491060256958 9:0.22852036356925964 10:0.079020485281944275 11:0.19047874212265015 12:0.77491360902786255 13:0.37403875589370728 14:0.77928268909454346 15:-0.82996875047683716 16:0.47676581144332886 17:-0.69418495893478394 18:0.1101471409201622 19:-0.58469980955123901 20:-0.93877232074737549 21:-0.98417937755584717 22:0.41805446147918701 23:0.35911783576011658 24:-0.893424391746521 25:-0.28451302647590637 26:-0.78242135047912598 27:-0.58465123176574707 28:0.97099947929382324 29:0.19545634090900421 30:-1.824374794960022 31:-0.0024916052352637053 32:0.65486383438110352 33:0.18116830289363861 34:1.189051628112793 35:-0.096406184136867523 36:-0.96060627698898315 37:-0.53619104623794556 38:-0.27410814166069031 39:-0.029814116656780243 40:-1.4676651954650879 41:-0.051239736 42:-0.28658754 43:0.34319121 44:0.14093253 45:-0.21908839 46:-0.098751724 47:0.078506082 48:-0.060891476 49:0.20008431 50:-0.14257202 51:0.7868917 52:0.071409814 53:-0.1009173 54:0.14273414 55:-0.12032348 56:0.10546955 57:-0.25631997 58:0.26697889 59:0.14741941 60:-0.049186252  |EV|
-1 |BT| (ROOT (NP (NP (NNS RESULTS)) (: :) (S (NP (PRP It)) (VP (VBD was) (VP (VBN found) (SBAR (IN that) (S (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (JJ acylated) (, ,) (JJ desacylated) (NN ghrelin)) (, ,) (NP (JJ paraoxonase) (NN arylesterase)) (, ,) (NP (JJ total) (NN cholesterol)) (CC and) (NP (NN triglyceride))))) (VP (VBD were) (ADJP (ADJP (JJR lower)) (PP (IN in) (NP (JJ depressive) (NNS patients)))) (PP (IN before) (NP (NN citalopram) (NN treatment))) (PP (IN than) (PP (IN in) (NP (DT the) (NN control) (NN group)))))))))) (. .))) |ET| |BV| 1:-0.40574127435684204 2:0.058164272457361221 3:-0.55703866481781006 4:-0.45595854520797729 5:0.55642026662826538 6:-0.69570565223693848 7:-0.81506693363189697 8:-0.36349746584892273 9:-0.10663575679063797 10:0.16767016053199768 11:0.47130343317985535 12:-0.055568292737007141 13:-0.1427752822637558 14:0.29299291968345642 15:-0.92808806896209717 16:-0.24978071451187134 17:0.050095561891794205 18:-0.21021543443202972 19:1.0624300241470337 20:-0.29777443408966064 21:-0.72881132364273071 22:0.52908170223236084 23:0.59164303541183472 24:-0.024455303326249123 25:-0.52654778957366943 26:-0.36971461772918701 27:0.13414874672889709 28:-0.082332849502563477 29:-0.12963098287582397 30:0.58822077512741089 31:-0.046490177512168884 32:0.53263962268829346 33:0.26568892598152161 34:-0.3937089741230011 35:-0.34961393475532532 36:0.028063373640179634 37:-0.14020983874797821 38:0.32197952270507812 39:0.76699817180633545 40:0.2974456250667572 41:-0.39295569 42:0.1886147 43:-0.25878462 44:0.39115742 45:-0.0040546465 46:0.66834962 47:-0.1418177 48:0.0049863365 49:0.1131925 50:-0.024216022 51:0.44701204 52:-0.14832591 53:-0.055177383 54:-0.20652506 55:-0.11224238 56:0.12763985 57:0.29367417 58:-0.045456134 59:0.064795427 60:0.0031734896  |EV|
-1 |BT| (ROOT (S (NP (NP (NP (JJ Specific) (NNS activities)) (PP (IN of) (NP (NNP SOD) (, ,) (NNP CAT) (, ,) (NNP GPX) (, ,) (NNP GR) (CC and) (NNP GST)))) (CC and) (NP (NP (NN serum)) (ADJP (JJ testosterone) (CC and) (JJ progesterone)))) (VP (VBD were) (VP (ADVP (RB significantly)) (VBN decreased) (, ,) (SBAR (IN while) (S (NP (NNP H2O2) (, ,) (NNP LPO) (CC and) (NNP serum)) (ADVP (RB FSH)) (VP (VBD was) (VP (VBN increased) (PP (IN in) (NP (NP (JJ 50-parts)) (PP (IN per) (NP (NP (CD million) (-LRB- -LRB-) (NN ppm) (-RRB- -RRB-)) (CC and) (NP (CD 200) (JJ ppm-treated) (NNS rats)))))) (PP (IN in) (NP (DT an) (JJ age-dependent) (NN manner))))))))) (. .))) |ET| |BV| 1:-0.21002721786499023 2:0.6938927173614502 3:0.55721479654312134 4:0.14590901136398315 5:-0.43242931365966797 6:-0.65587526559829712 7:0.25277820229530334 8:-0.98675036430358887 9:-0.13765193521976471 10:0.48209729790687561 11:0.71145683526992798 12:0.0018130689859390259 13:-0.090216413140296936 14:0.23047630488872528 15:0.2643323540687561 16:0.22392234206199646 17:-0.07805265486240387 18:0.13959673047065735 19:0.54265320301055908 20:0.34579405188560486 21:-0.70291984081268311 22:0.10596521198749542 23:0.40353924036026001 24:-0.0082024643197655678 25:0.51516556739807129 26:-0.42482960224151611 27:0.15003122389316559 28:0.12399149686098099 29:0.20275136828422546 30:0.48732560873031616 31:0.47781708836555481 32:-0.14894188940525055 33:0.51152008771896362 34:0.33163288235664368 35:-0.59081339836120605 36:0.57499492168426514 37:0.029747411608695984 38:0.1139160692691803 39:0.40241897106170654 40:0.63742589950561523 41:-0.73575509 42:-0.52072817 43:-0.13551107 44:0.11380048 45:-0.024229728 46:-0.10147609 47:-0.16631822 48:0.051990826 49:0.03252105 50:-0.049800087 51:0.85123843 52:-0.25786796 53:0.12621595 54:-0.91563308 55:0.082193032 56:-0.070582598 57:0.38757965 58:-0.040254798 59:0.1011998 60:0.10898614  |EV|
-1 |BT| (ROOT (S (NP (NP (NP (NNS Studies)) (PP (IN of) (NP (NP (VBN combined) (NN therapy)) (PP (IN with) (NP (NN pemetrexed)))))) (, ,) (CC and) (NP (NP (NN bevacizumab)) (PP (IN beyond) (NP (NN progression)))) (, ,)) (VP (VBP are) (ADJP (JJ ongoing))) (. .))) |ET| |BV| 1:-1.3908823728561401 2:-0.11869227141141891 3:0.23167699575424194 4:0.20158879458904266 5:0.51931130886077881 6:0.15928104519844055 7:-0.9472196102142334 8:-0.71603250503540039 9:0.5303729772567749 10:0.30137166380882263 11:-1.0751276016235352 12:0.034899134188890457 13:0.29326963424682617 14:0.060902319848537445 15:-0.11565397679805756 16:0.021296026185154915 17:0.44529137015342712 18:-0.70981979370117188 19:-0.15477675199508667 20:-1.3002903461456299 21:-1.2117177248001099 22:-0.36075294017791748 23:0.064280353486537933 24:-0.16516032814979553 25:0.29850730299949646 26:-0.075363375246524811 27:0.017898917198181152 28:-0.709300696849823 29:0.69164448976516724 30:0.64934754371643066 31:-1.8740338087081909 32:-0.71959877014160156 33:1.7490357160568237 34:-0.78083962202072144 35:-0.57003623247146606 36:1.0593169927597046 37:0.36552858352661133 38:-0.48745784163475037 39:0.5764586329460144 40:-1.8443197011947632 41:0.10336014 42:0.11610208 43:-0.12481127 44:0.21785234 45:-0.060024712 46:-0.078616686 47:-0.1064215 48:-0.18285896 49:0.29520079 50:0.21553503 51:0.39706475 52:0.045637619 53:0.073875763 54:-0.042854551 55:0.40837374 56:-0.060209844 57:0.16769862 58:0.05472903 59:0.21526819 60:-0.52857339  |EV|
-1 |BT| (ROOT (S (NP (NP (CD 24) (NN ml)) (PP (IN of) (NP (NP (NNP Bupivacaine)) (ADJP (CD 0.5) (NN %)) (PP (IN with) (NP (NN injection) (NNP Dexamethasone) (CD 4)))))) (ADVP (RB mg)) (VP (VBD was) (VP (VBN used) (S (VP (TO to) (VP (VB block) (NP (NP (DT the) (JJ individual) (CD four) (NNS nerves)) (PP (IN with) (NP (NP (CD 6) (NN ml)) (PP (IN of) (NP (NP (DT the) (JJ local) (JJ anaesthetic) (NN solution)) (PP (IN per) (NP (NN nerve))) (ADVP (RB namely)) (NP (NN ulnar) (, ,) (NN radial) (, ,) (NN median) (CC and) (NNS musculocutaneous)))))))))))) (. .))) |ET| |BV| 1:-0.89050740003585815 2:-0.068780981004238129 3:-0.47116345167160034 4:-0.32579430937767029 5:-0.21974571049213409 6:-0.086479373276233673 7:0.31466415524482727 8:-0.11319269239902496 9:0.079392373561859131 10:0.18790373206138611 11:0.23570172488689423 12:-0.12637585401535034 13:0.10259231925010681 14:-0.49600061774253845 15:-0.25592780113220215 16:0.32329067587852478 17:0.42616134881973267 18:0.28018206357955933 19:-0.76101130247116089 20:0.10418049246072769 21:-0.37860354781150818 22:-0.77694696187973022 23:0.15381135046482086 24:-0.30914473533630371 25:0.17392580211162567 26:-0.03874872624874115 27:-0.12139929831027985 28:-0.30365684628486633 29:-0.37887203693389893 30:0.9753606915473938 31:-0.1092710867524147 32:-0.26525720953941345 33:0.15702246129512787 34:-0.080765247344970703 35:0.040583889931440353 36:0.4782106876373291 37:-0.29756030440330505 38:-0.32002869248390198 39:-0.079881735146045685 40:0.0094199497252702713 41:-0.1219848 42:0.090587869 43:-0.2645717 44:0.303177 45:0.30610082 46:0.062370043 47:0.20278507 48:-0.11053276 49:-0.4231897 50:-0.27317315 51:-0.090461411 52:-0.020297233 53:-0.026960362 54:-0.12974785 55:-0.15520893 56:-0.32401338 57:0.017402904 58:0.41060919 59:-0.51318979 60:-0.08102008  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Faecal) (NNS concentrations)) (PP (IN of) (ADJP (JJ butyrate) (, ,) (JJ histamine) (, ,) (JJ agmatine) (CC and) (JJ spermine)))) (VP (VBD were) (ADJP (ADJP (JJR lower)) (PRN (-LRB- -LRB-) (S (VP (VB P) (S (VP (SYM =) (NP (CD 0.05)))))) (-RRB- -RRB-)) (CC and) (ADJP (JJ faecal) (SBAR (S (NP (NN pH)) (VP (VBD was) (ADJP (JJR higher)))))) (PRN (-LRB- -LRB-) (S (VP (VB P) (S (VP (SYM =) (NP (CD 0.03)))))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (JJR older) (NNS dogs)) (PP (IN than) (PP (IN in) (NP (JJ mature) (NN adult) (NNS dogs)))))) (, ,) (S (VP (VBG suggesting) (NP (DT an) (NN alteration)) (PP (PP (IN in) (NP (JJ bacterial) (JJ metabolic) (NN activity))) (, ,) (CC or) (PP (IN in) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NP (JJ intestinal) (NN absorption)) (PP (IN of) (NP (DT these) (NNS compounds))))))))))) (. .))) |ET| |BV| 1:-0.90909707546234131 2:-0.4379083514213562 3:1.3501079082489014 4:-1.3608216047286987 5:0.081174321472644806 6:-0.21249093115329742 7:-1.0717818737030029 8:0.80661725997924805 9:-0.76155024766921997 10:0.22594225406646729 11:1.2293902635574341 12:0.55379337072372437 13:-0.024003908038139343 14:-0.59998881816864014 15:-0.59560304880142212 16:0.64742386341094971 17:0.17508698999881744 18:0.9019884467124939 19:0.77773487567901611 20:-1.8298786878585815 21:-0.840312659740448 22:0.22099512815475464 23:0.51324707269668579 24:-0.33907508850097656 25:-0.41379722952842712 26:0.3911575973033905 27:-1.0843089818954468 28:0.81841558218002319 29:-0.59977799654006958 30:0.32891619205474854 31:1.270140528678894 32:0.37494269013404846 33:-0.013257501646876335 34:-0.74156749248504639 35:-0.50359576940536499 36:0.39174270629882812 37:-0.23141629993915558 38:0.95422351360321045 39:0.57688093185424805 40:-1.4863200187683105 41:-0.50033259 42:-0.066424809 43:0.15158926 44:-0.13875812 45:0.13058163 46:0.012020104 47:-0.28837678 48:-0.32502675 49:-0.21197565 50:-0.21649404 51:-0.1153959 52:-0.19725558 53:0.12191854 54:-0.16530961 55:0.22591056 56:0.073661432 57:-0.23677075 58:0.10379894 59:-0.17816325 60:0.31161132  |EV|
-1 |BT| (ROOT (S (PP (IN In) (NP (NP (JJ vitro) (NNS chemosensitivities)) (PP (IN of) (NP (NP (JJ pancreatic) (NN carcinoma) (NNS cells)) (PP (TO to) (NP (CD 5-FU))))))) (, ,) (NP (NN gemcitabine) (CC and) (NN oxaliplatin)) (VP (VBD were) (ADJP (JJR lower)) (PP (IN than) (NP (NP (DT those)) (PP (IN of) (NP (JJ gastrointestinal) (NN carcinoma)))))) (. .))) |ET| |BV| 1:-0.9649387001991272 2:-0.22778066992759705 3:0.24806629121303558 4:0.35060077905654907 5:1.6634490489959717 6:0.54817026853561401 7:0.32789483666419983 8:-0.13410073518753052 9:-0.49568343162536621 10:0.29095801711082458 11:0.32065418362617493 12:-0.11118593811988831 13:1.0687401294708252 14:0.40582746267318726 15:-0.4973297119140625 16:0.93356448411941528 17:-0.56273549795150757 18:-0.61297696828842163 19:-1.0885471105575562 20:-0.65223276615142822 21:-1.0761337280273438 22:-0.72653055191040039 23:-0.047030564397573471 24:-0.095044218003749847 25:0.87921142578125 26:0.14182645082473755 27:0.56299537420272827 28:0.3043750524520874 29:0.050402730703353882 30:0.2984650731086731 31:-0.08135475218296051 32:0.20232106745243073 33:0.73375540971755981 34:-0.26733201742172241 35:-0.2360379695892334 36:0.81133437156677246 37:-0.324349045753479 38:-1.4542429447174072 39:-0.42247280478477478 40:-0.82956928014755249 41:0.034843843 42:-0.17812763 43:-0.19747502 44:0.081864744 45:0.017517984 46:-0.48645061 47:-0.24189919 48:-0.22510134 49:-0.07895121 50:0.37073612 51:0.27127957 52:0.20653842 53:-0.42993429 54:0.0025436913 55:-0.081034549 56:0.10166813 57:-0.071511105 58:-0.18758696 59:0.470404 60:0.54819953  |EV|
-1 |BT| (ROOT (S (NP (NP (NP (JJ Relative) (NNS increases)) (PP (IN in) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NN lactate) (, ,) (NN alanine) (, ,) (NN low-density) (JJ lipoprotein-very) (NN low-density) (NN lipoprotein)))))) (, ,) (CC and) (NP (JJ unsaturated) (NN fatty) (NNS acids)) (, ,) (CC and) (NP (NP (NNS decreases)) (PP (IN in) (NP (NP (NN choline)) (, ,) (NP (NN phosphocholine)) (, ,) (CC and) (NP (NN glucose)))))) (VP (VBD were) (VP (VBN observed) (PP (IN after) (NP (NN swimming))))) (. .))) |ET| |BV| 1:-0.7277105450630188 2:0.70699548721313477 3:0.43232452869415283 4:0.33550581336021423 5:-0.89898371696472168 6:0.18198440968990326 7:0.0091723008081316948 8:0.187703937292099 9:1.3347712755203247 10:0.64334410429000854 11:0.30550798773765564 12:0.54952681064605713 13:0.89580816030502319 14:-0.30918323993682861 15:-0.11821036040782928 16:0.26000285148620605 17:-0.30350744724273682 18:0.23642003536224365 19:0.88033038377761841 20:0.11831602454185486 21:-1.0504351854324341 22:1.2657102346420288 23:0.20934516191482544 24:0.38566321134567261 25:-0.35332852602005005 26:-0.27085354924201965 27:-0.46577709913253784 28:0.20200645923614502 29:0.86259692907333374 30:0.38503661751747131 31:0.1210068017244339 32:0.5146140456199646 33:1.2604243755340576 34:-0.5761789083480835 35:-1.0637105703353882 36:0.41204535961151123 37:-0.96071708202362061 38:0.57232868671417236 39:0.51873379945755005 40:0.24707116186618805 41:-0.31770325 42:0.0140311 43:0.083081953 44:0.021874022 45:0.029208083 46:0.081701852 47:0.024770077 48:-0.20869172 49:0.076163255 50:0.33787704 51:0.52550435 52:0.25710011 53:0.14520063 54:-0.75008464 55:0.10759242 56:0.30930993 57:0.62188518 58:0.39399984 59:-0.068045534 60:0.36697903  |EV|
-1 |BT| (ROOT (NP (NP (NNP CONCLUSION)) (: :) (NP (NP (NNP Exposure)) (PP (TO to) (NP (NP (NP (NN ethanol)) (PP (IN during) (NP (NN pregnancy) (NNS increases) (NNP IGF-I) (CC and) (NNP IGF-II)))) (CC and) (NP (NP (NNS decreases)) (VP (VBN leptin) (PP (IN during) (NP (JJ early) (NN childhood)))))))) (. .))) |ET| |BV| 1:-1.192335844039917 2:0.36651092767715454 3:0.14956016838550568 4:-0.25442144274711609 5:-0.74738132953643799 6:0.29904133081436157 7:0.63527578115463257 8:0.27886191010475159 9:0.45418372750282288 10:0.062229525297880173 11:0.63828611373901367 12:-0.17143264412879944 13:0.40124374628067017 14:0.10097073018550873 15:0.77508127689361572 16:-0.084373779594898224 17:-1.0932121276855469 18:0.10228245705366135 19:1.046500563621521 20:-0.54566127061843872 21:-0.18262425065040588 22:-0.27455565333366394 23:-0.63187038898468018 24:-0.20303082466125488 25:-0.49805775284767151 26:-0.36358526349067688 27:-0.67585134506225586 28:-0.18507486581802368 29:0.57143604755401611 30:-0.13132448494434357 31:0.033105544745922089 32:0.3947727382183075 33:0.014030230231583118 34:-0.085290499031543732 35:0.069696143269538879 36:0.078646555542945862 37:-0.25420689582824707 38:-0.09992583841085434 39:0.4503624439239502 40:0.5757184624671936 41:-0.055515446 42:-0.080653176 43:-0.070444487 44:0.22189337 45:0.13441584 46:0.095493071 47:0.12557183 48:-0.69311935 49:-0.11840862 50:0.16673094 51:0.16080832 52:0.23540422 53:0.26769853 54:0.20856482 55:0.022768565 56:0.3142567 57:0.6107133 58:0.19407818 59:-0.12783302 60:0.14827177  |EV|
-1 |BT| (ROOT (NP (NP (NNP PURPOSE)) (: :) (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (JJ diffuse) (JJ diabetic) (NN macular) (NN oedema)) (PRN (-LRB- -LRB-) (NP (NNP DME)) (-RRB- -RRB-))))))) (PP (IN with) (NP (NP (NP (JJ difluprednate) (JJ ophthalmic) (NN emulsion)) (ADVP (CD 0.05) (NN %))) (PRN (-LRB- -LRB-) (NP (NNP Durezol) (. ?)) (-RRB- -RRB-))))))))) |ET| |BV| 1:0.0074482057243585587 2:0.29499730467796326 3:1.438726544380188 4:-1.1476662158966064 5:-0.64328652620315552 6:0.43120196461677551 7:-0.076076507568359375 8:-0.018693238496780396 9:-0.3028033971786499 10:0.37171095609664917 11:0.56226038932800293 12:0.31723472476005554 13:-0.91562837362289429 14:0.44643798470497131 15:0.23893417418003082 16:-0.64331084489822388 17:0.48012441396713257 18:-0.20058265328407288 19:-0.52912825345993042 20:-1.3126281499862671 21:-0.14188018441200256 22:-0.94352543354034424 23:0.81149566173553467 24:-0.44199204444885254 25:1.0645791292190552 26:1.3857076168060303 27:0.25393989682197571 28:1.0044878721237183 29:0.3539218008518219 30:-0.36450770497322083 31:0.47678646445274353 32:0.023343704640865326 33:-1.2897380590438843 34:0.64845150709152222 35:0.35698288679122925 36:0.040471822023391724 37:-1.4861710071563721 38:-0.95685505867004395 39:-0.028377657756209373 40:-0.90302407741546631 41:0.21191996 42:-0.18754245 43:0.10140096 44:0.23462889 45:0.34704784 46:-0.14721571 47:0.20495027 48:0.40999645 49:-0.26365712 50:0.38600507 51:-0.020621007 52:0.037403658 53:-0.25752446 54:0.37224379 55:0.023043158 56:0.67274588 57:0.57435364 58:-0.26281261 59:-0.22206716 60:0.18009809  |EV|
-1 |BT| (ROOT (S (NP (PRP They)) (VP (VBP have) (ADVP (RB also)) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB reduce) (NP (NP (NN alcohol) (NN consumption)) (, ,) (NP (NP (JJ suppress) (NN reward)) (VP (VBN induced) (PP (IN by) (NP (NN alcohol) (, ,) (NN cocaine) (CC and) (NN amphetamine)))))))))))) (. .))) |ET| |BV| 1:0.04645971953868866 2:-0.24341200292110443 3:-0.12847506999969482 4:-0.020735494792461395 5:0.046708986163139343 6:-0.63118833303451538 7:-0.37865597009658813 8:-0.7709348201751709 9:0.74587637186050415 10:-0.46059706807136536 11:0.0066282842308282852 12:-0.22267381846904755 13:-0.17692463099956512 14:-0.36518228054046631 15:-0.20190101861953735 16:0.29322820901870728 17:-0.080923497676849365 18:-0.1887049674987793 19:0.15922586619853973 20:0.54918378591537476 21:-0.51009583473205566 22:-0.56838345527648926 23:0.018959643319249153 24:-0.8073391318321228 25:-0.028113126754760742 26:-0.51623201370239258 27:0.14834246039390564 28:-0.50347131490707397 29:0.91042083501815796 30:0.16682194173336029 31:0.37457370758056641 32:-0.095307551324367523 33:0.23110786080360413 34:-0.50809144973754883 35:-0.55485570430755615 36:-0.40123346447944641 37:0.6509438157081604 38:-0.029162149876356125 39:0.42906674742698669 40:1.1775617599487305 41:-0.26822233 42:-0.45637035 43:0.31215826 44:-0.10864807 45:0.9119668 46:-0.066393852 47:0.044901386 48:-0.31448659 49:0.058841076 50:0.068024352 51:0.24292949 52:0.14088732 53:-0.11221211 54:-0.21386984 55:0.20427245 56:0.12289384 57:0.57200038 58:-0.11666305 59:0.16181985 60:0.30399641  |EV|
-1 |BT| (ROOT (S (NP (NNP Amycolatopsis) (NNP balhimycina)) (VP (VP (VBZ produces) (NP (DT the) (JJ vancomycin-like) (NN glycopeptide) (NN balhimycin))) (CC and) (ADVP (RB therefore)) (VP (VBZ has) (S (VP (TO to) (VP (VB protect) (NP (PRP itself)) (PP (IN from) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (DT the) (NN glycopeptide)))))))))) (. .))) |ET| |BV| 1:-0.13414563238620758 2:0.18827158212661743 3:-0.24861152470111847 4:0.041680168360471725 5:1.3678233623504639 6:-1.7454969882965088 7:1.0956512689590454 8:0.61100625991821289 9:1.0161031484603882 10:0.37403690814971924 11:1.2081023454666138 12:-0.68180751800537109 13:-0.57862561941146851 14:0.64649957418441772 15:1.6305290460586548 16:0.2492695152759552 17:-0.22660104930400848 18:-0.52584242820739746 19:1.0271123647689819 20:-0.54040813446044922 21:-0.2997586727142334 22:-0.90835148096084595 23:-0.35928812623023987 24:-0.40498751401901245 25:-0.070239365100860596 26:-0.54183667898178101 27:-0.41281372308731079 28:0.56097722053527832 29:-0.59817785024642944 30:0.68011802434921265 31:-1.066428542137146 32:-0.33847963809967041 33:-0.050172816962003708 34:1.0202810764312744 35:-0.51219433546066284 36:0.73061972856521606 37:-0.31654056906700134 38:-0.64519917964935303 39:-0.52202326059341431 40:0.206183061003685 41:0.070051014 42:0.16281335 43:0.17735888 44:0.038011342 45:0.19181298 46:-0.49094817 47:0.12295219 48:0.017939292 49:0.13433383 50:0.25992981 51:0.29989624 52:-0.28517362 53:0.17889977 54:-0.13441737 55:-0.0044565229 56:0.16566184 57:0.1166174 58:-0.37749651 59:0.11853175 60:0.41051045  |EV|
-1 |BT| (ROOT (S (NP (PRP We)) (VP (VBD showed) (SBAR (IN that) (S (NP (NN vanadium)) (VP (VP (VBZ accelerates) (NP (NP (NN transfer)) (PP (IN of) (NP (NP (NP (DT the) (JJ tetracycline) (NN resistance) (NN gene) (NN tet)) (PRN (-LRB- -LRB-) (NP (NNP M)) (-RRB- -RRB-))) (PP (IN from) (NP (NNP Photobacterium)))))) (PP (TO to) (NP (NNP Escherichia) (NNS coli)))) (, ,) (CC and) (VP (VBD found) (NP (NP (DT a) (JJ positive) (NN correlation)) (PP (IN between) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NP (NP (NN vanadium)) (PP (IN in) (NP (JJ natural) (JJ marine) (NN sediment)))) (CC and) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (JJ oxytetracycline) (NN resistance)))))))))))))) (. .))) |ET| |BV| 1:-0.63782364130020142 2:1.0624147653579712 3:0.045017536729574203 4:0.26631644368171692 5:0.16656385362148285 6:-0.44899556040763855 7:0.61517125368118286 8:-0.17606386542320251 9:0.4434075653553009 10:0.8154834508895874 11:0.11764481663703918 12:0.068545155227184296 13:0.045241877436637878 14:1.0374330282211304 15:0.19346681237220764 16:-0.47470611333847046 17:-0.16641999781131744 18:0.63013064861297607 19:0.11350364238023758 20:0.87358379364013672 21:-1.0853487253189087 22:1.5168384313583374 23:-0.87191224098205566 24:0.52222228050231934 25:-0.30203065276145935 26:-0.20989640057086945 27:0.39682024717330933 28:-0.28059399127960205 29:0.22387348115444183 30:0.59591072797775269 31:0.61155295372009277 32:1.9145528078079224 33:-0.1840205043554306 34:0.63377749919891357 35:0.99932467937469482 36:-0.020008150488138199 37:-0.89096724987030029 38:0.86428570747375488 39:-0.0050041400827467442 40:-0.17774805426597595 41:-0.088618167 42:0.43587509 43:-0.039854843 44:-0.47982305 45:-0.53028309 46:-0.16205473 47:-0.07508745 48:-0.64378512 49:0.35403571 50:0.11403154 51:0.33243772 52:0.33273461 53:-0.21982794 54:0.081220709 55:0.45193362 56:0.24719366 57:0.17658286 58:-0.043427121 59:-0.31201085 60:0.37575802  |EV|
-1 |BT| (ROOT (S (NP (NNP Carvedilol)) (VP (VBZ seems) (ADJP (RBR more) (JJ potent) (PP (IN in) (NP (DT this) (NN regard)))) (, ,) (SBAR (IN whereas) (S (NP (NN nebivolol)) (VP (VP (ADVP (RBR more) (RB effectively)) (VBZ prevents) (NP (DT the) (NN shift)) (PP (TO to) (NP (DT a) (VBG nondipping) (NNP BP) (NN profile)))) (CC and) (VP (VBZ is) (ADJP (RBR better) (JJ tolerated))))))) (. .))) |ET| |BV| 1:-0.45039117336273193 2:0.38605701923370361 3:-0.4260934591293335 4:-0.37955847382545471 5:-0.22535276412963867 6:-0.34834569692611694 7:-1.016614556312561 8:-0.46308749914169312 9:-0.036711063235998154 10:0.82484084367752075 11:0.29723334312438965 12:-0.24628274142742157 13:-0.047303818166255951 14:0.79926580190658569 15:-1.0971370935440063 16:1.1578539609909058 17:-0.49170932173728943 18:-0.54788106679916382 19:-0.22961011528968811 20:-0.99260610342025757 21:-0.0042967023327946663 22:0.03428332507610321 23:-0.21294766664505005 24:0.3163902759552002 25:-0.40563651919364929 26:-0.14845497906208038 27:0.0062819253653287888 28:0.38031819462776184 29:0.50935041904449463 30:0.38778004050254822 31:0.10416379570960999 32:-0.25147205591201782 33:0.7191808819770813 34:-0.3687710165977478 35:-0.25780647993087769 36:-0.32105728983879089 37:-0.49079656600952148 38:-1.0289201736450195 39:0.19370993971824646 40:0.16015957295894623 41:-0.37132189 42:-0.03870187 43:-0.013332527 44:0.021456603 45:0.18104921 46:-0.25221601 47:-0.010084689 48:-0.2544716 49:0.19561294 50:0.091618694 51:0.50530028 52:-0.013907106 53:0.18033877 54:0.3722831 55:0.20084439 56:-0.096450329 57:0.056584619 58:0.17607246 59:-0.1357988 60:0.18655547  |EV|
-1 |BT| (ROOT (FRAG (NP (NNP TAKE) (NNP HOME) (NNP MESSAGE)) (: :) (S (NP (NP (DT The) (JJ triple) (NN combination) (NN therapy)) (PP (IN of) (NP (NN simvastatin/ER) (NN niacin/laropiprant)))) (VP (MD may) (VP (VP (VB reduce) (NP (JJ flushing) (NN side) (NNS effects))) (CC and) (VP (VB facilitate) (NP (NP (DT a) (ADJP (RBR more) (JJ comprehensive)) (NN treatment)) (PP (IN for) (NP (NNS patients)))) (PP (IN with) (NP (VBN mixed) (NN dyslipidemia))))))) (. .))) |ET| |BV| 1:1.1755447387695312 2:-1.677553653717041 3:-1.1906594038009644 4:0.61045360565185547 5:0.70769035816192627 6:-0.031282342970371246 7:0.94075429439544678 8:-0.33137652277946472 9:0.78358227014541626 10:0.53738695383071899 11:-0.15538401901721954 12:1.1314316987991333 13:0.17060194909572601 14:-0.69844198226928711 15:-0.82150435447692871 16:1.1374702453613281 17:-0.5780867338180542 18:-0.068459443747997284 19:1.4661563634872437 20:0.54127603769302368 21:-0.12533670663833618 22:-0.15019465982913971 23:-0.21028245985507965 24:0.47810676693916321 25:0.60104864835739136 26:-0.29292216897010803 27:-0.027071103453636169 28:-0.054589707404375076 29:-0.12048684805631638 30:0.70986199378967285 31:-0.53128153085708618 32:-0.012126103043556213 33:0.036642201244831085 34:-0.1527617871761322 35:-0.65743714570999146 36:0.53913813829421997 37:-0.41278499364852905 38:0.16837848722934723 39:0.86304891109466553 40:0.013139965012669563 41:0.055222802 42:-0.36201236 43:-0.080147125 44:-0.1283403 45:0.6775806 46:0.30834919 47:-0.22131686 48:0.19909947 49:0.22284813 50:0.62098342 51:-0.20983891 52:-0.015792197 53:-0.18879044 54:0.21441358 55:-0.17812967 56:-0.43472257 57:0.37388122 58:0.020790638 59:0.62976539 60:-0.29366228  |EV|
-1 |BT| (ROOT (S (NP (NP (NNP Riboflavin)) (PRN (-LRB- -LRB-) (NP (NN vitamin) (NN B2)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (NP (DT the) (JJ universal) (NN precursor)) (PP (IN of) (NP (DT the) (JJ coenzymes) (NN flavin) (NN mononucleotide) (CC and) (NN flavin) (NN adenine) (NN dinucleotide)))) (: --) (NP (NP (NNS cofactors)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ essential) (PP (IN for) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (DT a) (JJ wide) (NN variety)) (PP (IN of) (NP (NP (JJ metabolic) (NNS enzymes)) (PP (IN in) (NP (NNS animals) (, ,) (NNS plants) (, ,) (CC and) (NNS microbes)))))))))))))))) (. .))) |ET| |BV| 1:-1.0573043823242188 2:-0.64755392074584961 3:1.228437066078186 4:-1.6444205045700073 5:0.064398087561130524 6:0.86615628004074097 7:0.1228310763835907 8:-0.15457145869731903 9:1.1453032493591309 10:-0.40508604049682617 11:-0.60766440629959106 12:-0.44789674878120422 13:-0.31325790286064148 14:0.41718527674674988 15:-0.52481818199157715 16:0.016087865456938744 17:1.2331975698471069 18:-0.25023433566093445 19:0.42599061131477356 20:-0.028924649581313133 21:-0.98417937755584717 22:0.41805446147918701 23:0.35911783576011658 24:-0.893424391746521 25:-0.28451302647590637 26:-0.78242135047912598 27:-0.58465123176574707 28:0.97099947929382324 29:0.19545634090900421 30:-1.824374794960022 31:-0.0024916052352637053 32:0.65486383438110352 33:0.18116830289363861 34:1.189051628112793 35:-0.096406184136867523 36:-0.96060627698898315 37:-0.53619104623794556 38:-0.27410814166069031 39:-0.029814116656780243 40:-1.4676651954650879 41:-0.42625639 42:-0.42338812 43:0.46504939 44:0.072148435 45:0.14118558 46:-0.0083054807 47:-0.13131417 48:-0.22267748 49:0.10933387 50:0.053466953 51:0.83714551 52:0.48635641 53:0.016989956 54:0.009752267 55:0.30446112 56:-0.10523754 57:-0.0068945372 58:-0.15791787 59:-0.25664511 60:0.41441447  |EV|
-1 |BT| (ROOT (S (NP (NN Tobramycin) (CC and) (NN gentamicin)) (VP (MD can) (ADVP (RB safely)) (VP (VB be) (VP (VBN given) (PP (IN by) (NP (JJ slow) (NN push)))))) (. .))) |ET| |BV| 1:-0.9014473557472229 2:-0.77357274293899536 3:-0.98598629236221313 4:0.32056945562362671 5:0.56900829076766968 6:-0.34711796045303345 7:0.0996132493019104 8:-0.91540294885635376 9:-0.10529343038797379 10:0.9992406964302063 11:-1.3118937015533447 12:0.25720065832138062 13:-0.73304843902587891 14:-0.50897765159606934 15:-0.20677986741065979 16:-0.022683532908558846 17:-0.53631645441055298 18:-0.83129674196243286 19:-0.71905070543289185 20:0.53638476133346558 21:-0.22913230955600739 22:-1.2405341863632202 23:-0.30050903558731079 24:-0.1435655802488327 25:0.29575043916702271 26:0.11060968041419983 27:0.2045469731092453 28:0.01711747795343399 29:0.074474416673183441 30:0.25095799565315247 31:-0.4320131242275238 32:-0.99625641107559204 33:-0.2813853919506073 34:0.76117563247680664 35:-0.12153184413909912 36:-0.056398767977952957 37:-0.64857172966003418 38:-0.27979826927185059 39:-0.59806585311889648 40:0.59601575136184692 41:-0.13940489 42:-0.13985452 43:-0.037979092 44:-0.085790396 45:0.016450102 46:-0.58741885 47:0.060406182 48:-0.28220025 49:0.08495187 50:0.093223758 51:0.14306502 52:0.085696876 53:0.00018746342 54:0.40823203 55:0.35357884 56:-0.25287384 57:0.26182187 58:-0.045700382 59:-0.43640217 60:-0.43985346  |EV|
-1 |BT| (ROOT (SINV (S (S (NP (NNP IFNT)) (ADVP (RB also)) (VP (VBZ suppresses) (NP (NP (NN expression)) (PP (IN of) (NP (JJ classical) (JJ IFN-stimulated) (NNS genes)))) (PP (IN by) (NP (NP (JJ uterine) (JJ lumenal) (NN epithelium)) (PRN (-LRB- -LRB-) (NP (NNP LE)) (-RRB- -RRB-)))))) (CC and) (S (NP (NP (JJ superficial) (NN glandular)) (PRN (-LRB- -LRB-) (NP (NN sGE)) (-RRB- -RRB-))) (VP (VBP epithelium) (ADVP (CC but)) (, ,) (S (VP (VBG acting) (PP (IN in) (NP (NN concert))) (PP (IN with) (NP (NN progesterone)))))))) (, ,) (VP (VBZ affects)) (NP (NP (NN expression)) (PP (IN of) (NP (NP (DT a) (NN multitude)) (PP (IN of) (NP (NP (NNS genes)) (ADJP (JJ critical) (PP (TO to) (NP (NP (NN growth) (CC and) (NN development)) (PP (IN of) (NP (DT the) (NNS conceptus))))))))))) (. .))) |ET| |BV| 1:-0.70291984081268311 2:0.10596521198749542 3:0.40353924036026001 4:-0.0082024643197655678 5:0.51516556739807129 6:-0.42482960224151611 7:0.15003122389316559 8:0.12399149686098099 9:0.20275136828422546 10:0.48732560873031616 11:0.47781708836555481 12:-0.14894188940525055 13:0.51152008771896362 14:0.33163288235664368 15:-0.59081339836120605 16:0.57499492168426514 17:0.029747411608695984 18:0.1139160692691803 19:0.40241897106170654 20:0.63742589950561523 21:-0.096222363412380219 22:0.94451558589935303 23:0.38732513785362244 24:0.33220046758651733 25:0.6958467960357666 26:0.4615885317325592 27:0.089183717966079712 28:0.71234726905822754 29:0.23575858771800995 30:-0.68371903896331787 31:-0.48470005393028259 32:0.017183763906359673 33:0.82850325107574463 34:0.46577826142311096 35:0.49960997700691223 36:-0.28507906198501587 37:-1.0442582368850708 38:0.68104499578475952 39:-0.16396787762641907 40:-0.78167802095413208 41:-0.3750062 42:-0.24547464 43:0.29125211 44:-0.058199205 45:-0.011699778 46:-0.16996717 47:-0.16920634 48:-0.06767752 49:0.16542676 50:0.42751682 51:0.45431086 52:0.10216087 53:0.27360913 54:-0.4327924 55:-0.043652076 56:0.54760718 57:0.22510488 58:0.11421139 59:-0.03462711 60:-0.06513574  |EV|
-1 |BT| (ROOT (S (NP (JJ Rizatriptan) (CD 10) (NN mg)) (VP (VBZ has) (VP (VBN demonstrated) (, ,) (PP (IN in) (NP (NP (DT a) (JJ head-to-head) (NN study)) (, ,) (NP (JJR higher) (NN response) (NNS rates)) (CC and) (NP (NP (DT a) (ADJP (RBR more) (JJ rapid)) (NN onset)) (PP (IN of) (NP (NP (NN action)) (PP (IN than) (NP (NN sumatriptan) (CD 100) (NN mg)))))))) (, ,) (ADVP (RB together)) (PP (IN with) (NP (DT a) (JJ favorable) (NN tolerability) (NN profile))))) (. .))) |ET| |BV| 1:-0.32797491550445557 2:-0.94069474935531616 3:-0.60456752777099609 4:-0.65981048345565796 5:0.75001150369644165 6:-0.10764538496732712 7:-0.48857605457305908 8:-1.0108658075332642 9:0.41849395632743835 10:-0.75902396440505981 11:-0.33411329984664917 12:-0.64211088418960571 13:0.10719255357980728 14:-0.20691953599452972 15:-0.52022510766983032 16:-0.76019632816314697 17:0.59634751081466675 18:0.12651818990707397 19:0.92679297924041748 20:-0.52777057886123657 21:0.47001791000366211 22:-0.62756586074829102 23:1.0812581777572632 24:-0.8170352578163147 25:0.64208084344863892 26:-0.74925142526626587 27:-0.18517151474952698 28:-0.39398288726806641 29:-0.31712973117828369 30:0.61805939674377441 31:0.18569587171077728 32:1.3691579103469849 33:0.29236260056495667 34:-1.2151913642883301 35:-0.51034468412399292 36:-0.34254208207130432 37:-0.095466524362564087 38:0.10040470957756042 39:0.055905848741531372 40:-0.58425545692443848 41:0.09560924 42:0.17644545 43:0.2682246 44:-0.30543253 45:0.65958643 46:0.33287817 47:0.023871539 48:-0.28657869 49:-0.34527224 50:0.12421337 51:0.22246784 52:0.11028741 53:-0.30035987 54:0.23523124 55:0.0048748953 56:0.051284734 57:0.37455076 58:-0.08612404 59:0.22434585 60:0.24387553  |EV|
